OA17200A

OA17200A - Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B.

Info

Publication number: OA17200A
Application number: OA1201500047
Authority: OA
Inventors: Koen Vandyck; Stefaan Julien Last; Geert Rombouts; Wim Gaston Verschueren; Pierre Jean-Marie Bernard Raboisson
Original assignee: Janssen Sciences Ireland Uc
Priority date: 2012-08-28
Filing date: 2013-08-28
Publication date: 2016-04-05

Abstract

Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B. Inhibitors of HBV replicant of formula (I)

Description

SULFAMOYL-ARYLAMIDES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B.

Background Art

The Hepatitis B virus (HBV) is an enveloped, partially double-stranded DNA (dsDNA) virus of the Hepadnavirus family (Hepadnaviridae). Its genome contains 4 overlapping reading frames: the precore/core gene; the polymerase gene; the L, M, and S genes, which encode for the 3 envelope proteins; and the X gene.

Upon infection, the partially double-stranded DNA genome (the relaxed circular DNA;

rcDNA) is convertcd to a covalently closed circular DNA (cccDNA) in the nucléus of the host cell and the viral mRNAs are transcribed. Once encapsidated, the pregenomic RNA (pgRNA), which also codes for core protein and Pol, serves as the template for reverse transcription, which régénérâtes the partially dsDNA genome (rcDNA) in the nucleocapsid.

HBV has caused épidémies in parts of Asia and Africa, and it is endemie in China.

HBV has infected approximately 2 billion people worldwide of which approximately 350 million people hâve dcvelopcd chronic infections. The virus causes the disease hepatitis B and chronic infection is correlated with a strongly increased risk for the development cirrhosis and hepatocellular carcinoma.

Transmission of hepatitis B virus results from exposure to infectious blood or body fluids, while viral DNA has been detected in the saliva, tears, and urine of chronic carriers with high titer DNA in sérum.

An effective and well-tolcrated vaccine exists, but direct treatment options are currently 25 limited to interferon and the following antivirals; tenofovir, lamivudine, adefovir, entecavir and telbivudine.

In addition, heteroaryldihydropyrimidînes (HAPs) were identifïed as a class of HBV inhibitors in tissue culture and animal models (Weber et al., Antiviral Res. 54:69-78).

WO2013/006394, published on January 10,2013, and WO2013/096744, published on June 27,2013 relate to subclasses of Sulphamoyl-arylamides active against HBV.

Amongst the problems which HBV direct antivirals may encounter arc toxicity, mutagenicity, lack of selectivity, poor efïïcacy, poor bioavailabiIity and difficulty of synthesis.

F

-2There is a need for additional HBV înhibitors that may overcome at least one of these disadvantages or that hâve additional advantages such as increased potency or an increased safety window.

Description of the Invention

The présent invention relates to compounds of Formula (I) (D or a stereoisomer or tautomeric form thereof, wherein:

B rcpresents a monocyclic 5 to 6 membered aromatic ring, optionally containing one or more heteroatoms each independently selected from the group consisting of O, S and N, such 5 to 6 membered aromatic ring optionally being substituted with one or more substituents each independently selected from the group consisting of hydrogen, halogen, Cj-Cjalkyl, CN, CFH₂, CF₂H andCFj;

Ri rcpresents hydrogen or Ci-Cjalkyl;

R₂ représente Ci-Cealkyl, Ci-C6alkcnyl, Ci-Cealkyl-Rj, C(=O)-Rj, CFH₂, CF₂H, CFj.a dihydro-indenyl or tetrahydronaphtalcnyl moiety optionally substituted with OH, or a 3-7 membered saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of O, S and N, such 3-7 membered saturated ring, Cj-Cealkyl-Rjor Ci-Cealkyl optionally being substituted with one or more substituents each independently selected from the group consisting of hydrogen, halogen, C|-C₄alkyloxy, Ci -C₄alkyloxy carbony 1, oxo, C(=O)-C|-C₂ alkyl, Ci-C₄alkyl, OH, CN, CFH₂, CF₂H and CFj;

Or Ri and R₂ together with the Nitrogen to which they are attached form a 6-10 membered bicyclic or bridged ring or a 5-7 membered saturated ring, such bicyclic, bridged or saturated ring moiety optionally containing one or more additional heteroatoms each independently selected from the group consisting of O, S and N, such 5-7 membered saturated ring optionally being substituted with one or more substituents each independently selected from the group consisting of hydrogen, halogen, Ci-C₄alkyloxy, Ci-C₄alkyloxycarbonyl, oxo, C(=O)-Ci-Cjalkyl, C|-C₄alkyl, OH, CN, CFH₂, CF₂H and CF/,

Each R4 is independently selected from hydrogen, halogen, Ci-C₄alkyloxy, Ci-C₄alkyl, C)-C₄alkenyl, OH, CN, CFH₂, CF2H, CF₃, HC^C or a 3-5 membered saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting ofO and N, such Ci-C₄alkyl optionally substituted with OH;

Rs represents Ci-Cealkyl, CFH₂, CF2H, CFj.phenyl, pyridyl or a 3-7 membered saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of O, S and N, such 3-7 membered saturated ring optionally being substituted with one or more substituents each independently selected from the group consisting of hydrogen, halogen, Ci-C₄alkyloxy, Ci-C₄alkyloxycarbonyl, oxo, C(=O)-Cj-C₃alkyl, Ci-C₄alkyl, OH, CN, CFH₂, CF₂H and CFj;

or a pharmaceutically acceptable sait or a solvaté thereof.

The invention further relates to a pharmaceutical composition comprising a compound of Formula (I), and a pharmaceutically acceptable carrier.

The invention also relates to the compounds of Formula (I) for use as a médicament, preferably for use in the prévention or treatment of an HBV infection in a mammal.

In a further aspect, the invention relates to a combination of a compound of Formula (I), and another HBV inhibitor.

Définitions

The terni Ci-salkyl* or Ci-C₃alkyr as a group or part of a group refers to a hydrocarbyl radical of Formula C_nH2_a+j wherein n is a number ranging from 1 to 3. In case C|.₃alkyl is coupled to a further radical, it refers to a Formula CJkn.. Cj.₃alkyl groups comprise from 1 to 3 carbon atoms, more preferably 1 to 2 carbon atoms. Ci. ₃alkyl includes ail linear, or branched alkyl groups with between 1 and 3 carbon atoms, and thus includes such as for example methyl, ethyl, n-propyl, and /-propyl. Cualkyl as a group or part of a group defines straight or branched chain saturated hydrocarbon radicals having from I to 4 carbon atoms such as the group defined for Ci.₃alkyl and butyl and the lîke.

Ci_6alkyl as a group or part of a group defines straight or branched chain saturated hydrocarbon radicals having from 1 to 6 carbon atoms such as the groups defined for Cm al kyl and pentyl, hexyl, 2-methylbutyl and the like.

Cualkenyl as a group or part of a group dcfines straight or branched chaîn hydrocarbon radicals having from l to 4 carbon atoms with at least one double bond at any possible position. Examplcs of such alkenyls are ethenyl, propenyl, l-butenyl,

2-butcnyl. Ci^alkenyl as a group or part of a group defmes straight or branched chaîn 5 hydrocarbon radicals having from t to 6 carbon atoms with at least one double bond.

The term “Cualkyloxy” as a group or part of a group refera to a radical having the Formula —0R^e wherein R^e is Ci-jalkyL Non-limiting examples ofsuitable Cijalkyloxy include methyloxy (also methoxy), ethyloxy (also ethoxy), propyloxy and isopropyloxy.

The term oxo, C(=O), or carbonyl refera to a group composed of a carbon atom double bonded to an oxygen atom.

As used herein, the term “3-7 membered saturated ring” means saturated cyclic hydrocarbon with 3,4,5,6 or 7 carbon atoms and is generic to cyclopropyl, cyclobutyl, cyclopentyl, cyclohcxyl and cycloheptyl.

Such saturated ring optionally contains one or more heteroatoms, such that at least one carbon atom is replaced by a heteroatom selected from N, O and S, in particular from N 20 and O. Examples include oxetane, azetidine, tetrahydro-2H-pyranyl, pîperidinyl, tetrahydrofùranyl, morpholînyl and pyrrolidinyl, Preferred are saturated cyclic hydrocarbon with 3 or 4 carbon atoms and I oxygen atom. Examples include oxetane and tetrahydrofùranyl.

As used herein, the term monocyclic 5 to 6 membered aromatic ring (“aryl”), means an aromatic cyclic hydrocarbon with 5 or 6 carbon atoms. A preferred example of an aryl group is phenyl.

Such saturated ring optionally contains one or more heteroatoms each independentiy selected from the group consisting of O, S and N(hcteroaryl) For the purposes of the 30 invention, a heteroaryl group need only hâve some degree of aromatic character.

Illustrative examplcs of heteroaryl groups include, but are not limited to, pyridinyl, pyridazinyl, pyrimidyl, pyrazyl, triazinyl, pyrrolyl, pyrazolyl, imidazolyl, (1,2,3,)- and (l,2,4)-triazolyl, pyrazinyl, pyrimidinyl, tetrazolyl, fùryl, thienyl, isoxazolyl, thiazolyl, isoxazolyl, and oxazolyl. A heteroaryl group can be unsubstituted or substituted with 35 one or more suitable substituents.

As used herein, the term 6-10 membered bicyclic ring indicates a saturated bi-cyclic ring with 6-7-8-9 or 10 atoms. Such saturated bi-cyclic ring optionally contains one or

-5more heteroatoms, such that at least one carbon atom is replaced by a heteroatom selected from N, O and S, in particular from N and O.

Examples of such 6-10 membered bicyclic ring as used herein areanl,4-dioxa-8 azaspiro[4.5] decyl moîety indicating a group with structural formula

structural formula a 6-Oxa-2-azaspiro[3.4]octane moiety indicating a group with

a 2-oxa-6-azaspiro[3.3]heptyl moiety indicating a group with structural formula

or a 6-oxa-l-azaspiro[3.3]heptyl moiety withstructural formula

As used herein, the term 6-10 membered bridged ring indicates a saturated bridged ring with 6-7-8-9 or 10 atoms. Such saturated bi-cyclic ring optionally contains one or more heteroatoms, such that at least one carbon atom is replaced by a heteroatom selected from N, O and S, in particular from N and O. An example of such 6-10 membered bridged ring as used herein is -oxabîcyclo[2.2.l]heptan represented by structure

As used herein, a dihydroindenyl moiety represents a group with structural formula

. Such dihydroindcnyl moiety can be optionally substituted with OH. One example as used herein, a 2-hydroxy-2,3-dihydro-lH-indcnyl moiety, îndicates a group with structural formula

As used herein, a tetrahydronaphtalcnyl moiety represents a group with structural formula

lf not indicated, for any of the moieties above, the attachment to the main structure may be anywhere on such moiety as long as ît is chemically stable.

It should be noted that different isomers of the various heterocycles may exist within the définitions as used throughout the spécification. For example, pyrrolyl may be

1 H-pyrrolyl or 2H-pyrrolyl.

The term halo and halogen are generic to fluoro, chloro, bromo or iodo. Preferred halogens are fluoro and Chloro.

It should also be noted that the radical positions on any molecular moiety used in the définitions may be anywhere on such moiety as long as it is chemically stable. For instance pyridyl includes 2-pyridyl, 3-pyridyl and 4-pyridyl; pentyl includes 1-pentyl, 2-pcntyl and 3-pentyl.

Positions indicated on phenyl (e.g. ortho, meta and/orpara) are indicated relative to the bond connecting the phenyl to the main structure. An example with regard to the

position of R4, any location is indicated relative to the nitrogen (*) connected to the main structure:

When any variable (e.g. halogen or Ci.4alkyl) occurs more than one time in any constituent, each définition is indcpendent.

For therapeutic use, the salts of the compounds of formula (I) are those wherein the counter ion is pharmaceutically or physiologically acceptable. However, salts having a 10 pharmaceutically unacceptable counter ion may also find use, for example, in the préparation or purification of a pharmaceutically acceptable compound of formula (I). Ail salts, whethcr pharmaceutically acceptable or not are included within the ambit of the présent invention.

The pharmaceutically acceptable or physiologically tolerable addition sait forms which the compounds ofthe présent invention are able to form can conveniently be prepared using the appropriate acids, such as, for example, înorganic acids such as hydrohalic acids, e.g. hydrochloric or hydrobromic acid; sulfuric; hemisulphuric, nitric; phosphoric and the like acids; or organic acids such as, for example, acetic, aspartic, dodecylsulphuric, heptanoic, hexanoic, nicotinic, propanoic, hydroxyacetic, lactic, pyruvic, oxalic, malonic, succinic, maleic, fiimaric, malic, tartane, citric, methanesulfonic, ethanesulfonic, benzenesulfonic,p-toluenesulfonic, cyclamic, salicylic.p-aminosalicylic, pamoic and the like acids.

Convcrsely said acid addition sait forms can be converted by treatment with an appropriate base into the free base form.

The term “salts” also comprises the hydrates and the solvent addition forms that the compounds of the présent invention are able to form. Examples of such forms are e.g. hydrates, alcoholates and the like.

The présent compounds may also exist in their tautomeric forms for example, tautomeric forms of amide (-C(=0)-NH-) groups are iminoalcohols (-C(0H)=N-). Tautomeric forms, although not explicitly indicated in the structural formulae

represented herein, are intended to be included within the scope of the présent invention.

The term stereochemically isomerie forms of compounds of the présent invention, as used hereinbefore, de fines al! possible compounds made up of the same atoms bonded by the same sequence of bonds but having different three-dimensional structures which are not interchangeable, which the compounds of the présent invention may possess. Unless otherwise mentioned or indicated, the chemical désignation of a compound encompasses the mixture of ail possible stereochemically isomerie forms which said compound may possess. Said mixture may contain ail diastereomers and/or enantiomers ofthe basic molecular structure ofsaid compound. Ail stereochemically isomerie forms ofthe compounds of the présent invention both in pure form or in admixture with each other are intended to be embraced within the scope of the présent invention.

Pure stereoisomeric forms of the compounds and intermediates as mentioned herein are defined as isomers substantially free of other enantiomeric or diastereomeric forms of the same basic molecular structure of said compounds or intermediates. In particular, the term 'stereoisomeric al ly pure' concems compounds or intermediates having a stereoisomeric excess of at least 80% (i. e. minimum 90% of one isomer and maximum 10% of the other possible isomers) up to a stereoisomeric excess of 100% (i.e. 100% of one isomer and none of the other), more in particular, compounds or intermediates having a stereoisomeric excess of 90% up to 100%, even more in particular having a stereoisomeric excess of 94% up to 100% and most in particular having a stereoisomeric excess of97% up to 100%. The terms 'cnantiomerically pure’ and 'diastereomerically pure' should be understood in a similar way, but then having regard to the enantiomeric excess, respectively the diastereomeric excess of the mixture in question.

Pure stereoisomeric forms of the compounds and intermediates of this invention may be obtained by the application of art-known procedures. For instance, enantiomers may be separated from each other by the sélective crystallization of their diastereomeric salts with optically active acids or bases. Examples thereof are tartane acid, dibenzoyltartaric acid, ditoluoyltartaric acid and camphosulfonic acid. Altematively, enantiomers may be separated by chromatographie techniques using chiral stationary phases. Said pure stereochemically isomerie forms may also be derived from the corresponding pure stereochemically isomerie forms of the appropriate starting materials, provided that the reaction occurs stereospecifically. Preferably, if a spécifie

stereoisomer is dcsircd, said compound will be synthcsizcd by stereospecific methods of préparation. These methods will advantageously employ enantîomerically pure starting materials.

The diastereomeric racemates of formula (I) can be obtained scparately by conventional methods. Appropriate physical séparation methods that may advantageously be employed are, for example, sélective crystallization and chromatography, e.g. column chromatography.

The présent invention is also intended to include ail isotopes of atoms occurring on the présent compounds. Isotopes include those atoms having the same atomic number but different mass numbers. By way of general example and without limitation, isotopes of hydrogen include tritium and deutérium. Isotopes of carbon include C-13 and C-14.

Detailed description of the invention

Whencvcr used hereinafter, the term “compounds of formula (I)”,

or “the présent compounds” or simiiar term is meant to include the compounds of general formula (D,(I*), (la) ,(Ib),(Ic) and (Id), salts, stereoisomcric forms and racemic 20 mixtures or any subgrou ps therco f.

Compounds for use in the prévention or treatment ofan HBV infection in a mammal are disclosed as compounds per se and not limited to this use unless restricted by the daims.

The présent invention relates to compounds of Formula (I)

or a stereoisomer or tautomcric form thereof, wherein:

B represents a monocyclic 5 to 6 membered aromatic ring, optionally containing one or more heteroatoms each independently seiected from the group consisting of O, S and N, such 5 to 6 membered aromatic ring optionally being substituted with one or more substituents each independently seiected from the group consisting of hydrogen, halogen, Ci-Cjalkyl, CN, CFH₂, CF₂H and CF₃;

Ri represents hydrogen or Ci-CjaUcyl;

R₂ represents Ci-Cealkyl, C|-C«alkenyl, Ci-Ccalkyl-Rj, C(=O)-Rj, CFH₂, CF₂H, CFj.a 10 dihydro-indenyl or tetrahydronaphtalenyl moiety optionally substituted with OH, or a 3-7 membered saturated ring optionally containing one or more heteroatoms each independently seiected from the group consisting of O, S and N, such 3-7 membered saturated ring, Ci-Cealkyl-Rîor Ci-Cealkyl optionally being substituted with one or more substituents each independently seiected from the group consisting of hydrogen, halogen, Ci-C₄alkyloxy, Ci-C₄alkyloxycarbonyl, oxo, C(=O)-Ci-C₃alkyl, Ci-C₄alkyl, OH, CN, CFH₂, CF₂H and CF₃;

Or Ri and R₂ together with the Nitrogen to which they are attached form a 6-10 membered bicyclic or bridged ring or a 5-7 membered saturated ring, such bicyclic, bridged or saturated ring moiety optionally containing one or more additional 20 heteroatoms each independently seiected from the group consisting of O, S and N, such 5-7 membered saturated ring optionally being substituted with one or more substituents each independently seiected from the group consisting of hydrogen, halogen, C|-C₄alkyloxy, Ci-C₄alkyloxycarbonyl, oxo, C(=O)-Ci-C₃alkyl, C|-C₄alkyl, OH, CN, CFH₂, CF₂H and CF₃;

Each R» is independently seiected from hydrogen, halogen, Ci-C₄alkyloxy, Ci-C₄alkyl, C|-C₄alkenyl, OH, CN, CFH₂, CF₂H, CF₃, HC^C or a 3-5 membered saturated ring optionally containing one or more heteroatoms each independently seiected from the group consisting of O and N, such Ci-C₄alkyl optionally substituted with OH;

Rj represents Ci-Cealkyl, CFH₂, CF₂H, CF₃. phenyl, pyridyl or a 3-7 membered saturated ring optionally containing one or more heteroatoms each independently seiected from the group consisting of O, S and N, such 3-7 membered saturated ring optionally being substituted with onc or more substituents each independently seiected from the group consisting of hydrogen, halogen, Ci-C₄alkyloxy, Ci-C₄alkyloxycarbonyl, oxo, C(=O)-Ci-C₃alkyl, Ci-C₄alkyl, OH, CN, CFH₂, CF₂H and CF₃;

or a pharmaceutically acceptable sait or a solvaté thereof.

ln a first aspect, the invention further provides compound of Formula (I)

or a stereoisomer or tautomeric form thereof, wherein:

B represents a monocyclic 5 to 6 membered aromatic ring, optionally containing one or more heteroatoms each independently selected from the group consisting of 0, S and N, such 5 to 6 membered aromatic ring optionally being substituted with one or more substituents each independently selected from the group consisting of hydrogen, halo, Ci-Cjalkyl, CN, CFH₂, CF₂H and CFj;

Ri represents hydrogen or Ci-Cjalkyl;

R₂ represents Ci-Cealkyl, Ci-Cealkenyl, Ci-Cealkyl-Rj, C(=O)-Rj, CFH₂, CF₂H, CFî_ra 15 2-hydroxy-2,3-dihydro-l H-indenyl moiety or a 3-7 membered saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of 0, S and N, such 3-7 membered saturated ring, Ci-CealkylRs or Ci-Cealkyl optionally being substituted with one or more substituents each independently selected from the group consisting of hydrogen, halogen, Ci-C₄alkyl20 oxy, Ci-C₄alkyloxycarbonyl, oxo, C(=O)-Ci-Cjalkyl, Ci-C₄alkyl, OH, CN, CFH₂, CF₂H and CF₃;

Or Ri and R₂ together with the Nitrogen to which they are attached form a l,4-dioxa-8-azaspiro[4.5]decyl moiety, a 2-oxa-6-azaspiro[3.3]heptyl moiety or a 5-7 membered saturated ring optionally containing one or more additional heteroatoms each independently selected from the group consisting of O, S and N, such 5-7 membered saturated ring optionally being substituted with one or more substituents each independently selected from the group consisting of hydrogen, halogen, Ci-C₄alkyloxy, Ci-C₄alkyloxycarbonyl, oxo, C(=O)-Ci-C₃alkyl, C_rC₄alkyl, OH, CN, CFH₂, CF₂H and CF₃;

Each Ri is independently selected from hydrogen, halogen, Ci-C₄alkyloxy, Ci-C₄alkyl, Cj-C₄alkenyl, OH, CN, CFH₂, CF₂H, CF₃, HC^C or a 3-5 membered saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of O and N, such Ci-C₄alkyl optionally substituted with OH;

-12Rs represents Ci-Cealkyl, CFH₂, CF₂H, CF₃, phenyl, pyndyl or a 3-7 membered saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of O, S and N, such 3-7 membered saturated ring optionally being substituted with one or more substituents each independently selected from the group consisting of hydrogen, halogen, C|-C₄alkyloxy, Ci-C₄alkyloxycarbonyl, oxo, C(=O)-Ci-C₃alkyl, C|-C₄alkyl, OH, CN, CFH₂, CF₂H and CF₃;

or a pharmaceutically acceptable sait or a solvaté thereof.

In one embodiment, at least one R4 represents Fluor, and one other R4 is selected from the group consisting of Ci-C₃alkyl, Ci-C₃alkenyl, CHF₂ or cyclopropyl.

In a sub-embodiment, one R4 represents Fluor and one other R4 is selected from the group consisting of methyl or CHF₂. preferably methyl, and wherein the location of said Fluor is on the para position and the location of said methyl or CHF₂ is on the meta position related to the Nitrogen(*) as indicated In Formula (I*) below.

(I*)

In yet another embodiment, the invention provides compound of Formula (I) wherein at least one R4 represents Fluor, and one other R4 is selected from the group consisting of Ci-C₃alkyl, Ci-C₃alkenyl, CHF₂ or cyclopropyl; more preferably, one R» represents Fluor and one other R4 is selected from the group consisting of methyl or CHF₂ and wherein the location of said Fluor is on the para position and the location of said methyl or CHF₂ is on the meta position related to the Nitrogen (*) and R₂ represents a

4-7 membered saturated ring containing carbon and one or more oxygen atoms, such

4-7 membered saturated ring optionally being substituted with one or more substituents each independently selected from the group consisting of hydrogen, halo, Ci-Qalkyloxy, C|-C₄alkyloxycarbonyl, C(=O)-Ci-C₃alky|, Ci-C₄alkyl, OH, CN, CFH₂, CF₂H and CF₃.

In yet another embodiment, compounds are disclosed wherein one R4 on the para position represents Fluor and the other one R4 on the meta position represents methyl and such compound is not

In another embodiment of the présent invention, compounds according to Formula (I) are provided wherein R₂ represents a 4-7 membered saturated ring containing carbon and one or more oxygen atoms, such 4-7 membered saturated ring optionally being substituted with one or more substituents each independently selected from the group consisting of hydrogen, halogen, Ci-C₄alkyloxy, Ci-C₄alkyloxycarbonyl, C(=O)-Ct-Cjalkyl, Ci-C₄alkyl, OH, CN, CFH₂, CF₂H and CF3. A preferred substituent for such a 4-7 membered saturated ring containing carbon and one or more oxygen atoms is Ci-C₄alkyl. In a sub-embodiment, the saturated ring is a 4,5 or 6 membered ring.

In another embodiment of the présent invention, compounds according to Formula (1) are provided wherein R₂ represents a 4-7 membered saturated ring containing carbon and one or more nitrogen atoms, such 4-7 membered saturated ring optionally being substituted with one or more substituents each independently selected from the group consisting of hydrogen, halogen, Ci-C₄alkyloxy, C|-C₄alkyloxycarbonyl, C(=O)-Ci-C3aIkyl, C|-C₄alkyl, OH, CN, CFH₂, CF₂H and CFj In a further embodiment, 20 R₂ represents a 4-7 membered saturated ring containing carbon and one or more oxygen atoms, such 4-7 membered saturated ring optionally being substituted with one or more substituents each independently selected from the group consisting of hydrogen, halogen, Ci-C₄alkyloxy, Ci-C₄alkyloxycarbonyl, C(=O)-Ci-C3alkyl, Ci-C₄alkyl, OH, CN, CFH₂, CF₂H and CFj wherein such compound is not

Preferably, any optional substituent on such 3-7,4-7 and 5-7 membered saturated ring,

6-10 membered bicyclic or bridged ring, Ci-Cealkyl-Rs or Cj-Cealkyl is independently selected from the group consisting of hydrogen, Fluoro, OH, Ci-Cjalkyl and CFj, most preferably from the group consisting of hydrigen Ci-Cjalkyl, Fluoro and CF3.

In another embodiment of the présent invention, compounds according to Formula (I) are provided wherein B represents phenyl or thiophene, optionally being substituted with one or more substituents each independently selected from the group consisting of hydrogen, halogen, Ct-Cjalkyl, CN, CFH₂, CF₂H and CFj.

In one sub-embodiment, compounds according to the présent invention arc represented by Formula (la)

(la), wherein R», R₂ and R4 are defined as in any one of the embodiments as described.

In a sub-embodiment, such compounds arc represented by Formula (Ib)

wherein R|, R₂, Ri are defined as in any one of the embodiments as described and Rj is selected from the group comprising hydrogen, halogen, Ci-Cjalkyl, CN, CFH₂, CF₂H,

-15CFj. In a preferred embodiment, R₃ represents Fluor or hydrogen, more preferably hydrogen.

In yet another sub-embodiment, compounds are represented by Formula (le):

(le) wherein R|, R₂ and R4 are defined as in any one of the embodiments as described.

In one sub-embodiment, compounds according to the présent invention are represented by Formula (Id)

(Id) wherein Ri, R₂ and R« are defined as in any one of the embodiments described and R₃is selected from the group comprising hydrogen, halogen, Ci-C₃alkyl, CN, CFH₂, CF₂H, cf₃.

In a preferred embodiment, the compounds according to the invention are envisioned for use in the prévention or treatment of an HBV infection in a mammal.

In one further aspect, the présent invention provides compounds which can bc represented by Formula (I):

(D or a stereoisomer or tautomcric form thereof, wherein:

.0

B represents a monocyclic 5 to 6 membered aromatic ring, optionally containing one or more heteroatoms each independently selected from the group consisting of O, S and N, such 5 to 6 membered aromatic ring optionally being substituted with one or more substituents each independently selected from the group consisting of hydrogen, halo, Ci-Cjalkyl, CN, CFH₂, CF₂H and CF₃;

Ri represents hydrogen orCi-C₃alkyl;

R₂ represents Cj-Cealkyl, Ci-Cjalkyl-Rj, benzyl, C(=O)-Rj, CFH₂, CF₂H, CFjor a 10 3-7 membered saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of O, S and N, such

3-7 membered saturated ring or Ci-Cealkyl optionally being substituted with one or more substituents each independently selected from the group consisting of hydrogen, halo, C]-C₄alkyloxy, oxo, C(=O)-Ci-C₃alkyl, Ci-C₄alkyl, OH, CN, 15 CFH₂, CF₂H and CF₃;

Or Ri and R₂ together with the Nitrogen to which they are attached form a l,4-dioxa-8-azaspîro[4.5] moiety or a 5-7 membered saturated ring, optionally containing one or more additional heteroatoms each independently selected from 20 the group consisting of O, S and N, such 5-7 membered saturated ring optionally being substituted with one or more substituents each independently selected from the group consisting of hydrogen, halo, Ci-C₄alkyloxy, oxo, C(=O)-Ci-Cja!kyI, Ci-C₄alkyl, OH, CN, CFH₂, CF₂H and CF₃;

Each R4 is independently selected from hydrogen, halo, Ci-C₄alkyloxy, C)-C₄alkyl, OH, CN, CFH₂, CF₂H, CFj , HC=C or a 3-5 membered saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of O and N;

Rj represents Ci-Cealkyl, CFH₂, CF₂H, CFj or a 3-7 membered saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of O, S and N, such 3-7 membered saturated ring optionally being substituted with one or more substituents each independently selected from the group consisting of hydrogen, halo, Ci-C₄alkyloxy, oxo, C(=O)-Ci-Cjalkyl,

Ci-C₄alkyl, OH, CN, CFH₂, CF₂H and CF₃;

-17or a pharmaceutically acceptable sait or a solvaté thereof. These compounds are cspecially suited for use in the prévention or treatment of an HBV infection in a mammal.

In yet a further aspect, the invention relates to compounds according to Formula (I) (D or a stereoisomer or tautomeric form thereof, wherein:

B represents a monocyclic 5 to 6 membered aromatic ring, optionally containing one or more heteroatoms each independently selected from the group consisting of O, S and N, such 5 to 6 membered aromatic ring optionally being substîtuted with one or more substituents each independently selected from the group consisting of hydrogen, halo, C|-C₃alkyl, CN, CFH₂, CF₂H and CF₃;

Ri represents hydrogen or Ci-C₃alkyl;

R₂ represents a 4-7 membered saturated ring consisting of carbon atoms and one or more heteroatoms each independently selected from the group consisting of O or S, such 4-7 membered saturated ring optionally being substîtuted with one or more substituents each independently selected from the group consisting of hydrogen, halo, Ci-C₄alkyloxy, oxo, C(=O)-Ct-C₃alkyI, Ci-C₄alkyl, OH, CN, CFH₂, CF₂H and CF₃;

Each Rj is independently selected from hydrogen, halo, Ci-C₄alkyloxy, Ci-C₄alkyl, OH, CN, CFH₂, CF₂H, CF₃, HC=C or a 3-5 membered saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of O and N;

or a pharmaceutically acceptable sait or a solvaté thereof.

The présent invention additionally relates to compound of Formula (I)

or a stcrcoisomcr or tautomeric form thereof, or a pharmaceutically acceptable sait or a solvaté thereof wherein:

B represents a monocyclic 5 to 6 membered aromatic ring, optionaily containing one or more heteroatoms each independently selected from the group consisting of O, S and N, such 5 to 6 membered aromatic ring optionaily being substituted with one or more substituents each independently selected from the group consisting of hydrogen, halo, Ci-C₃alkyl, CN, CFH2, CF2H and CF₃;

Ri represents hydrogen or Ci-C₃alkyl;

R2 represents Ci-Cealkyl, CrC₃alkyl-Rj, benzyl, C(=O)-R₃, CFH2, CF₂H, CF₃or a

3-7 membered saturated ring optionaily containing one or more heteroatoms each independently selected from the group consisting of O, S and N, such

3-7 membered saturated ring or Cj-Cê alkyl optionaily being substituted with one or more substituents each independently selected from the group consisting of hydrogen, halo, C|-C₄alkyloxy, oxo, C(=O)-Ci-C₃alkyl, C|-C₄alkyl, OH, CN, CFH₂, CF₂H and CF₃;

Or Ri and R2 together with the Nitrogen to which they are attached form a l,4-dioxa-8-azaspiro[4.5] moîety or a 5-7 membered saturated ring, optionaily containing one or more additional heteroatoms each independently selected from the group consisting of O, S and N, such 5-7 membered saturated ring optionaily 25 being substituted with one or more substituents each independently selected from the group consisting of hydrogen, halo, Ci-C₄alkyloxy, oxo, C(=O)-Ci-C₃alkyl, C_rC₄alkyl, OH, CN, CFH_Z| CF₂H and CF₃;

Each R4 is independently selected from hydrogen, halo, C|-C₄alkyloxy, Ci-C₄alkyl, 30 OH, CN, CFH2, CF2H, CF₃, HOC or a 3-5 membered saturated ring optionaily containing one or more heteroatoms each independently selected from the group consisting of O and N;

-19Rî represents Ci-Qalkyl, CFH₂, CF₂H, CFjor a 3-7 membered saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of O, S and N, such 3-7 membered saturated ring optionally being substituted with one or more substituents each independently selected from the group consisting of hydrogen, halo, C|-C₄alkyloxy, oxo, C(=O)-C|-C₃alkyl, Ci-C₄alkyl, OH, CN, CFH₂, CF₂H and CF₃;

One sub-embodiment of the invention provides compounds which can bc represcnted by formula (la)

R. t (la) wherein Ri, R2, B are defined as above and each R« is independently selected from hydrogen, halo, Ci-C₄alkyloxy, Cj-C₄alkyl, OH, CN, CFH₂, CF₂H, CFjor a 3-5 membered saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of O and N.

In one embodîment, R2 represents a 3-7 membered saturated ring, containing one or more heteroatoms each independently selected from the group consisting of O, S and N, such 3-7 membered saturated ring optionally being substituted with one or more substituents each independently selected from the group consisting of hydrogen, halo, Ci-Qalkyloxy, oxo, C(=O)-Cj-C₃alkyl, Ci-C₄alkyl, OH, CN, CFH₂, CF₂H and CFj.

In yet another embodîment, R2 represents a 4-7 membered saturated ring containing carbon and one or more oxygen atoms, such 4-7 membered saturated ring optionally being substituted with one or more substituents each independently selected from the group consisting of hydrogen, halo, C|-C₄alkyloxy, C(=O)- Ci-C₃alkyl, Ci-C₄alkyl, OH, CN, CFH₂, CF₂H and CF₃.

In another embodîment, R[ and R2 together with the Nitrogen to which they are attached form a 5-7 membered saturated ring, optionally containing one or more additional heteroatoms each independently selected from the group consisting of O, S and N, such 5-7 membered saturated ring optionally being substituted with one or more substituents each independently selected from the group consisting of hydrogen, halo, Ci-C₄alkyloxy, oxo, C(=O)-C|-C₃alkyl, Ci-C₄alkyl, OH, CN, CFH₂, CF₂H and CF₃.

In a preferred embodiment of the invention, B represents phenyl or thiophene, optionally being substituted with one or more substituents each independently selected from the group consisting of hydrogen, halogen, Ci-Cjalkyl, CN, CFH2, CF2H and CF3.

In a sélection of compounds according to the invention, or compounds for use in the prévention or treatment of an HBV infection in a mammal at least one R4 represents Fluor, Ci-Cjalkyl, CHF2 or cyclopropyl.

Preferably, at least one R4 represents methyl, f-propyl or cyclopropyl. In another embodiment, one R4 represents methyl, ί-propyl or cyclopropyl and the other R4 represents Fluor, or hydrogen. The position of R4 preferably is meta and/or para (position indicated from -N~).

One spécifie embodiment is a compound of Formula (I) wherein one Ri on the para position represents Fluor and the other one R4 on the meta position represents Fluor or methyl (position indicated from -N~).

One sub-embodiment of the invention provides compounds which can be represented 20 by formula (Ib)

wherein Ri, R2, Ri are defined as above and R3 is selected from the group comprising hydrogen, halo, Cj-Cjalkyl, CN, CFH₂, CF2H, CFj. In a preferred embodiment, Rj 25 represents Fluor or hydrogen.

The invention further relates to compounds according to Formula (I)

(0

-21or a stereoisomer or tautomeric form thereof, wherein:

B represents a monocyclic 5 to 6 membered aromatic ring, optionally containing one or more heteroatoms each independently selected from the group consisting of O, S and N, such 5 to 6 membered aromatic ring optionally being substituted with one or 5 more substituents each independently selected from the group consisting of hydrogen, halo, Ci-Caalkyl, CN, CFH2, CF₂H and CF3;

Ri represents hydrogen or Ci-Csalkyl;

R₂ represents Ci-C3alkyl-R«or a 4-7 membered saturated ring consisting of carbon atoms and one or more heteroatoms each independently selected from the group consisting of O or S, such 4-7 membered saturated ring optionally being substituted with one or more substituents each independently selected from the group consisting of hydrogen, halo, Ci-C₄alkyloxy, oxo, C(=O)-Ci-C3alkyl, C|-C₄alkyl,

OH, CN, CFH₂, CF₂H and CF_J;

Each Ri is independently selected from hydrogen, halo, Ci-C₄alkyloxy, Ci-C₄alkyl, OH, CN, CFH₂, CF₂H, CF3, HC=C or a 3-5 membered saturated ring optionally containing one or more heteroatoms each independently selected from the group 20 consisting of O and N;

R$ represents a 4-7 membered saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of O or S, such

4-7 membered saturated ring optionally being substituted with one or more substituents each independently selected from the group consisting of hydrogen, halo, Ci-C₄alkyloxy, oxo, C(=O>Ci-C3alkyl, Ci-C₄alkyl, OH, CN, CFH₂, CF₂H and CF3;

or a pharmaceutically acceptable sait or a solvaté thereof.

One sub-embodiment of the invention provides compounds which can be represented by formula (la)

-22wherein Ri, R₂, B are defincd as above andeach R4 is independently selected from hydrogen, halo, C]-C4alkyloxy, C|-C4alkyl, OH, CN, CFH₂, CF₂H, CFjor a 3-5 membered saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of O and N.

In one embodiment, R2 represents Ci-Cjalkyl-Rjor a 4-7 membered saturated ring consisting of carbon atoms and one or more heteroatoms each independently selected from the group consisting of O or S, such 4-7 membered saturated ring optionally being substituted with one or more substituents each independently selected from the group consisting of hydrogen, halo, Ci-C4alkytoxy, oxo, C(=O)-C|-Cjalkyl, Ci-C₄alkyl, OH, CN, CFH₂, CF₂H and CFj.

In a preferred embodiment for the compounds of the invention, B represents phenyl or thiophene, optionally being substituted with one or more substituents each independently selected from the group consisting of hydrogen, halogen, Cj-Cjalkyl, CN, CFH₂, CF2H and CFj.

In a sélection of compounds according to the invention at least one R4 represents Fluor, Ci-Cjalkyl .CHFîOr cyclopropyk Preferably, at least one R4 represents methyl, i-propyl or cydopropyl. In another embodiment, one R4 represents methyl, Tpropyl or cyclopropyl and the other R4 represents Fluor, or hydrogen. The position of R4 preferably is meta and/or para.

One spécifie embodiment is a compound of Formula (I) wherein one R4 on the para position represents Fluor and the other one R4 on the meta position represents Fluor or methyl.

One sub-embodiment of the compounds of the invention relates to compounds according Formula (Ib)

R₃

(Ib) wherein Ri represents hydrogen or C|-C₃alkyl;

R₂ represents C)-C₃alkyl-Ri or a 4-7 membered saturated ring consisting of carbon atoms and one or more heteroatoms each independently selected from the group consisting of 0 or S, such 4-7 membered saturated ring optionally being substituted 5 with one or more substituents each independently selected from the group consisting of hydrogen, halo, Ci-C4alkyloxy, oxo, C(=O)-Ci-C₃alkyl, Cj-Cialkyl, OH, CN, CFH₂, CF₂H and CF_3;

Each Ri is independently selected from hydrogen, halo, Cj-Cialkyloxy, C)-C4alkyl,

OH, CN, CFH₂, CF₂H, CF₃ or a 3-5 membered saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of 0 and N;

R< represents a 4-7 membered saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of 0 or S, such

4-7 membered saturated ring optionally being substituted with one or more substituents each independently selected from the group consisting of hydrogen, halo, C|-C4alkyloxy, oxo, C(=O)-C)-C₃alkyl, C)-C4alkyl, OH, CN, CFH₂, CF₂H and CF₃;

R₃ is selected from the group comprising hydrogen, halo, Ci-C₃alkyl, CN, CFH₂, CF₂H, CF₃. In a preferred embodiment, R₃ represents Fluor or hydrogen.

In one embodiment, R$ represents a 4-7 membered saturated ring consisting of carbon 25 atoms and one or more heteroatoms each independently selected from the group consisting of O or S, such 4-7 membered saturated ring optionally being substituted with one or more substituents each independently selected from the group consisting of hydrogen, halo, Ci-Cialkyloxy, oxo, C(=O)-Ci-C₃alkyl, C)-C4alkyl, OH, CN, CFH₂, CF₂H and CF₃.

Further combinations of any of the sub- or preferred embodiments are also envisioned to be in the scope of the présent invention.

Preferred compounds according to the invention are compounds or a stereoisomer or 35 tautomeric form thereof with a formula or référencé to a formula selected from the following tables I and 2:

Table 2.

Co. no.
1
2
3
4
5
6
7
8
9
10
11
12
14
16
17
18
19
38
39
42
43
45
46
48
56
63

Co. no.
64
65
66
67
68
69
70
71
72
73
74
76
77
79
81
82
83
84
85
86
87
89
90
91
92
93

Co. no.
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
lll
112
113
114
115
116
117
118
119

Co. no.
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145

Co. no.
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171

Co. no.
172
173
174
175
176
177
178
179
180
181
182
183
184
184a
184b
185
186
187
188
189
190
191
192
193
194
195

Co. no.
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221

Co. no.
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243

or a pharmaceutically acceptable sait or a solvaté thereof

In a further aspect, the présent invention concems a pharmaceutical composition comprising a therapeutically or prophylactically effective amount of a compound of Formula (I) as specified herein, and a pharmaceutically acceptable carrier. A prophylactically effective amount in this context is an amount sufficient to prevent 10 HBV infection in subjects being at risk of being infected. A therapeutically effective amount in this context is an amount sufficient to stabilîze HBV infection, to reduce HBV infection, or to eradicate HBV infection, in infected subjects. In still a further aspect, this invention relates to a process of preparing a pharmaceutical composition as specified herein, which comprises intimately mixing a pharmaceutically acceptable

carrier with a therapeutically or prophylactically effective amount of a compound of Formula (I), as specifïed herein.

Therefore, the compounds of the présent invention or any subgroup thereof may be formulated into various pharmaceutical forms for administration purposes. As appropriate compositions there may be cited ail compositions usually employed for systemically administering drugs. To prépare the pharmaceutical compositions of this invention, an effective amount of the particular compound, optionally in addition sait form, as the active ingrédient is combined in intimate admixture with a pharma10 ceutically acceptable carrier, which carrier may take a wide variety of forms depending on the form of préparation desired for administration. These pharmaceutical compositions are désirable in unitary dosage form suitable, particularly, for administration orally, rectally, percutaneously, or by parentéral injection. For example, in preparing the compositions in oral dosage form, any of the usual pharmaceutical media may be employed such as, for example, water, glycols, oils, alcohols and the like in the case of oral liquid préparations such as suspensions, syrups, élixirs, émulsions and solutions; or solid carriers such as starches, sugars, kaolin, lubricants, binders, disintegrating agents and the like in the case of powders, pills, capsules, and tablets. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit forms, in which case solid pharmaceutical carriers are employed. For parentéral compositions, the carrier will usually comprise stérile water, at least in large part, though other ingrédients, for example, to aid solubility, may be included. Injectable solutions, for exampie, may be prepared in which the carrier comprises saline solution, glucose solution or a mixture of saline and glucose solution.

Injectable suspensions may also be prepared in which case appropriate liquid carriers, suspending agents and the like may be employed. Also included are solid form préparations intended to be converted, shortly before use, to liquid form préparations. In the compositions suitable for percutaneous administration, the carrier optionally comprises a pénétration enhancing agent and/or a suitable wetting agent, optionally 30 combined with suitable additives of any nature in minor proportions, which additives do not introduce a significant delcterious effect on the skin. The compounds of the présent invention may also be adminîstered via oral inhalation or insufflation in the form of a solution, a suspension or a dry powder using any art-known delivery system.

It is especially advantageous to formulate the aforementloned pharmaceutical compositions in unit dosage form for ease of administration and uniformity of dosage. Unit dosage form as used herein refers to physically discrète units suitable as unitary dosages, each unit containing a prcdetcrmined quantityof active ingrédient calculated

to produce the desired therapeutic effect in association with the required pharmaceutical carrier. Examples of such unit dosage forms are tablets (including scored or coated tablets), capsules, pills, suppositories, powder packcts, wafers, injectable solutions or suspensions and the like, and segregated multiples thereof.

The compounds of Formula (I) are active as inhibitors of the HBV réplication cycle and can be used in the treatment and prophylaxis of HBV infection or diseases associated with HBV. The Iatter include progressive liver fibrosis, inflammation and necrosis leading to cirrhosis, end-stage liver disease, and hepatocellular carcinoma.

Due to their antiviral properties, particularly their anti-HBV properties, the compounds of Formula (I) or any subgroup thereof, are useful in the inhibition ofthe HBV réplication cycle, in particular in the treatment of warm-blooded animais, in particular humans, infected with HBV, and for the prophylaxis of HBV infections. The présent invention furthermore relates to a method of treating a warm-blooded animal, in particular human, infected by HBV, or being at risk of infection by HBV, said method conprising the administration of a therapeutically effective amount of a compound of Formula (I).

The compounds of Formula (1), as specifïed herein, may therefore be used as a medicine, in particular as medicine to treat or prevent HBV infection. Said use as a medicine or method of treatment comprises the systemie administration to HBV infected subjects or to subjects susceptible to HBV infection of an amount effective to combat the conditions associated with HBV infection or an amount effective to prevent 25 HBV infection.

The présent invention also relates to the use of the présent compounds in the manufacture of a médicament for the treatment or the prévention of HBV infection. In general it is contemplated that an antiviral effective daily amount would be from 30 about 0.01 to about 50 mg/kg, or about 0.01 to about 30 mg/kg body weight. It may be appropriate to administer the required dose as two, three, four or more sub-doses at appropriate intervals throughout the day. Said sub-doses may be formulated as unit dosage forms, for example, containing about 1 to about 500 mg, or about l to about 300 mg, or about 1 to about 100 mg, or about 2 to about 50 mg of active ingrédient per 35 unit dosage form.

The présent invention also concems combinations of a compound of Formula (I) or any subgroup thereof, as specifïed herein with other anti-HBV agents. The term

“combination” may relate to a product or kit containing (a) a compound of Formula (I), as specifïed above, and (b) at Ieast one other compound capable of treating HBV infection (herein designated as anti-HBV agent), as a combined préparation for simultaneous, separate or sequential use in treatment of HBV infections. In an embodiment, the invention concems combination of a compound of Formula (I) or any subgroup thereof with at Ieast one anti-HBV agent. In a particular embodiment, the invention concems combination of a compound of formula (I) or any subgroup thereof with at least two anti-HBV agents. In a particular embodiment, the invention concems combination of a compound of formula (I) or any subgroup thereof with at least three ! 0 anti-HBV agents. In a particular embodiment, the invention concems combination of a compound of formula (I) or any subgroup thereof with at least four anti-HBV agents.

The combination of previously known anti-HBV agents, such as interferon-α (IFN-a), pegylated interferon-α, 3TC, adefovir or a combination thereof, and, a compound of 15 formula (I) or any subgroup thereof can be used as a medicine in a combination therapy.

Generic synthesis:

Compound according to Formula (I) can be synthesized as described in general schemes 1 to 7.

A carboxylic acid chloride of general Formula II can be selectively reacted with an aniline of general formula III, for example in an organic solvent like CH2CI2 in the 25 presence of an organic base like triethylamine or DIPEA (N,N-diisopropylethylamine), or, as another example, by addition of the aniline III to a refluxing toluene solution of compound II, resulting in compound IV. The remaining sulfonic acid chloride functionality in compound IV is further reacted with an amine of general formula V, resulting in a compound of general Formula (I). Altematively a compound of general 30 Formula (1) might be obtained as described in scheme 2. This time the sulfonic acid chloride VI is reacted with an amine of general formula V, for example in an organic solvent like CH2CI2 in the presence of an organic base like triethylamine or DIPEA or or, as another example, in the presence of Na₂COj in a mixture of H2O/THF. The formed compound VII is coupled with aniline of general formula III in the presence of 35 an activating rcagcnt like for example HATU and an organic base like triethylamine or DIPEA.

Scheme 1

VI

Scheme 2

A general synthesis of compounds of formula IX and X is described in scheme 3. Intermediate IV is reacted with ammonia, resulting in a compound of formula VIII.

This intermediate can be further transformed to a compound of formula IX by reacting with a carbonyl chloride, for example cyclohexane carbonyl chloride in the presence of S1O2 and H2SO4 at reflux in CHCb. The compound of general formula IX can be further transformed to a compound of formula X. In case Ri equals Me, this can be done by reacting IX with TMSCHN₂ in McOH/CHiCb

Scheme 3

In another example, compound IV can be reacted with an amino acid XI, in the presence of a base like NaOH, resulting in compound XII as described in scheme 4.

This intermediate XII can then optionally be cyclised to compound XIII for example by heating with acetic anhydride and KOAc in toluene, or converling the carboxylic acid to an acid chloride followed by cyclisation in the presence of a base like triethylamine. Suitable examples of amino acids of structure XI are dérivatives of 5-aminopentanoic 10 acid or 4-aminobutanoic acid

R4

IV XII

XIII

Scheme 4

Scheme 5

A synthetic route to compounds of general formula XVI is described in Scheme 5. A aminoethanol dérivative XIV, prepared as described in scheme 1 for the compounds of general Formula (I), is transformed in a aziridîne dérivative XV by trcatcment with Diethyl diazcnc-l,2-dicarboxylate and PPhj in THF. The aziridîne of general formula XV is reacted with a nucleophile Nu, resulting in a compound of general formula XVI. Examples of such nucleophiles (Nu) are, but are not limited to, morpholine and l-mcthylpipcrazine. Examples of a compound synthesizcd according to the route described in scheme 5, are compounds 116 and 117.

Scheme 6

An alternative method for the synthesis of compounds of general formula VII, is via ester XVII as described in scheme 6. Reaction of XVII with amine V, for example in an organic solvent like CH2CI2 or THF in the presence of an organic base like for example

tricthylamïne or DIPEA, followcd by hydrolysis of the ester, for example with LiOH in THF/H₂0, followed by acidification, results in a compound of general formula Vil. A compound of general formula Vil, obtained via the route in scheme 2 or scheme 6, can be transformed to and acid chloride of formula XIX, for example by treatement with 5 oxalyl chloride or thionyl chloride. A compound of general formula XIX can then be transformed to a compound of general Formula (I) by reaction with an aniline of general formula III.

A compound of general formula VI can be converted to a compound of general formula II, for example by treatement with oxalyl chloride in CH2CI2.

o

JL s (C,-C₃alkyl)—0 8 ''Ry

XXII

I (C|-C3alkyl)-O

O

---------►(C_rC₃alkyf)—O^B

(CpCjalkyl)—O

NH₂

XX

O

X

ΗΟ'Έ

XXI

XVII

XXV

XXIV

VI

J

HO'^B^'^S'^R?

XXIII

Scheme 7

Possible synthetic routes, for compounds of general formula XVII or VI are described in scheme 7, and further exemplificd in the experimental section. Chlorosulfonation of carboxylic acids XXI or carboxylic esters XX, can results in compounds ofgeneral formula VI or XVII respectively, for example by treatement with chlorosulfonic acid (for example as reviewed in Phosphores, Sulfur, and Silicon and the Related Eléments

VoL 56, Iss. 1-4,1991). Altematively, compounds of general formula XXV or XXIV, may be converted to compound of general formula XVII and VI respectively, by conversion to the corresponding diazonium salts (for example by NaNC^/HCI), followed by conversion of the diazonium sait to a sulfonyl chloride (for example by

-32SO₂/CuCl)(for example as described in Organic Process Research & Development, 13(5), 875-879; 2009). Altematively, compounds of general formula XXII and ΧΧΙΠ (with Rj equaling H, benzyl or methyl) may be converted to compound of general formula XVII and VI respectively, for example by treatement with Cl₂or N5 Chlorosuccinimide in AcOH/H₂O.

The subsitutents represented by R< in this general synthesis section are meant to inciude any substituent or reactive species that is suitable for transformation into any R< subsitutent according to the présent invention without undue burden for the person 10 skilled in the art.

Compounds not specifically described in the synthesis of compounds section below can be sysnthesized according to the Schemes 1-7 above and were commercially acquired.

Synthesis of compounds:

LC-MS methods:

Method A: mobile phase A : H₂O (O.I%TFA; B:CH₃CN (0.05% TFA) Stop Time :

min; gradient time(min) [%A/%B] 0.0 [100/0] to 1 [100/0] to 5 [40/60] to 7.5 [40/60] to 8.0 [100/0]; flow: 0.8 mL/min; column temp.: 50°C, YMC-PACK ODS-AQ, 50*2.0mm 5gm

Method B: mobile phase A : H₂O (0.1%TFA; B:CH₃CN (0.05% TFA) Stop Time : 10 min; gradient time(min) [%A/%B] 0.0 [90/10] to 0.8 [90/10] to 4.5 [20/80] to 7.5 [20/80] to 8.0 [90/10]; flow: 0.8 mL/min; cohimn temp.: 50°C, YMC-PACK ODS-AQ, 50^x2.0mm 5pm

Method C: mobile phase A : H₂O (0.1 % TFA); B:CH₃CN (0.05 % TFA) Stop Time : 10 min; gradient time(min) [%A/%B] 0.0 [90/10] to 0.8 [90/10] to 4.5 [20/80] to 7.5 [20/80]; 9.5 [90/10] flow: 0.8 mL/min; column temp.: 50°C; Agilent TC-C18, 50*2.Imm, 5pm

Method D: mobile phase A : H₂O (0.05 % NHj.H₂O ); B: CH₃CN Stop Time : 10 min; gradient time(min) [%A/%B] 0.0 [100/0] to 1 [100/0] to 5 [40/60] to 7.5 [40/60]; 8 [100/0] flow: 0.8 mL/min; column temp.: 40 °C, XBridge Shield-RPI8,50*2.Imm 5pm

Method E: mobile phase A : H₂O (0.1%TFA; B:CH₃CN (0.05% TFA) Stop Time : 10 min; Post Time: 0.5 min; gradient tïme(min) [%A/%B]0 [100/0] to I [100/0] to 5

-33[40/60] to 7.5 [15/85] to 9.5 [100/0]; flow: 0.8 mL/min; column tcmp.: 50°C, Agilent TC-C18,50*2.lmm, 5pm

Method F: The LC measurement was performed using an Acquity UPLC (Waters) System with column heater (set at 55 °C). Reversed phase UPLC (Ultra Performance Liquid Chromatography) was carried out on a bridged ethylsiloxane/silica hybrid (BEH) C18 column (1.7 pm, 2.1 x 50 mm; Waters Acquity) with a flow rate of 0.8 mL/min. Two mobile phases (10 mM ammonium acetate in H₂0/acctonitrile 95/5; mobile phase B: acetonitrile) were used to run a gradient condition from 95 % A and 5 % B to 5 % A and 95 % B in 1.3 minutes and hold for 0.3 minutes. An injection volume of 0.5 μΐ was used. Cône voltage was 10 V for positive ionization mode and 20 V for négative ionization mode.

Method G: The LC measurement was performed using an Acquity UPLC (Waters) with column heater (set at 55 °C). Reversed phase UPLC (Ultra Performance Liquid Chromatography) was carried out on a Acquity UPLC HSS T3 column (1.8 μτη, 2.1 x 100 mm; Waters Acquity) with a flow rate of 0.8 mL/min. Two mobile phases (A: 10 mM ammonium acetate in H₂O/acetonitrile 95/5; mobile phase B: acetonitrile) were used to run a gradient condition from 100 % A and 0 % B to 5 % A and 95 % B in 2.1 minutes and subsequently to 0 % A and 100 % B in 0.9 minutes to 5% A and 95% B in 0.5 min. An injection volume of 1 μΐ was used. Cône voltage was 30 V for positive ionization mode and 30 V for négative ionization mode.

Method H: Reversed phase HPLC was carried out on an Atlantis Cl8 column (3.5 pm, 4.6 x 100 mm) with a flow rate of 1.6 mL/mtn. Column heater was set at 45 °C. Two mobile phases (mobile phase A: 70 % methanol + 30 % H₂O; mobile phase B: 0.1 % formic acid in H₂O/methanol 95/5) were employed to run a gradient condition from 100 % B to 5 % B + 95 % A in 9 minutes and hold these conditions for 3 minutes. An injection volume of 10 pl was used. Cône voltage was 10 V for positive ionization mode and 20 V for négative ionization mode.

Compounds 21,49-55,57-62 were purchased from Aurora Fine Chemicals.

O.

Compound 1

-343-(chlorosulfonyl)benzoyl chloride (207 mg, 1 mmol) was dissolved in dichloromethane (3 mL) and 4-fluoroanîline (111 mg, 1.0 mmol) and triethylamine (112 mg, l.Ommol) in dichlorométhane (2 mL) were added to the mixture at 0°C. The mixture was next stirred at 20°C for 1 hour. To this reaction mixture containing 3-(4-fluorophenylcarbamoyl)benzene- 1-sulfonyl chloride at 0°C, a solution of triethylamine (121 mg, 1.2 mmol) and 4-aminotetrahydropyran (88 mg, 0.861 mmol) in dichloromethane (3 mL) was added. The mixture was stirred at 20°C for I hour. The solvent was removed in vacuo. The residue was purified by high performance liquid chromatography (Column: Phenomcnex Syncrgi C18 150*20mm*5um. A: H2O+0.1 %TFA; B: MeCN)· The product fractions were collected and the organic solvent was evaporated. The fraction was neutralized by saturated NaHCOj. The mixture was extracted with dichlorométhane. The organic layer was dried over Na2SOi and concentrated resultîng in compound 1 (85.4 mg) Method A; Rt: 4.88 min. m/z :

379.2 (M+H)⁺ Exact mass: 378.1

Following compounds were prepared similarly as compound 1 using the corresponding amines instcad of 4-aminotetrahydropyran:

Compound

Method B; Rt: 4.27 min. m/z : 363.1 (M+H)⁺ Exact mass: 362.1

Compound 3

Method A; Rt: 4.64 min. m/z : 351.1 (M+H)⁺ Exact mass: 350.1

Compound 4

Method A; Rt: 4.87 min. m/z : 365.1 (M+H)⁺ Exact mass: 364.1

-35Compound 5

Method A; Rt: 5.32 min. m/z : 349.1 (M+H)⁺ Exact mass: 348.1

Compound 79

Method A; Rt: 5.39 min. m/z : 3652 (M+H)⁺ Exact mass: 364.1 ’H NMR (400 MHz, CHLOROFORM-<0 δ ppm 8.37 (1 H, t, >1.5 Hz), 8.16 (1 H, br. s.), 8.11 (1 H, dm, >8.0 Hz), 8.05 (1 H, dm, >8.0 Hz), 7.57 - 7.70 (3 H, m), 7.08 (2 H, t, >8.7 Hz), 4.78 (1 H, s), 1.55 (2 H, q, >7.5 Hz), 1.18 (6 H, s), 0.84 (3 H, t, >7.5 Hz).

Compound 83

Method A; Rt: 4.20 min. m/z : 415.0 (M+Na)⁺ Exact mass: 392.1;

Purified by silica gel chromatography (gradient eluent: petroleum ether/ethyl acetate from 100/1 to 1/1). ’H NMR (400 MHz, DMSO-</₆) δ ppm 10.57 (1 H, br. s), 8.33 8.47 (1 H, m), 8.19 (1 H, dm, >7.5 Hz), 8.06 (1 H, dm, >7.5 Hz), 7.72 - 7.85 (3 H, m), 7.66 - 7.73 (1 H, br. s), 7.12-7.31 (2 H, m), 3.42 - 3.58 (4 H, m), 1.71-1.92 (2 H, m), 1.27 - 1.50 (2 H, m), 1.06 (3 H, s).

Compound 87

Method B; Rt: 3.94 min. m/z : 363.1 (M+H)⁺ Exact mass: 362.1

Purified by high performance liquid chromatography over RP-18 (eluent: CHjCN in water (0.1%TFA) from 25 to 55, v/v). ’H NMR (400 MHz, DMSO-di), δ ppm 0.340.42 (m, 2 H), 0.46-0.54 (m, 2H), 0.75(t,>7.3 Hz, 3 H), 1.28 (q, >7.3 Hz, 2 H), 7.15-

7.25 (m,2 H) 7.67-7.83 (m, 3 H), 7.97 (d, >8.3 Hz; 1 H), 8.14-8.25 (m, 2 H), 8.33 (s, 1 H), 10.55 (s, 1 H).

Compound 89

Method E; Rt: 4.83 min. m/z : 379.1 (M+H)⁺ Exact mass: 378.1; ^lH NMR (400 MHz, DMSO-d6), δ ppm 10,60 (s, IH), 8.48 (br. s., IH), 8.39 (s, IH), 8.23 (d, >7.8 Hz, 1 H), 8.04 (d, >7.8 Hz, 1 H), 7.74-7.87 (m, 3 H), 7.23 (t, >9.0 Hz, 2 H), 4.5l(d, >

6.5 Hz, 2 H), 4.20(d, >6.5 Hz, 2 H), 1.84 (q, >7.3 Hz, 2 H), 0.64(t, >7.3 Hz, 3 H). Prepared similarly as described for compound 1, using 3-ethyloxetan-3-amine instead of 4-aminotetrahydropyran. Synthesis of 3-ethyloxetan-3-amine: 3-ethyloxetane-3carboxylic acid (3.0g, 23.1 mmol), DPPA (Diphenylphosphoryl azide, 7.61 g,

27.7 mmol), triethylamine (3.0 g, 23.1 mmol) and BnOH (2.99 g, 27.7 mmol) were dissolved in toluene (50 mL). The mixture was stirred at 110°C ovemight. The solvent was removed in vacuo. Dichloromethane (50 mL) was added. The mixture was washed with IN HCl (20 mL). The aqueous layer was extracted with dichloromethane (20 mL). The combined organic layers were washed with brine and dried over Na₂SO₄. The solvent was removed in vacuo. The residue was purified by column chromatography over silica gel (eluent: petroleum ether / ethyl acetate from 100/1 to 60/40) resulting in benzyl 3-ethyloxetan-3-ylcarbamatc (4.0 g). To a solution of benzyl 3-ethyloxetan-3-ylcarbamate (2.0g, 8.5mmol) and cyclohexa-1,4-diene (1.02 g, 12.75 mmol) in MeOH (20 mL) was added Pd-C ( 10%, 0.2 g) under N₂. The mixture was stirred under H₂balloon at 25°C for 4 hours. After filtration, the filtratc was concentrated resulting in 3-ethyloxetan-3-amine (860 mg), which was used as such in the next reaction.

Synthesis of compound 6:

Compound 6

To a solution of 3-(chlorosulfonyl)benzoic acid (1 g, 4.53 mmol) in CH₂CI₂ (20 mL) at 5°C, cyclohexanamine (0.899 g, 9.06 mmol) and triethylamine (1.38 g, 13.60 mmol) were successively added drop wise.The solution was stirred at room température ovemight. The mixture was washed with 1N HCl (50 mL). The organic phase was dried over MgSO₄ and concentrated resulting in 3-(N-cycIohexylsulfamoyl)benzoic acid as a white solid (1.2 g), which was used in the next step without purification. To a solution of 3-(N-cyclohexylsulfamoyl)benzoic acid (1.2 g, 4.24 mmol) in DMF

-37(15 mL) at 5°C, 4-fluoroamlme (0.52 g, 4.66 mmol) and DIPEA (1.64 g, 12.71 mmol) were successively added.. The mixture was stirred for 20 minutes and then HATU (1.93 g, 5.08 mmol) was added. The solution was stirred at room température overnight. To the réaction mixture aqueous NaHCOj (50 mL) was added foliowed by EtOAc (50 mL). The organic layer washed with HCl (5%; 50 mL) and brine. The organic layer was dried with MgSCL and concentrated, resulting in a residue. The obtained residue was purified by a silica gel chromatography coiumn (Petroleum ether;EtOAc=2:l) resulting in compound 6 as a white solid (850 mg). Method B; Rt:

4.50 min. m/z : 3112 (M+H)⁺ Exact mass: 376.1

Synthesis of compound 7

Compound 7

To 5-(chlorosulfonyl)-2-fluorobenzoic acid (10 g, 41.91 mmol) in EtOAc (150 mL) cyclohexanamine (12.47 g, 125.72 mmol) was added at room température. The reaction mixture was stirred at room température for 10 minutes and washed with IN HCl ( 100 mL). The organic phase was dried over MgSO₄ and concentrated resulting in 5-(N-cyclohexylsulfamoyl)-2-fluorobenzoic acid as a white solid (10.9 g), which was used in the next steps without further purification. To a solution of 5-(N-cyclohexylsulfamoyl)-2-fluorobcnzoic acid (1 g, 3.32 mmol) in DMF (15 mL) 3-(trifluoromethyl)anilinc (0.54 g, 3.32 mmol) and DIPEA (1.29 g, 9,96 mmol) were successively added at 5°C. The mixture was stirred for 20 minutes and then HATU ( 1.51 g, 3.98 mmol) was added. The solution was stirred at room température overnight. To the reaction mixture aqueous NaHCOj (50 mL), was added followed by EtOAc (50 mL). The organic layer was washed with HCl (5%) and brine. The organic layer was dried with MgSO₄, concentrated in vacuo, and the obtained residue was purified by préparative HPLC resulting in compound 7 (902 mg) as a white solid. Method B; Rt: 4.85 min. m/z :

445.2 (M+H)⁺ Exact mass: 444.1; ’H NMR (400 MHz, DMSO-î/₆) δ ppm 10.94 (1 H, br. s), 8.15 - 8.22 (1 H, m), 8.12 (1 H, dd, >6.5,2.5 Hz), 8.03 (1 H, ddd, >9.0,4.5,

2.5 Hz), 7.88 - 7.97 (1 H, m), 7.83 (1 H, d,>7.5 Hz), 7.58 - 7.67 (2 H, m), 7.46 - 7.54 (1 H, m), 2.90 - 3.07 (1 H, m), 1.51 -1.67 (4 H, m), 1.38 -1.51 (1 H, m), 0.96 -1.27 (5 H, m)

Examples of compounds prepared similar as compound 7, using the corresponding anilines instead of 3-(trifluoromethyl)aniline:

-38Compound 18

‘H NMR (400 MHz, DMSO-ds) δ ppm 10.68 (1 H, br. s), 8.08 (1 H, dd, >6.0,2.5 Hz), 8.01 (1 H, ddd, > 8.5,4.5,2.5 Hz), 7.83 (1 H, br. s), 7.70 - 7.77 (2 H, m), 7.60 (1 H, app. t, > 9.0 Hz), 7.18 - 7.27 (2H, m), 2.90 - 3.07 (1 H, m), 1.53 - 1.67 (4 H, m), 1.40 -

1.53 (1 H, m), 0.96 - 1.25 (5 H, m). Method C; Rt: 4,21 min. m/z : 395.1 (M+H)⁺Exact mass: 394.1

Compound 43

Cl

Method C; Rt: 4.53 min. m/z :411.1 (M+H)⁺ Exact mass: 410.1

To a solution of (/?)-tctrahydrofuran-3-amine (0.87 g, 9.97 mmol) in THF (20 mL) aqueous sodium hydroxide was added (4 mL, 5 N) in ice bath followed by 3-(chlorosulfonyl)benzoic acid (2.2 g, 9.97 mmol). After stirring at 25°C for 3 hours, the réaction mixture was diluted with H₂O (20 mL) and extracted with EtOAc (20 mL). The aqueous layer was adjusted to pH=3 by aq. HCl (2 N) and then the resulting mixture was extracted with EtOAc (3 x 20 mL). The combined organic layer was washed by brine, dried over anhydrous MgSO₄ and concentrated in vacuo resulting in

-39compound (Æ)-3-(N-(tetrahydrofûran-3-yl)sulfamoyl)benzoic acid (900 mg). To a solution of compound (Æ)-3-(N-(tetrahydrofûran-3-yl)sulfamoyl)benzoic acid (0.80 g,

2.95 mmol), 4-fluoroaniline (0.39g, 3.54 mmol), and HATU (3.36 g, 8.85 mmol) în CH₂Cb (10 mL) cooled in an ice bath under N₂ atmosphère,DIPEA (0.57g, 0.44 mmol) was added. The resulting mixture was diluted with CH2CI2 (15 mL) and washed with saturated aqueous NaHCOj (15 mL) and brine (10 mL). After drying over anhydrous MgSO₄ the solvent was removed in vacuo. The obtained residue was purified by préparative high performance liquid chromatography over RP-18 (eluent: CH3CN în H2O: from 40% to 80%, v/v; 0.05% TFA as addition). The pure fractions were collected and the volatiles were removed in vacuo. The aqueous layer was adjusted to PH=7 with Amberlite IRA-900 ion exchange resin (OH form), filtrated and lyophilized. The obtained residue was further purified by prep. SFC (Column:Chiralpak AD-3 150><4.6mm I.D., 3um Mobile phase: 40% of methanol (0.05% diethylamine) in CO₂. Flow rate: 2.5 mL/min) resulting in compound 8 (370 mg) Method A; Rt: 4.6 min. m/z : 365.2 (M+H)* Exact mass: 364.1; [«]□ — 13.60 (c=0.11, MeOH)¹ H NMR (400 MHz, DMSO-i/e) S ppm 10.57 (1 H, br. s), 8.34 - 8.40 (1 H, m), 8.18 - 8.27 (1 H, m), 8.09 (l H, br. s), 7.99 - 8.06 (I H, m), 7.74 - 7.84 (3 H. m), 7.13 - 7.33 (2 H, m),

3.64 - 3.83 (2 H, m), 3.50 - 3.64 (2 H, m), 3.35 - 3.39 (1 H, m), 1.80 -1.99 (1 H, m), 1.51-1.68(1 H.m).

Compound 9

To an iced-cooled mixture of (S)-tetrahydrofùran-3-amine hydrochloride (0.500 g,

4.41 mmol) and NaOH (0.485 g, 12.138 mmol) in H₂O (5 mL) and THF (5 mL) 3-(chlorosulfonyl)benzoic acid (0.893 g, 4.406 mmol) was added in several portions. Then, the reaction mixture was stirred at 20°C for 2 hours. The resulting mixture was diluted with H₂O (10 mL) and extracted with ethyl acetate (10 mL). The pH value of aqueous layer was adjusted to 3 by adding IN HCl and then the mixture was extracted with ethyl acetate (3x10 mL). The combined organic layer was washed by brine (10 mL), dried over anhydrous Na2SO₄ and concentrated under reduced pressure resulting in (S)-3-(N-(tetrahydrofùran-3-yl)sulfamoyl)benzoic acid (0.60 g). To an ice cooled mixture of (5)-3-(N-(tctrahydrofuran-3-yl)sulfamoyl)benzoic acid (600 mg, 2.212 mmol),4-fluoroanilinc(270mg,2.433mmol) andHATU(1.01 g, 2.654mmol) in DMF (5 mL) DIPEA (1.15 mL, 6.636 mmol) was added under N2 atmosphère. The resulting mixture was stirred at 20°C for 2 hour. The solvent was removed in vacuo.

The mixture was washed with saturated aqueous cntic acid (10 mL), brine and dried over NaîSCU The solvent was removed in vacuo. The residue was purified by column chromatography over silica gel (gradient eluent: petroleum ether/ethyl acetate from 100/0 to 10/90). The pure fractions were collected and the solvent was removed in vacuo. The residue was further purified by préparative high performance liquid chromatography over RP-18 (eluent: CH₃CN in H_ZO from 40% to 80%, v/v; 0.06% NHjHCOj as addition). The pure fractions were collected and the volatiles were removed in vacuo. The aqueous layer was lyophilized to dryness resulting in compound (0.48 g) Method A; Rt: 4.6 min. m/z : 365.2 (M+H)⁺ Exact mass: 364.1 ;[«]“= +15.56 (c 0.10, MeOH); ^lH NMR(400 MHz, 80°C, DMSO-c/s) δ ppm 10.35 (l H, br. s), 8.32 -

8.48 (1 H, m), 8.15 - 8.32 (1 H, m), 8.03 (1 H, br. s), 7.83 - 7.94 (1 H, m), 7.68 - 7.83 (3 H, m), 7.06 - 7.31 (2 H, m), 3.70 - 3.87 (2 H, m), 3.51 - 3.70 (2 H, m), 3.32 - 3.48 (1 H, m), 1.85 - 2.04 (1 H, m), 1.59 - 1.78 (1 H, m)

Compounds prepared similarly as described for compound 8 and 9 from the corresponding amines instead of tetrahydrofuran-3-amine :

Compound 10

Method B; Rt: 4.24 min. m/z : 365.2 (M+H)* Exact mass: 364.1;

Compound 76

Using 1-mcthylcyclopentanamine instead of tetrahydrofuran-3-amine, purified using Gemini 250*20mm*5um (eluent: CH₃CN in H2O (0.1% TFA) from 40% to 70%, v/v).Method B; Rt: 4.24 min. m/z : 377.2 (M+H)* Exact mass: 376.1;

Synthesis of 3-(N-cyclopentylsulfamoyl)benzoic acid:

To an iced-cooled mixture of cyclopentanamine (1.93 g, 22.66 mmol) and a solution of NaOH (1.81 g, 45.32 mmol) in H₂O (25 mL) and THF (25 mL) was added 3-(chlorosulfonyl)benzoic acid (5.0 g, 22.66 mmol) in portions. The reaction mixture was stirred at 20°C for 2 hours. The resulting mixture was diluted with H_ZO (20 mL) and extracted with ethyl acetate (30 mL). The aqueous layer was separated and adjusted pH =2 by 4 N HCl and extracted with dichloromethane (3 x 30 mL). The combined organic layer

-41was washed by brine (15 mL), dned over anhydrous NaîSO₄ and concentrated under reduced pressure to afford 3-(N-cyclopentylsulfamoyl)benzoic acid (4.5 g).

Compound 11

To an ice cooled mixture of 3-(N-cyclopentylsulfamoyI)benzoic acid (250 mg, 0.928 mmol), 4-fluoro-3-methylaniline (116.2 mg, 0.928 mmol), HATU (388.2 mg, 1.021 mmol) in CH2CI2 (15 mL) DIPEA (359.8 mg, 2.784 mmol) was added under a N2 atmosphère. The resulting mixture was stirred at 20°C for 16 hours. The solvent was removed in vacuo. The mixture was washed with saturated aqueous cri tic acid (10 mL), brine and dried over Na2SO₄. The solvent was removed in vacuo. The residue was purified by column chromatography over silica gel (gradient eluent: petroleum cther/ethyl acetate from 100/0 to 10/90). The pure fractions were collected and the solvent was removed in vacuo. The residue was further purified by préparative high performance Iiquid chromatography over RP-18 (eluent: CHjCN in H2O from 45% to 75%, v/v; 0.01% HCl as addition). The pure fractions were collected and the volatiles were removed in vacuo. The aqueous layer was adjusted to Ph=7 with Amberlite IRA900 ion exchange resin (OH form), filtrated and lyophilized to dryness to afford compound 11 (170.0 mg). Method B; Rt: 4.31 min. m/z : 377.2 (M+H)* Exact mass:

376.1; ^lH NMR (400 MHz, DMSO-/5) 5 ppm 10.47 (1 H, br. s), 8.33-8.35 (1 H, m),

8.17 (1 H, dm,/=8.0), 7.98 (1 H, dm,/=8.0), 7.78 (I H, d,/=7.0 Hz), 7.74 (1 H, t, /=8.0 Hz), 7.62 - 7.68 (1 H, m), 7.53 - 7.61 (1 H, m), 7.13 (1 H, t, /=9.0 Hz), 3.37 -

3.48 (1 H, m), 2.23 (3 H, d,/=1.8 Hz), 1.44 - 1.69 (4 H, m), 1.12 -1.45 (4 H, m)

Prepared similarly as compound 11 starting from the corresponding anilines instead of

4-fluoro-3-methylaniline :

Compound 12 ’H NMR (400 MHz, DMSO-t/e) 5 ppm 10.60 (1 H, bs), 8.36 (1 H, t,/=1.5 Hz), 8.19 (1 H, dm, /=7.5 Hz), 8.02 (1 H, dm, /=7.5 Hz), 7.81 (1 H, d, /=7.5 Hz), 7.78 (1 H, t, /=7.5 Hz), 7.55 (1 H, dm,/=11.0 Hz), 7.38 - 7.46 (1 H, m), 6.82 (1 H, dm,/=9.5 Hz),

3.41 - 3.54 (1 H, m), 2.34 (3 H, s), 1.45 - 1.70 (4 H, m), 1.19-1.45 (4 H, m); Method B; Rt: 4.41 min. m/z : 377.2 (M+H)* Exact mass: 376.1

Compound 13

The residue was purified by column chromatography over silica gel (gradient eluent: petroleum ether/ethyl acetate from 100/0 to 40/60). Method B; Rt: 4.41 min. m/z :

377.2 (M+H)* Exact mass: 376.1

Compound 14

Method B; Rt: 4.34 min. m/z : 381.2 (M+H)* Exact mass: 380.1 ’H NMR (400 MHz, DMSOA_e) δ ppm 1.20 - 1.44 (m, 4 H), 1.44 - 1.68 (m, 4 H), 3.44 (sxt, >6.8 Hz, 1 H), 7.45 (dt, J= 10.6,9.0 Hz, 1 H), 7.51 - 7.60 (m, 1 H), 7.77 (t,>7.8 Hz, 1 H), 7.80 (d, >7.2 Hz, 1 H), 7.93 (ddd, >13.2,7.5,2.5 Hz, 1 H), 8.02 (d, >7.8 Hz, 1 H), 8.19 (d, >7.7 Hz, 1 H), 8.35 (t, >1.7 Hz, 1 H), 10.70 (s, 1 H)

Method B; Rt: 4.43 min. m/z : 381.2 (M+H)* Exact mass: 380.1

Compound 77

Method B; Rt: 5.45 min. m/z : 363.2 (M+H)* Exact mass: 362.1

Compound 81 purified by préparative high performance liquid chromatography (column: Phenomenex Synergi 200mm*77mm, 1 Oum; mobile phase: CHjCN in water (0.1% TFA) from 45% to 75%,). Method A; Rt: 5.87 min. m/z : 413.2 (M+H)⁺ Exact mass: 412.1

Compound 16

A solution of 3-(N-cyclopentylsulfamoyl)bcnzoic acid (500 mg, 1.73 mmol) in oxalyl dichloride (10 mL) was stirred at 45°C for 5 hours. The solvent was removed in vacuo. The crude 3-(N-cyclopentylsulfamoyl)benzoyl chloride (600 mg) was used as such in the next step.To an ice cooled mixture of 3-(N-cyclopentylsulfamoyl)benzoyl chloride (600 mg, 1.74 mmol) and 4-amino-2-methylbenzonitrile (230 mg, 1.74 mmol) in CHiCh (5 mL) was added pyridine (10 mL) under N2 atmosphère. The resulting mixture was stirred at 20°C for 16 hours. The solvent was removed în vacuo. The residue was purified by préparative high performance liquid chromatography over RP-18 (eluent: CH3CN in H2O from 50% to 80%, v/v; 0.05% TFA as addition). The pure fractions were collected and the volatiles were removed in vacuo. The aqueous layer was adjusted to PH=7 with Amberlite IRA-900 ion exchange resin (OH form), filtrated and lyophilized resulting in compound 16 (250mg). Method B; Rt: 4.23 min. m/z : 384.2 (M+H)⁺ Exact mass: 383.1.

Compound 75

Prepared similarly as described for compound 16 using 3-aminobenzonitrile instead of

4-amino-2-mcthylbcnzonitrile. Method A; Rt: 5.24 min. m/z : 370.2 (M+H)⁺ Exact mass: 369.1.

Compound 80

Prepared similarly as described for compound 16 using 4-amÎnobenzonitrile instead of

4-amino-2-methylbenzonitrile. Method A; Rt: 5.32 min. m/z : 370.2 (M+H)⁺ Exact mass: 369.1.

Compound 82

Prepared similarly as described for compound 16 using 3-amino-5-methylbenzonitrile instead of 4-amino-2-mcthylbenzonitrile. Method A; Rt: 5.52 min. m/z : 384.2 (M+H)⁺Exact mass: 383.1. .

To a solution of compound 2,4-dichloro-5-(pipcridin-l-ylsulfonyl)benzoÎc acid (1.0 g,

2.96 mmol), m-toluidinc (0.38 g, 3.55 mmol), and HATU (1.69 g, 4.44 mmol) in CH2CI2 (10 mL) cooled in an ice bath, D1PEA (1.15g, 8.88 mmol) was added under N₂atmosphère. The resulting mixture was diluted with CH2CI2 (15 mL) and washed with saturated aqueous NaHCOj (15 mL) and brine (10 mL), dried over anhydrous MgSOi and the solvent was removed in vacuo. The residue was purified by column chromatography over silica gel (gradient eluent: petrolcum ether/ethyl acetate from 100/0 to 40/60). The pure fractions were collected and the solvent was removed in vacuo, resulting in compound 17 (0.65 g). Method B; Rt: 4.70 min. m/z : 427.1 (M+H)⁺Exact mass:426.1

Compound 46

To a solution of 3-(chlorosulfonyl)benzoic acid (1.10 g, 4.97 mmol) in THF (60mL) sodium hydroxide was added (aq., 2 mL, 5N) in ice bath followed by adding N-methyl

-45cyclopentanamme (0.50 g, 4.97 mmol). After stirring at 25°C for 3 hours, the reaction mixture was diluted with H2O (50mL) and extracted with EtOAc (50mL). The aqueous layer was adjusted to pH=3 by HCl (2N) and extracted with EtOAc (3 x 50mL). The combined organic layer was washed by brine, dried over anhydrous MgSO₄ and concentrated in vacuo resulting in 3-(N-cyclopentyl-N-methylsulfamoyl)benzoic acid (0.8 g). To a solution of 3-(N-cyclopentyl-N-methylsulfamoyl)benzoic acid (0.80 g,

2.82 mmol), 4-fluoroaniline (0.31 g, 2.82 mmol), and HATU (1.61 g, 4.24 mmol) in CH2C12 (10 mL), cooled in an icebath, DIPEA (L09 g, 8.47mmol) was added under N2 atmosphère. The resulting mixture was diluted with CH2CI2 (15 mL) and washed with saturated aqueous NaHCOj (15 mL) and brine (10 mL), dried over anhydrous MgSO₄and the solvent was removed in vacuo. The obtained residue was purified by préparative high performance liquid chromatography over RP-18 (eluent: CHjCN in H2O from 30% to 80%, v/v; 0.05% TFA as addition). The pure fractions were collected and the volatiles were removed in vacuo. The aqueous layer was adjusted to Ph=7 with Amberlite IRA-900 ion exchange resin (OH form), filtrated and lyophilized to dryness resulting in compound 46 (0.73g). Method B; Rt: 4.43 min. m/z : 377.2 (M+H)⁺ Exact mass:376.1

Compound 56 ^F

4-fluoroanîline (0.93 g, 8.366 mmol) and DIPEA (2.91 mL, 16.732 mmol) were dissolved in CH2CI2 (20 mL). 3-(chlorosutfonyt)benzoyl chloride (2 g, 8.366 mmol) in CH2CI2 (20 mL) was added in one portion at 0°C. The mixture was stirred for 1 hour at 0°C. The réaction mixture (40 mL) containing 3-(4-fluorophenylcarbamoyt)benzene-lsulfonyl chloride was used to the next step without further purification. Ammonia (2.52 g, 18 mmol, 25-28% wt) was added to a solution of 3-(4-fluorophenytcarbamoyl)benzene-l-sulfonyt chloride (obtained as above, 6 mmol) in CH2CI2 (30 mL) at 0°C. The mixture was stirred for 1 hour at 20°C. 1 N HCl (30 mL) was added to the reaction mixture and the volatiles were partely removed in vacuo. The formed precipitate was filtered and co-evaporated with toluene (10 mL), resulting in N-(4-fluorophenyl)-3sulfamoylbenzamide (L6 g). A solution ofN-(4-fluorophenyl)-3-sulfamoylbenzamide (1.8 g, 6.12 mmol) and cyclohexanecarbonyt chloride (1.79 g, 12.23 mmol) in chloroform (40 mL) with S1O2 (180 mg) and H2SO₄ (0.5 mL) was refluxed for 1 hour. Dichloromethane (20 mL) was added and the solid was filtered off. The filtrate was washed with water ( 10 mL) and dried over Na₂SO₄, The solvent was removed in vacuo. The obtained residue was purified by silica gel column chromatography (gradient cluent: petrolcum ether/ethyl acetate from 100/0 to 70/30). The obtained product (1.2 g, purity 95%) was further washed with methyl t-butyl ether (10 mL) resulting in compound 56 (500 mg, 99.7 % purity). Method A; Rt: 5.51 min. m/z : 405.2 (M+H)⁺Exact mass: 404.1; *H NMR (400 MHz, DMSO-</₆) δ ppm 12.16 (1 H, br. s), 10.62 (1 H, br. s), 8.41 (1 H, t, J=2.0 Hz), 8.27 (1 H, dm, >7.5 Hz), 8.09 (1 H, dm, >7.5 Hz),

7.73 - 7.82 (3 H, m), 7.07 - 7.33 (2 H, m), 2.11-2.31 (1 H, m), 1.43 - 1.80 (5 H, m), 0.94- 1.32 (5 H, m)

Compound 48

Compound 56 (600 mg) was dissolved in CH2CI2 (6 mL) and MeOH (2 mL) and TMSCHN₂ (3.7 mL, 7.415 mmol, 2M in hexane) were added drop wise at 20°C. The mixture was stirred for 2 hours at 20°C. The solvent was removed in vacuo. The residue was purified by flash column (gradient eluent: petroleum ether/ethyl acetate from 100/0 to 70/30) resulting in a residue (0.41 g). The obtained product was further purified by préparative high performance liquid chromatography over RP-18 (eluent: CHjCN in H₂O (0.1% TFA) from 20% to 50%, v/v). The pure fractions were collected and the volatiles were removed in vacuo. The precipitatc was filtered and the residual water was removed by lyophilization resulting in compound 48 (300 mg). Method B; Rt: 4.60 min. m/z : 419.2 (M+H)⁺ Exact mass:418.1; Ή NMR (400 MHz, DMSO-</₆) δ ppm 10.62 (1 H, br. s), 8.40 - 8.45 (1 H, m), 8.28 (1 H, dm, >7.5 Hz), 8.13 (1 H, dm, >7.5 Hz), 7.66 - 7.95 (3 H, m), 7.07 - 7.33 (2 H, m), 3.40 (3 H, s), 2.73 - 2.92 (1 H, m), 1.42 - 1.77 (5 H, m), 0.90 - 1.35 (5 H, m).

Compound 63

A mixture of ethyl 2-(chlorosulfonyl)-lH-imidazole-4-carboxylatc (1 g, 4.19 mmol), EtjN (1.27 g, 12.55 mmol) and cyclohexanamine (0.623 g, 6.28 mmol) in THF (25 mL) was stirred at room température for 15 hours. The mixture was concentrated and purified by préparative HPLC (Column: Cl8; Mobile phase A: purified water (0.075%TFA, V/V); Mobile phase B: acetonitrile; Flow rate: 80mL/min; Gradient:

-4725-55%, 30 min) resulting in ethyl 2-(N-cyclohcxylsulfamoyl)-lH-imidazolc-4carboxylate (0.6 g) as a light yellow solid. To a solution of ethyl 2-(N-cyclohexylsulfamoyl)-lH-imidazole-4-carboxylate (0.6 g, 1.99 mmol) in EtOH-HîO (3/1; 20 mL), LtOH (0.145 g, 6.055 mmol) was added. The mixture was stirred at room température for 15 hours. The réaction mixture was neutralized with HCl (2M), diluted with water and then extracted into EtOAc, dried over MgSOj, filtered and concentrated resulting in 2-(N-cyclohexylsulfamoyl)-lH-imidazolc-4-carboxylic acid (400 mg) as a white solid. A mixture of 2-(N-cyclohexylsuIfamoyl)-lH-imidazole-4-carboxylic acid (0.3 g, 1.098 mmol), aniline (0.102 g, 1,098 mmol), DIPEA (0.284 g, 2.196 mmol) and HATU (0.501 g, 1.317 mmol) in DMF (25 mL) was stirred at room température for 15 hours. The mixture was purified by préparative HPLC (Column: YMC 150x30mm.

Mobile phase A: purified water (0.075%TFA, V/V); Mobile phase B: acetonitrile; Flow rate: 30mL/min; Gradient: 40-70%, 8 min) resulting in compound 63 (218 mg). Method

B; Rt: 3.98 min. m/z : 349.2 (M+H)⁺ Exact mass:348.1. *H NMR (400 MHz, METHANOL·^) δ ppm 1.26 (s, 5 H) 1.51 -1.62 (m, 1 H) 1.65 - 1.80 (m, 4 H) 3.23 -

3.29 (m, 1 H) 7.10 - 7.18 (m, I H) 7.32 - 7.39 (m, 2 H) 7.67-7.74 (m, 2 H) 7.86 (s,

IH);

Compound 64

A mixture of ethyl 2-(chlorosulfonyl)thiazole-4-carboxylate (3 g, 11.73 mmol), EtjN (3.56 g, 35.2 mmol) and cyclohexanaminc (1.75 g, 17.65 mmol) in THF (100 mL) was stirred at room température for 15 hours. The mixture was concentrated and purified by préparative HPLC resulting in ethyl 2-(N-cyclohexylsulfamoyl)thiazolc-4-carboxylate (2 g) as a white solid. To a solution of ethyl 2-(N-cyclohexylsulfamoyl)thiazole-4carboxylate (2 g) in EtOH-THF (1/1,60 mL) was added LiOH (0.451 g, 18.83 mmol). The mixture was stirred at room température for 15 hours. The reaction mixture was neutralized with HCI (2M), diluted with water and then extracted into EtOAc, dried over MgSOj, filtered and concentrated in vacuo, resulting în 2-(N-cyclohexytsulfamoyl)thiazolc-4-carboxylic acid (1.7 g) as a white solid. A mixture of 2-(N-cyclohexylsulfamoyl)thiazolc-4-carboxylic acid (1 g), aniline (0.321 g, 3.44 mmol), DIPEA (1.33 g, 10.29 mmol) and HATU (1.57 g, 4.13 mmol) in DMF (40 mL) was stirred at room température for 15 hours. The mixture was concentrated and purified by préparative HPLC (Column: SYNERG1 250*50 lOum; Mobile phase A: purified water (0.075%TFA, V/V); Mobile phase B: acetonitrileFlow rate: 80 mL/min Gradient: 3517200

-4865%, 30min) resulting in compound 64 (895 mg) as a white solid. Method B; Rt: 4.45 min. m/z : 366.1 (M+H)⁺ Exact mass: 365.1

Compound 65

The mixture of 6-chIoro-N-phenylpicolinamide (4 g, 17.19 mmol), phenyl methanethiol (3.23g, 25.79 mmol) and K₂COj (4.75g, 34.38 mmol) in DMF was stirred at 80°C for 18 hour. The reaction mixture was diluted with EtOAc (150 mL), and washed with brine (2 x 200 mL). The organic layer was dried over MgSO₄, filtered and concentrated. The residue was purified by flash chromatography on silica gel (20% EtOAc in petroleum ether) to obtain 6-(benzylthio)-N-phenylpicolinamide (2.8 g). N-Chlorosuccinimide (3.42 g, 25.6 mmol) was added to the mixture of 6-(benzylthio)N-phenylpïcolinamide (2 g, 6.24 mmol) in acetic acid (60 mL) and water (40 mL). The reaction mixture was stirred at room température for 3 hours. The reaction was diluted with CH2CI2 ( 100 mL). After washing with water, the organic layer was added to the mixture of cyclohexanamine (12.4 g, 125 mmol) and EtjN (50 mL) in CH2CI2 (200 mL). The resulting mixture was stirred at room température for 4 hours. The reaction mixture was washed with NH4CI (saturated), brine, dried over MgSO₄, filtered and concentrated. The obtained residue was purified by préparative HPLC (Column: Synergi l50*30mm*5um; Mobile phase A: purified water (0.075%TFA, V/V); Mobile phase B: acetonitrilc; Flow rate: 30mL/min; Gradient: 46-76% (solvent B), 8min) resulting in compound 65 (330 mg). Method B; Rt: 4.46 min. m/z : 360.2 (M+H)⁺Exact mass: 359.1. *H NMR (400 MHz, DMSCM») δ ppm 1.00 - 1.31 (m, 5 H) 1,34 1.47 (m, 1 H) 1.51-1.71 (m, 4 H) 3.02 - 3.13 (m, 1 H) 7.15-721 (m, 1 H) 7.40-7.46 (tn, 2 H) 7.82 - 7.88 (m, 2 H) 8.15 (dd, >6.3,2.5 Hz, 1 H) 823 - 828 (m, 1 H) 8298.36 (m, 2 H) 10.47 (s, 1 H)

Compound 66

A mixture of 2-chloro-N-phenylisonÎcotinamide (2 g, 8.6 mmol), phenylmethanethiol (2.11 g, 17 mmol) and K2COj(2.35 g, 17 mmol) in DMF was stirred at 80°C for 18 hours. The reaction was diluted with water (200 mL) and extracted with EtOAc (2 x

100 mL). The combined organic layers were washed with brine, dried over MgSO₄,

-49filtered and concentrated. The obtained residue was purified by silica gel chromatography (0-20 % EtOAc in petroleum ether) resultîng in 2-(benzylthio)-N-phenylisonicotinamide (1.7 g). N-Chlorosuccinimidc (2.56 g, 19.2 mmol) was added to a mixture of 2-(benzylthio)-N-phcnyIisonicotïnamide (1.5 g, 4.68 mmol) in acetic acid (20 mL) and water ( 10 mL). The reaction mixture was stirred at room température for 4 hours. The reaction was diluted with CH₂C1₂ (20 mL). After washing with water, the organic layer was added to the mixture of cyclohexanamine (4.641g, 46.8 mmol) and EtjN (10 mL, 71.74 mmol) in CH2CI2 (50mL). The resultîng mixture was stirred at room température for 4 hours. The reaction mixture was washed with NH4CI (saturated), brine, dried over MgSOj, filtered and concentrated. The obtained residue was purified by préparative HPLC (Column: C18-10um; Mobile phase A: purified water (0.075%TFA, V/V); Mobile phase B: acetonitrile; Flow rate: 80mL/min; Gradient: 40-70% (solvent B), 25min) resultîng in compound 66 (250 mg). Method B; Rt: 4.22 min. m/z: 360.2 (M+H)⁺ Exact mass: 359.1. *H NMR (400 MHz, DMSO-</_e) δ ppm 0.96 - 1.08 (m, 1 H) 1.08 - 1.24 (m, 4 H) 1.40 - 1.52 (m, 1 H) 1.53 - 1.67 (m, 4 H) 3.11 - 3.22 (m, 1 H) 7.14 - 7.21 (m, 1 H) 7.37 - 7.44 (m, 2 H) 7.78 (d,>7.8 Hz, 2 H)

7.97 (br. s, 1 H) 8.12 (dd, >5.0, 1.5 Hz, 1 H) 8.40 (s, 1 H) 8.94 (d,>5.0 Hz, 1 H) 10.75 (s, 1 H)

Compound 67

2-chloro-N-cyclohexylpyridine-4-sulfonamidc (540 mg, 1.965 mmol), PdCl₂dppf (100 mg, 0.137 mmol) and EtjN (5.89 mmol) in methanol (50 mL) was stirred at 50°C for 18 hours under CO (50Psi) atmosphère. The solvent was removed under reduced pressure. The obtained residue (700 mg) containing methyl 4-(N-cyclohexylsulfamoyl)picolinate was used in the next step without further purification. K2COJ (421 mg, 3.05mmol) was added to the mixture of methyl 4-(N-cyclohexylsulfamoyl)picolÎnate in methanol and water. The mixture was stirred at 20°C for 18 hour. The solvent was removed, the residue was diluted with water (50 mL) and washed with EtOAc (2 x 50 mL). The aqueous layer was then acidified to pH = 3 with 1 M HCl and extracted with EtOAc (2 x 50mL). The combined organic layers were dried over MgSOj, filtered and concentrated resultîng in 4-(N-cyclohexylsulfamoyl)picolinic acid (380 mg). HATU (0.76 g, 2.0 mmol) was then added to a mixture of 4-(N-cyclohexylsulfamoyl)picolinic acid (380 mg, 1.34 mmol), aniline (251 mg, 2.7 mmol) and D1PEA (0.517 g, 4.0 mmol) in DMF (50 mL) at room température The resultîng mixture was stirred at

-50room température for 18 hour. The mixture was diluted with water (200 mL), and extracted with EtOAc. The organic layers were washed with brine, dried over MgSO₄, filtered and concentrated in vacuo. The obtained residue was purified by silica gel chromatography (10-20% EtOAc in petroleum ether) resulting in compound 67 as a white solid (330 mg). Method B; Rt: 4.58 min. m/z : 360.2 (M+H)⁺ Exact mass: 359.1. ‘H NMR (300 MHz, DMSO-</₆) 5 ppm 0.93 - 1.26 (m, 5 H) 1.37 - 1.50 (m, 1 H) 1.50 -

1.69 (m, 4 H) 2.98-3,12 (m, 1 H) 7.15 (t, >7.2 Hz, 1 H) 7.32-7.45 (m, 2 H) 7.86-7.97 (m, 2 H) 8.03 (dd,>5.0,1.5 Hz, 1 H) 8.25 (d,>7.3 Hz, 1 H) 8.47 (d, >1.5 Hz, 1 H) 9.00 (d,>5.0 Hz, 1 H) 10.78 (s, 1 H)

Compound 68

Thionyl chloride (10 mL, 137 mmol) was added drop wise to water (60 mL) at 0-5°C. The mixture was stiired at room température for 16 hour. CuCl (40 mg, 0.4 mmol) was added, and the mixture (mixture A) was cooled to -5°C. To a mixture of 5-aminonicotinic acid in con. HCl (35 mL), a solution of NaNO₂ (2.76g, 40 mmol) in of water (40 mL) at -5°C to 0°C, was added (mixture B). The mixture B was added portionwise to the mixture A over 30 minutes, maintaining température at -5°C to 0°C.After stirring at 0°C for 1 hour, the solid was collected by filtration, washed with water, and dried in vacuo resulting in 5-(chlorosulfonyl)nicotinic acid (1.05 g). The mixture of

5-(chlorosulfonyl)nicotinic acid (1 g, 4.5 mmol), cyclohexanamine (0.893g, 9 mmol) and EtjN (1.37 mmol, 13.5 mmol) in CH₂Cl₂(30 mL) was stiired at room température for 18 hours. The solvent was removed under reduced pressure. The residue was purified by HPLC (Coiumn: C18 lOum; Mobile phase A: purified water (0.075%TFA, V/V); Mobile phase B: acetonitrile; Flow rate: 80mL/min; Gradient: 30-60% (solvent B), 30 min) resulting in 5-(N-cyclohexylsulfamoyl)nicotinic acid as a white solid (1 g). HATU (2.6g, 7mmol) was added to the mixture of 5-(N-cyclohexylsulfamoyl)nicotinic acid (1 g, 3.5 mmol), aniline (391 mg, 4.2 mmol) and DIPEA (1.36 g, 10.5 mmol) in DMF (50 mL) at room température The resulting mixture was stirred at room température for 18 hour. The mixture was diluted with of water (200 mL) and extracted with EtOAc. The organic layers were washed with brine, dried over MgSO₄, filtered and concentrated. The residue was purified by silica gel chromatography (10-100% EtOAc in petroleum ether) resulting in compound 68 (708 mg) as white solid. Method B; Rt: 4.58 min. m/z : 360.2 (M+H)⁺ Exact mass: 359.1

To an ice-cooled solution of 5-aminopentanoic acid (1.2 g, 3.44 mmol) and IN NaOH (8 mL) in THF (16 mL) was added 3-(4-fiuorophenylcarbamoyl)benzene-l-sulfonyl chloride (0.444 g, 3.78mmol). Then the reaction mixture was stirred at 25°C ovemight. The resulting mixture was diluted with IN HCl (10 mL) and extracted with ethyl acetate (2 x 30 mL). The combined organic layers were washed with brine, dried over anhydrous Na₂SOi and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (gradient eluent: petroleum ether: ethyl acetate: from 100:0 to 65:35) resulting in 5-(3-(4-fluorophenylcarbamoyl)phenylsulfonamido) pentanoîc acid (0.9 g). A mixture of 5-(3-(4-fluorophenylcarbamoyl)phenylsulfonamido) pentanoîc acid (400 mg, 0.913 mmol), acetic anhydride (0.466 g, 4.57 mmol) and AcOK (1.79 g, 18.3 mmol) in toluene (25 mL) was heated by microwave irradiation at 150°C for 30 minutes. The formed precipitate was fîltered off and the filtrate was concentrated in vacuo. The residue was purified by préparative high performance liquid chromatography (eluent: CHaCN in H₂O (0.05% HCl) from0% to 35%, v/v). The pure fractions were collected and adjusted to pH=7 with Amberlite lRA-900(OH)anionic exchange resin. The resin was fîltered off and the filtrate was lyophilized to dryness resulting in compound 69 (200 mg). Method A; Rt: 4.97 min. m/z : 377.2 (M+H)⁺ Exact mass: 376.1; 'H NMR (400 MHz, CHLOROFORMA) δ ppm 1.78 - 1.87 (m, 2 H), 1.90 -1.99 (m, 2 H), 2.44 (ζ >6.8 Hz, 2 H), 3.95 (t, >6.0 Hz, 2 H), 7.08 (t, >8.7 Hz, 2 H), 7.55 - 7.70 (m, 3 H), 8.15 (d, >8.0 Hz, 1 H), 8.20 (d, >7.8 Hz, 1 H), 8.26 (br. s., 1 H), 8.49 (s, 1 H)

Compound 70

To an iced-cooled mixture of (R)-butan-2-amine (0.500 g, 6.837 mmol) and NaOH (0.547 g, 13.67 mmol) in H₂O (15 mL) and THF (15 mL), 3-(chlorosulfonyl)benzoîc acid was added (1.508 g, 6.84 mmol) in portions. The reaction mixture was stirred at 20°C for 2 hours. The resulting mixture was diluted with H₂O (15 mL) and extracted with ethyl acetate (15 mL). The aqueous layer was separated and pH was adjusted to 3 by 1 N HCl and extracted with ethyl acetate (3x10 mL). The combined organic layer

-52was washed by brine (10 mL), dried over anhydrous Na₂SO₄ and concentrated under reduced pressure resulting in (R)-3-(N-sec-butylsulfamoyl)benzoic acid (0.73 g). To an ice cooled mixture of (R)-3-(N-sec-butylsulfamoyl)benzoÎc acid (730 mg),

4-fIuoroaniline (347mg, 3.12Immol), HATU (1.294 g, 3.404 mmol) in DMF (10 mL) DIPEA (1.48 mL, 8.51 mmol) was added under N₂ atmosphère. The resulting mixture was stirred at 20°C for 2 hour. The solvent was removed in vacuo. The mixture was washed with saturated aqueous critic acid (10 mL), brine and dried over Na₂SO₄. The solvent was removed in vacuo, The residue was purified by column chromatography over silica gel (gradient eluent: petroleum ether/ethyl acetate from 100/0 to 55/45). The pure fractions were collected and the solvent was removed in vacuo. The residue was purified by SFC séparation (Chiralcel OJ, 20 pm; Supercritical CO₂ : MeOH (0.2% diethylamine)). The pure fractions were collected and the solvent was removed in vacuo, resulting in compound 70 (300 mg). Method A; Rt: 5.25 min. m/z : 351.2 (M+H)⁺ Exact mass: 350.1. [«]”= - ( c= 0.2, MeOH). [a]o = -9.9 (c 0.435 w/v%, DMF); Column: Chiralpak AD-3 150*4.6tnm I.D., 3um; Mobile phase: methanol (0.05% diethylamine) in CO₂ from 5% to 40%; Flow rate: 2.5 mL/min; Rt: 7.58 min; ’H NMR (400 MHz, DMSO-ifc) δ ppm 0.70 (t, >7.4 Hz, 3 H), 0.88 (d, >6.5 Hz, 3 H),

1.30 (quin, >7.2 Hz, 2 H), 3.01 - 3.18 (m, 1 H), 7.21 (t, >8.8 Hz, 2 H), 7.67 (br. d, >5.5 Hz, 1 H), 7.75 (t, >7.8 Hz, 1 H), 7.78 (dd, >8.8, 5.1 Hz, 2 H), 8.00 (d,>7.8 Hz, 1 H), 8.19 (d, >7.8 Hz, 1 H), 8.36 (s, 1 H), 10.55 (s, 1 H).

Compound 71

Prepared similar as described for compound 70 starting from (S)-butan-2 -amine instead of (/?)-butan-2-amine.Method B; Rt: 4.03 min. m/z : 351.2 (M+H)⁺ Exact mass: 350.1 ([α]“ = + ( c= 02, MeOH). [a]” = + 9.49 (c 0.611 w/v %, DMF), Column: Chiralpak AD-3 150^x4.6mm I.D., 3um; Mobile phase: methanol (0.05% diethylamine) in CO₂from 5% to 40%; Flow rate: 2.5 mL/min; Rt: 7.73 min. [a]S» +9.49 ’ (c 0.61 w/v %, MeOH)

Compound 72

-533-(chlorosulfonyl)benzoyl chloride (1200mg, 5.0 mmol) was dissolved in dichloromethane (15 mL). A solution of 4-fluoro-3-methylaniline (625 mg, 5.0 mmol) and triethylamine (606 mg, 6.0 mmol) in dichloromethane ( 15 mL) was added to the mixture at 0°C. The mixture was stirred at 25°C for 1 hour. The réaction mixture was used to the next step without fùrther purification. To the above reaction mixture a solution of triethylamine (606 mg, 6.0 mmol) and (S)-tetrahydrofùran-3-amine (460.0 mg, 5.3 mmol) in dichloromethane (15 mL) was added at 0°C. The mixture was stirred at 25°C for 1 hour. The solvent was removed in vacuo. The residue was purified by reversed phase high performance liquid chromatography (eluent: CHjCN in water (0.1% TFA) from 25 to 55, v/v). The pure fractions were collected and the organic solvent was evaporated. The aqueous layer was neutralized with saturated aqueous NaHCOj to pH=7-8. The mixture was extracted with dichloromethane (3x15 mL). The combined organic layers were dried over Na₂SO₄ and concentrated in vacuo resulting in compound 72 (620 mg). Method A; Rt: 4.88 min. m/z : 379.2 (M+H)⁺

Exact mass: 378.1. ‘H NMR (400 MHz, DMS(W₆) δ ppm 1.56 - 1.65 (m, 1 H), 1.85 1.94 (m, 1 H), 2.22 - 2.28 (m, 3 H), 3.33 - 3.39 (m, 1 H), 3.52 - 3.65 (m, 2 H), 3.65 3.73 (m, 1 H), 3.73 - 3.79 (m, 1 H), 7.14 (t,>9.2 Hz, 1 H), 7.56 - 7.62 (m, 1 H), 7.67 (dd, >7.0,2.3 Hz, 1 H), 7.78 (t,>7.8 Hz, 1 H), 8.02 (d, >7.8 Hz, 1 H), 8.10 (d, >4.5 Hz, 1 H), 8.21 (d, >7.8 Hz, 1 H), 8.37 (s, 1 H), 10.49 (s, 1 H)

Compound 85 ^F

Prepared similarly as described for compound 72 using l-cthylcyclopropanamine hydrochloride instead of (S)-tetrahydrofùran-3-amine. Compound 85 was purified by préparative high performance liquid chromatography over RP-18 (eluent: CHjCN in H₂O (0.5% NH-iHCOj) from 43% to 73%, v/v). Method B; Rt: 4.17 min. m/z : 377.1 (M+H)⁺ Exact mass: 376.1. ’HNMR (400 MHz, DMSO-</₆) δ ppm 0.35-0.45 (m, 2 H), 0.49-0.58 (m, 2 H), 0.77 (t,>7.2 Hz, 3 H), 1.31 (q,>7.1 Hz, 2 H), 2.26 (s, 3 H), 7.15 (t, >9.3 Hz, 1 H), 7.55 - 7.64 (m, 1 H) 7.69 (d,>7.0 Hz, 1 H), 7.76 (t, >7.8 Hz, 1 H),

7.98 (d, >7.8 Hz, 1 H), 8.16 - 8.25 (m, 2 H), 8.35 (s, 1 H), 10.50 (s, 1 H).

Compound 86

Prepared similarly as described for compound 72 using 2-methylbutan-2-aminehydrochloride instead of (S)-tetrahydrofuran-3-amine. Purified by high performance liquid chromatography over RP-18 (eluent: CHjCN in water from 47% to 77%, v/v). Method D; Rt: 5.97 min. m/z : 379.1 (M+H)* Exact mass: 378.1. 'H NMR (400 MHz, DMSO5 d₆), δ = 0.73 (t, >7.5 Hz, 3 H), 1.02 (s, 6 H), 1.44 (q,>7.5 Hz, 2 H), 2.23 (d, >1.0

Hz, 3 H), 7.12 (t,>9.3 Hz, 1 H), 7.52 - 7.61 (m, 2 H), 7.64 - 7,77 (m, 2 H), 8.01 (d, >7.8 Hz, 1 H), 8.14 (d,>7.8 Hz, 1 H), 8.36 (s, 1 H). 10.45 (s, 1 H).

Alternative synthesis of compound 72:

A mixture of3-(chlorosulfonyl)benzoyl chloride (4.61 g,19.28mmol) intoluene (45 mL) was refluxed under a gentle flow of nitrogen. 4-fluoro-3-methylaniline (2.19 g,

17.53 mmol) in toluene (15 mL) was added drop wise to the refluxing solution. After addition, the mixture was refluxed for another 30 minutes. The mixture was next cooled to room température, and a mixture of (S)-3-aminotetrahydrofùran tosylate (5 g,

19.28 mmol) and diisopropylethylamine (15 mL) in toluene (15 mL) and CH2CI2 ( 10 mL) was added drop wise. After addition, the mixture was stirred for 4 hours at room temperature.The resultingmixture was washed with HCl (2 x 100 mL, IM aq), water (2 x 100 mL) and NaHCOj (2 x 100 mL, sat. aq). The organic layer was dried on MgSO₄, filtered and concentrated under reduced pressure. The obtained residue was purified using silica gel chromatography (C^Ch-MeOH 100:0 to 95:5) yielding 3-(4-fluoro-3-methylphenylcaAamoyl)bcnzene-l-sulfonyl chloride (1.07 g) during CH2CI2 elution. followed by compound 72 (2.85 g) as a white solid after removal of the solvent (dried in a vacuum oven at 55°C for 20 hours). ([a]o= - 5.21 (c 0.67 w/v %, MeOH), Method F; Rt: 0.88 min. m/z : 379.1 (M+H)* Exact mass: 378.1. The compound was crystallized from CH2CI2: DSC (From 30 to 300 °C at 10°C/min): 149°C. [«]”= + 3.21 (c 0.65 w/v %, DMF).

Compound 73

To an iced-cooled solution of 3-(chlorosuIfonyl)benzoic acid (50.0 g, 226.6 mmol) in ethylacetate (1000 mL) was added isopropylamine (67.0 g, 1.13 mol) in one portion. The réaction mixture was stirred at 25°C for 3 hours. The resulting mixture was diluted with IN HCl (500 mL) and extracted with ethyl acetate (2 x 500 mL). The combined organic layers were washed with brine (400 mL), dried over anhydrous Na2SO₄ and concentrated under reduced pressure resulting 3-(N-isopropylsulfamoyl)benzoic acid

-55(46 g). To an ice-cooled mixture of 3-(N-isopropylsulfamoyl)benzoic acid (7.0 g, 28.77 mmol), 4-fluoro-3-methylaniline (3.6 g, 28.77 mmol) and DIPEA (18.6 g,

143.91 mmol) in CH₂CI₂ (70 mL) HATU (12.0 g, 31.56 mmol) was added under N₂atmosphère. The resulting mixture was stirred at 20° for 16 hours. The solvent was removed in vacuo. The mixture was washed with saturated aqueous critic acid (30 mL), brine (20 mL) and dried over Na₂SO₄. The solvent was removed in vacuo. The residue was purified by préparative high performance liquid chromatography on SYNERGI 250*50 lOum (eluent: CHjCN in H₂O (0.05% TFA) from 35% to 65%, v/v). The pure fractions were collected and adjusted to pH=7 with Amberlite 1RA-900(OH) anionîc exchange resin. The resin was filtered ofF. The filtrate was lyophilized to dryness resulting in compound 73 (7.5 g). Method B; Rt: 3.44 min. m/z : 351.1 (M+H)⁺ Exact mass: 350.1 *H NMR (400 MHz, DMSO-J₀) δ ppm 10.49 (1 H, br. s), 8.36 (l H, t, >1.5 Hz), 8.19 (1 H, ddd,>7.8,1.5,1.0 Hz), 8.01 (1 H, ddd,>7.8,1.5,1.0 Hz), 7.76 (1 H, t, >7.8 Hz), 7,68(1 H, dd, >7.0,3.0 Hz), 7.75(1 H, bs), 7.59(1 H,ddd,>9.0,

4.5,3.0 Hz), 7.15 (1 H, t,>9.0 Hz), 3.14 - 3.33 (1 H, m), 2.25 (3 H, d,>1.5 Hz), 0.96 (6 H, d,>6.5 Hz).

Compound 74

Prepared similarly as described for compound 73, using 4-fluoro-3-(triÎluoromethy!)aniline instead of 4-fluoro-3-methylaniline. Purified on HPLC Synergi 150x30mmx5u (eluent: CHjCN in H₂O (0.05% HCl) from 45% to 75%, v/v). Method A; Rt: 5.62 min. m/z : 405.2 (M+H)⁺ Exact mass: 404.1. *H NMR (400 MHz, DMSO-J₆) δ ppm 10.82 (1 H, s), 8.39 (1 H, t,>1.5 Hz), 8.17 - 8.30 (2 H, m), 8.07 - 8.17 (1 H, m), 8.03 (1 H, d, >7.8), 7.73-7.83 (2 H, m), 7.55 (1 H, t, >10.0 Hz), 3.20 - 3.33 (1 H, m), 0.95 (6 H, d, >6.5 Hz).

Compound 84

A mixture of N-(3-bromo-4-fluorophenyl)-3-(N-isopropylsulfamoyl)benzamide (prepared similarly as described for compound 73, using 3-bromo-4-fluoroaniline instead of 4-fluoro-3-methylaniline and purified via préparative high performance liquid chromatography over RP-18 (eluent: CHjCN in H₂O (0.05% NH4HCO3) from 40% to 70%, v/v); 700 mg, 1.69 mmol), cyclopropylboronic acid (0.22 g, 2.529 mmol),

-56Pd(PPh₃)4 (0.20 g, 0.169 mmol) and Na₂COj (1.43 g, 13.49 mmol) in water (7 mL), EtOH (7 mL) and toluene (7 mL) was heated by microwave irradiation for 40 minutes at 100°C under N2. The reaction mixture was filtered through celite. Water (10 mL) was added to the filtrate and the mixture was extracted with ethyl acetate (2 x 10 mL). The combined organic layers were washed with brine and dried over Na2SO4. The solvent was removed in vacuo. The residue was purified by préparative high performance liquid chromatography over RP-18 (eluent: CH3CN inH₂O (0.1%TFA) from 20% to 50%, v/v). The pure fractions were collected and the volatiles were removed in vacuo. The aqueous layer was adjusted to pH=7 with saturated aqueous NaHCOj and extracted with ethyl acetate (2 x 20 mL). The combined organic layers were dried over Na₂SO4. The solvent was removed in vacuo and the obtained residue was further purified by supercritical fluid chromatography (Column: Chiralpak AD-3 150x4.6mm I.D., 3um Mobile phase: methanol (0.05% diethylamine) in CO2 from 5% to 40%. Flow rate: 2.5mL/min). The pure fractions were collected and the volatiles were removed in vacuo. The residue was suspended in water (5 mL) and lyophilized to dryness resulting in compound 84 (35 mg) Method B; Rt: 4,18 min. m/z : 377.1 (M+H)⁺ Exact mass: 376.1; ’H NMR (400 MHz, chloroform-d) δ ppm 8,34 (s, 1 H),

8.12 (d, >8.0 Hz, 1 H), 7.97 - 8,07 (m, 2 H), 7.65 (t, >8.0 Hz, t H), 7.36 - 7.46 (m, 1 H), 7.15-7.22 (m, 1 H), 7.01 (t, >9.3 Hz, 1 H), 4.65 (d, >7.5 Hz, 1 H), 3.44-3.58 (m, 1 H), 2.04 - 2.16 (m, 1 H), 1.10 (d, >6.5 Hz, 6 H), 0.96 - 1,06 (m, 2 H), 0.71 - 0.82 (m, 2 H).

Compound 88

Prepared similarly as described for compound 73, using 3,4-difluoroaniline instead of

4-fluoro-3-methylaniline. Method E; Rt: 5.31 min. m/z : 355.1 (M+H)⁺ Exact mass: 354.1; ’H NMR (400 MHz, DMSOAs) Ô ppm 10.71 (s, 1 H), 8.36 (t,>1.5 Hz, 1 H),

8.19 (d, >7.8 Hz, 1 H), 7.98 - 8.08 (m, t H), 7.94 (ddd, >13.2,7.5,2.4 Hz, 1 H), 7.71

- 7.83 (m, 2 H), 7.53 - 7.59 (m, l H), 7.42 - 7.51 (m, 1 H), 3.21 - 3.29 (m, 1 H), 0.96 (d.

>6.5 Hz, 6 H).

Compound 90

3-(chlorosulfonyl)bcnzoyl chloride (1200 mg, 5.0 mmol) was dissolved in dichloromethane (15 mL). A solution of 3,4-difluoroanïline (650 mg, 5.0 mmol) and triethylamine (606 mg, 6.0mmol) in dichloromethane (15 mL) was added to the mixture at 0°C. The mixture was stirred at 25°C for 1 hour. To the obtained reaction mixture a solution of triethylamine (606 mg, 6.0 mmol) and (S)-tetrahydrofùran3-amine (460.0 mg, 5.3mmol) in dichloromethane (15 mL) was added at 0°C. The mixture was stirred at 25°C for 1 hour. The solvent was removed in vacuo. The obtained residue was purified by high performance liquid chromatography over RP-18 (eluent: CHjCN in water (0.1 %TFA) from 30 to 60, v/v). The pure fractions were collected and the organic solvent was evaporated. The aqueous layer was neutralized with saturated aqueous NaHCOj to pH=7-8. The mixture was extracted with dichloromethane (3x15 mL). The combined organic layers were dried over Na₂SO₄ and concentrated in vacuo resulting in compound 90 (710 mg) Method A; Rt: 4.16 min. m/z : 383.0 (M+H)⁺Exact mass: 382.1;’H NMR (400 MHz, DMSO-rfe) δ ppm 1.54-1.63 (m, 1 H), 1.83 - 1.93 (m, 1 H), 3.32 - 3.38 (m, I H), 3.52 - 3.63 (m, 2 H), 3.63 - 3.77 (m, 2 H), 7.45 (dt, 7=10.5,9.0 Hz, 1 H), 7.51 - 7.57 (m, 1 H), 7.78 (t, 7=7.8 Hz, 1 H), 7.92 (ddd, 7=13.3,7.5,2.5 Hz, 1 H), 8.02 (d,7=7.8Hz, 1 H), 8.09 (d, 7=6.5 Hz, 1 H),

8.20 (d, 7=7.8 Hz, 1 H), 8.35 (s, 1 H), 10.70 (s, I H). SFC: Column: Chiralcel OJ-H 250*4.6mm I.D., 5um; Flow: 2.35 mL/min; Mobile phase: methanol (0.05% diethylamîne) in CO₂ from 5% to 40%; Rt: 5.61 Min.[a]” = + 3.21 (c 0.624 w/v %, DMF)

Compound 91

N-(3-bromo-4-fluorophenyl)-3-(N-isopropylsulfamoyl)benzamidc (1.5 g, 3.61 mmol), ethynyltrimethylsilane (1.77 g, 18.06 mmol). Pd(PPhj)₂Cl₂ (0.127g, 0.181mmol) and copper iodide (34.4 mg, 0.181mmol) were dissolved in diisopropylamine (10 mL). The mixture was stirred at 80°C in autoclave for 24 hours. The solvent was removed in vacuo and dichloromethane (30 mL) was added. The mixture was washed with water (20 mL) and the aqueous layer was extracted with dichloromethane (20 mL). The combined organic layers were washed with brine and dried over Na₂SO₄. The solvent was removed in vacuo. The obtained residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate from 100/1 to 60/40) resulting in N-(4-fluoro-3-((trimethylsilyl)ethyny1)pheny1)-3-(N-isopropylsu1famoy1)benzamide

-58(0.8 g). N-(4-fluoro-3-((tnmethytsilyl)ethynyl)phenyl)-3-(N-isopropylsulfamoyl)benzamîde (0.8 g, 1.66 mmol) and TFA (4 mL) were dissolved in anhydrous CH2CI2 (16 mL). The mixture was stirred at 25°C ovemight and next concentrated in vacuo. The obtained residue was purified by silica gel column chromatography (gradient eluent: petroleum ether/ethyl acetate from 100/0 to 75/25) resulting in compound 91 (220 mg). Method A; Rt: 5.12 min. m/z : 361.3 (M+H)* Exact mass: 360.1. ^lH NMR (400 MHz, DMSO-de) δ ppm 10.60 (I H, s), 8.35 (1 H, t, >1.5 Hz), 8.18 (1 H, d, >8.0 Hz), 8.00 (1 H, d,>8.0 Hz), 7.97 (1 H, dd,>6.5,3.0 Hz), 7.77 - 7.84 (1 H, m),

7.70 - 7.79 (2 H, m), 7.32 (1 H, t, >9.0 Hz), 4.52 (IH, s) 3.22 - 3.31 (1 H, m), 0.94 (6 H, d,>6.5 Hz).

Compound 92

N-(4-fluoro-3-((trimethylsÎlyl)cthynyl)phenyl)-3-(N-isopropytsulfamoyl)benzamide (0.8g, 1.66mmol) and TFA (4 mL) were dissolved in anhydrous CH2CI2 (16 mL). The mixture was stirred at 25° ovemight. The mixture was concentrated resulting in crude N-(3-ethynyl-4-fluorophenyl)-3-(N-isopropylsulfamoyl)benzamide which was used as such in the next step (650 mg). To a solution of N-(3-ethynyl-4-fluorophenyl)-3(N-isopropylsulfamoyl)benzamide (0.6 g) in MeOH (20 mL) was added Pd-C (10%, 0.2 g) under N2 atmosphère. The mixture was stirred under hydrogen atmosphère (50 psi) at 25°C for 4 hours. After filtration on celite, the solvent was removed in vacuo and the obtained residue was purified by préparative high performance liquid chromatography on reversed phase C-18 (eluent: CH₃CN in H₂O (0.05% HCl) from 42% to 72%, v/v). The pure fractions were collected and the volatiles were removed in vacuo. The aqueous layer was adjusted to PH=7 with Amberlite IRA-900 anionic exchange resin (OH form), filtered and lyophilized to dryness resulting in compound 92 ( 160 mg). Method B; Rt: 4.13 min. m/z : 365.3 (M+H)* Exact mass: 364.1 ; *H NMR (400 MHz, DMSO-de) δ ppm 10.48 (1 H, s), 8.35 (1 H, t. >1.5 Hz), 8,18 (1 H, d, >8.0 Hz), 7.99 (1 H, d, >8.0 Hz), 7.70 - 7.78 (2 H, m), 7.65 - 7.70 (1 H, m), 7.57 -

7.65 (I H, m), 7.13 (1 H, t, >9.0 Hz), 3.21 - 3.32 (1 H, m), 2.62 (2 H, q, >7.5 Hz),

1.18 (3 H, t, >7.5 Hz), 0.94 (6 H, d, >6.5 Hz).

To a solution of 3-(chlorosulfonyI)benzoyl chloride (0.50 g, 2.09 mmol) in CH2CI2 (10 mL), DIPEA was added (1.35 g, 10.45 mmol) followed by slow addition of

4-fluoro-3-methylaniline (0.25 g, 1.99 mmol). After stirring at 25°C for 0.5 hour, 3-ethyloxetan-3-amine (0.21 g, 2.09 mmol) was added. After 1 hour, the resulting mixture was diluted with CH₂C1₂ (15 mL), washed with saturated aqueous NaHCOj (15 mL) and brine (10 mL) and dried over anhydrous MgSO₄. The solvent was removed in vacuo and the obtained residue was purified by silica gel coiumn chromatography (gradient eluent: petroleum ether/ethyl acetate from 100/0 to 80/20) resulting in compound 93 (70 mg). Method B; Rt: 3.79 min. m/z : 393.3 (M+H)⁺ Exact mass: 392.1; ^lH NMR (400 MHz, DMSO-rfe) 5 ppm 10.50 (1 H, s), 8.47 (1 H, br. s),

8.38 (1 H, t,>1.5 Hz), 8.22 (1 H, d,>8.0 Hz), 8.03 (1 H, d,>8.0 Hz), 7.78 (1 H, t, >8.0 Hz), 7.68 (1 H, dd, >7.5,2.5 Hz), 7.56 - 7.64 (1 H, m), 7.15 (1 H, t, >9.0 Hz), 4.5! (2 H, d,>6.5 Hz), 4.19 (2 H, d,>6.5 Hz), 2.25 (3 H, d. >1.5 Hz), 1.84 (2 H, q, >7.0 Hz), 0.64 (3 H, t,>7.0 Hz).

3-(chIorosulfonyl)bcnzoyl chloride (1200 mg, 5.0 mmol) was dissolved in dichloromethane (15 mL). A solution of 4-fluoro-3-methyIanîline (625 mg, 5.0 mmol) and triethylamine (606 mg, 6.0 mmol) in dichloromethane (15 mL) was added to the mixture at 0°C. The mixture was stirred at 25°C for 1 hour. The réaction mixture was used to the next step without further purification (crude, 30 mL). To the above reaction mixture was added a solution of triethylamine (606 mg, 6.0 mmol) and 1-methylcyclopropanamine (425.0 mg, 5.9 mmol) in dichloromethane (15 mL) at 0°C. The mixture was stirred at 25°C for 1 hour. The solvent was removed in vacuo. The residue was purified by high performance liquid chromatography on reversed phase (eluent: CHjCN in water from 40% to 70%, v/v). The pure fractions were collected and the organic solvent was evaporated. The aqueous layer was neutralized with saturated aqueous NaHCOj to pH=7-8. The mixture was extracted with dichloromethane (3 x

mL). The combined organic layers were dried over Na₂SO₄ and concentrated in vacuo resulting in compound 94 (365 mg). Method B; Rt: 3.40 min. m/z : 363.0 (M+H)* Exact mass: 362.1; ‘H NMR (400 MHz, DMSO-Je) δ ppm 10.49 (1 H, s), 8.35 (t H, t,>1.5 Hz), 8.17 - 8.23 (2 H, m), 7.99 (t H, d,>8.0 Hz), 7.76 (1 H, t,J=8.0

Hz), 7.68 (1 H, dd,/=7.0,2.5 Hz), 7.56 - 7.62 (1 H, m), 7.14 (1 H, t,/=9.0 Hz), 2.25 (3 H, d, >1.5 Hz), 1.06 (3 H, s), 0.58 - 0.63 (2 H, m), 0.37 - 0.42 (2 H, m)

Compound 95

A mixture of N-(3-bromo-4-fluorophcnyl)-3-(N-isopropylsulfamoyl)bcnzamide (800 mg, 1.93 mmol), 4,4,5,5-tetramcthyl-2-(prop-l-cn-2-yl)-l,3,2-dioxaborolane (0.65 g, 3.85 mmol), Pd(PPhj)₄ (111 mg, 0.096 mmol)) and K₂COj (0.53 g, 3.85 mmol) in dioxane (8 mL) and water (2 mL) was heated by microwave irradiation for 110 minutes at 120°C under N₂ atmosphère. The reaction mixture was diluted with ethyl acetate (20 mL) and the catalyst was filtered off. The filtrate was concentrated in vacuo. Water (20 mL) was added and the aqueous layer was extracted with ethyl acetate (2 x 20 mL). The combined organic layers were washed with brine and dried over Na₂SO₄. The solvent was removed in vacuo and the obtained residue was purified by préparative high performance Iiquid chromatography over reversed phase C-l 8 (eluent: CH₃CN in H₂O (0.1% TFA) from 40% to 70%, v/v). The pure fractions were collected and the organic solvent was removed in vacuo. The aqueous layer was lyophilized to dryness resulting inN-(4-fluoro-3-(prop-l-en-2-yI)phenyl)-3-(N-isopropylsulfamoyl)benzamide (300 mg). N-(4-fluoro-3-(prop-l-en-2-yl)phenyl)-3(N-isopropylsulfamoyl)benzamide (180 mg) and Pd/C(wet) (20 mg) were stirred in methanol (4 mL) under a hydrogen atmosphère at 25°C for 3 hours. The mixture was filtered over celite and the filtrate was evaporated to dryness in vacuo. The residue was purified by silica gel column chromatography (gradient eluent: petroleum ether/ethyl acetate from 100/0 to 70/30). The volatiles were removed in vacuo, resulting in compound 95 (175 mg). Method B; Rt: 4.33 min. m/z : 379.3 (M+H)* Exact mass:

378.1;

3-(difluoromethyl)-4-fluoroaniline (1.20 g, 7.448 mmol), 3-(N-isopropylsulfamoyl)benzoîc acid (0,90 g, 3.699 mmol) and DIPEA (1.93 mL, 11.10 mmol) were dissolved in CH2CI2 ( 10 mL) and HATU ( 1.41 g, 3.699 mmol) was added at 0°C. The mixture was stirred at 20 °C for 2 hours. The mixture was diluted with CH2CI2 (10 mL) and H2O (10 mL). The organic layer was separated, washed with saturated aqueous NaHCOj (10 mL) and brine (10 mL) and dried over Na₂SO4. The solvent was removed in vacuo and the obtained residue was purified by préparative high performance liquid chromatography over reversed phase C-18 (eluent: CHjCN in H₂O (0.1%o NHJiCOj) from 45% to 75%, v/v). The pure fractions were collected and the organic solvent was removed in vacuo. The aqueous layer was lyophilized to dryness resulting in compound 96 (0.885 g). Method A; Rt: 5.16 min. m/z : 387.3 (M+H)* Exact mass: 386.1; 'H NMR (400 MHz, DMSO</₆) δ ppm 10.72(1 H, s), 8.38(1 H, t,> 1.5 Hz),

8.21 (1 H, d,> 8.0 Hz), 8.06-8.13(1 H, m), 8.02(1 H, d,> 8.0 Hz), 7.92 -8.00(1

H, m), 7.72 - 7.82 (2 H, m), 7.40 (1 H, t, > 9.5 Hz), 7.25 (1 H. t, > 55 Hz), 3.23 - 3.32 (1 H, m), 0.95 (6 H, d, > 6.5 Hz).

To 3-(4-fluoro-3-methylphenyIcafbamoyl)benzene-l-suIfonyl chloride (500 mg,

1.53 mmol) in toluene (10 mL) at room température, a solution of diisopropylethylamine (0.657 mL, 141.6 mmol) and 3-mcthyl-3-oxetanamine hydrochloride (207 mg, 1.68 mmol) in toluene (5 mL) and dichioromethane (10 mL) was added drop 25 wise. After 2 hours, the reaction mixture was washed with IM hydrochloric acid (2 x mL, saturated NaHCOj (2 x 10 mL) and brine (2 x 10 mL). The organic layer was dried on MgSO₄, filtered and concentrated under reduced pressure until only toluene remained. The fonned white preclpitate was filtered and recrystallîsed out of diisopropylether and acetonitrile. The crystals were dried in a vacuum oven at 55°C for 30 20 hours yielding compound 97 (361 mg) as a white solid. Method F; Rt: 0.89 min. m/z : 379.0 (M+H)* Exact mass: 378.1; *H NMR (400 MHz, DMSO-î/î) 5 ppm 1.41 (s, 3

-62H), 2.25 (d, 7=1.5 Hz, 3 H), 4.14 (d, 7=6.3 Hz, 2 H), 4.56 (d, 7=6.3 Hz, 2 H), 7.14 (t, 7=9.0 Hz, 1 H), 7.52 - 7.64 (m, 1 H), 7.68 (dd, 7=7.0,2.2 Hz, 1 H), 7.77 (t, 7=8.0 Hz, 1

H), 7.99-8.06 (m, 1 H), 8.20 (d, 7=8.0 Hz, I H), 8.37(1,7=1.5 Hz, 1 H), 8.50 (br. s., 1 H), 10.48 (s, 1 H).

Compound 98 °

To 3-(4-fluoro-3-methylphenylcarbamoyl)benzene-l-sulfonyl chloride (500 mg,

1.53 mmol) in toluene (10 mL) at room température, a solution of diisopropylethylamine (0.657 mL, 141.6 mmol) and (Æ)-(-)-2-aminobutane (130 mg, 1.83 mmol) in toluene (5 mL) and dichloromethane (10 mL) was added drop wise. After 2 hours, the réaction mixture was washed with IM aqueous HCl (2 xlO mL), NaHCOj (2 x 10 mL) and brine (2x10 mL). The organic layer was dried on MgSO₄, filtered and concentrated under reduced pressure until only toluene remained. The formed white precipitate was filtered, recrystallised (diisopropylether and acetonitrilc) and dried in vacuo at 55°C for 20 hours resulting in compound 98 (257 mg) as a white solid. Method F; Rt: 1.04 min. m/z : 382.1 (Μ+ΝΗ0* Exact mass: 364.1; 'HNMR (400 MHz, DMSO-J₆) δ ppm 0.71 (t, 7=7.5 Hz, 3 H), 0.88 (d, 7=6.6 Hz, 3 H), 1.31 (quin, 7=7.5 Hz, 2 H), 2.25 (d, 7=1.8 Hz, 3 H), 3.05-3.18 (m, 1 H), 7.14 (t, 7=9.0 Hz, 1 H), 7.55 - 7.62 (m, 1 H), 7.63 - 7.72 (m, 2 H), 7.75 (t, 7=8.0 Hz, 1 H), 8.00 (d, 7=8.0 Hz, 1 H), 8.18 (d, 7=8.0 Hz, 1 H), 8.36 (t, 7=1.5 Hz, 1 H), 10.46 (s, 1 H).

Compound 99

A mixture of 3-(N-isopropylsulfamoyl)benzoic acid (2.3 g, 9.615 mmol), 3-bromo-4,5difiuoroaniline (2 g, 9.615 mmol) and DIPEA (5 mL) in CH₂C1₂ (30 mL) was cooled to 0°C and HATU (4.39 g, 11.538 mmol) was added. The mixture was stirred for 2 hours at 20°C. The mixture was washed with IN HCl (30 mL) and brine (30 mL) and dried over Na₂SO₄. The solvent was removed in vacuo. The residue was purified by silica gel column chromatography (gradient eluent: petroleum ether/ethyl acetate from 100/0 to

-6370/30) resulting in crude N-(3-bromo-4,5-difluorophenyl)-3-(N-isopropylsulfamoyl)benzamide (4 g). A mixture of N-(3-bromo-4,5-difluorophenyl)-3-(N-isopropylsulfamoyl)benzamide (1 g, 2.308 mmol), methylboronic acid (1 g, 4.616 mmol), CsîCOj (2.26 g, 6.924 mmol), 2-Dicyclohcxylphosphino-2',6'-dimethoxybÎphenyl (95 mg, 0.231 mmol) andTris(dibenzylideneacetone)dipaIladium(0) (0.21 g, 0.231 mmol) in dioxane (15 mL) was heated by microwave irradiation for 40 minutes at 120°C under N2 atmosphère. After cooling, the mixture was fïltered through celite and the filtrate was evaporated to dryness. The obtained residue was purified by silca gel column chromatography (gradient eluent: petroleum ether/ethyl acetate from 100/0 to 70/30) and further purified by préparative high performance liquid chromatography over reversed phase C-18 (eluent: CHjCN in H2O (0.1% TFA) from 38% to 68%, v/v). The pure fractions were collected and halfofthe volatiles were removed in vacuo. The mixture was adjusted to pH=7 with Ambcrlite IRA-900 (OH) anionic exchange resin and the resin was fïltered off. The organic solvent was concentrated in vacuo and the aqueous layer was lyophilized to dryness. The obtained product was further purified by silica gel chromatography (gradient eluent: petroleum ether/ethyl acetate from 100/0 to 70/30) resulting in compound 99 (190 mg). Method A; Rt: 6.09 min. m/z : 369.2 (M+H)* Exact mass: 368.1, *H NMR (400 MHz, CHLOROFORM-d) δ ppm 8.35 (1 H, t,.7=1.5 Hz), 8.09 - 8.17 (2 H, m), 8.04 (1 H, dt, >8.0, 1.5 Hz), 7.66 (1 H, t, .7=8.0 Hz),

7.54 (1 H, ddd, .7=11.5,6.5,3.0 Hz), 7.14 - 7.22 (1 H, m), 4.72 (1 H, d,.7=8.0 Hz), 3.43-3.60(1 H, m), 2.32 (3 H, d, .7=2.0 Hz), 1.10(6H,d, J=6.5 Hz).

F

Compound 100 ^F

5-(ch!orosulfony!)-2-fluorobenzoic acid (7g, 29.3 mmol) was dissolved in dichloromethane (70 mL). DMF (0.7 mL) was added, followed by drop wise addition of oxalyl chloride (4.46 g, 35.16 mmol) at 0°C. The mixture was stirred for 1 hour at 20°C. The mixture was concentrated in vacuo and the crude 5-(chlorosuIfonyl)-2-fluorobenzoyl chloride was dissolved ίη dichloromethane (15 mL). A solution of 3,4-dif!uoroani!ine (3.6g, 27.87 mmol ) and DIPEA (4.6g, 35.20 mmol) in dichloromethane (60 mL) was added to the mixture at 0°C. The mixture was stirred at 25°C for 1 hour and used to the next step directly. To the above reaction mixture, a solution of (R)-(-)-2-aminobutane (2.2 g, 29.34 mmol) and DIPEA (4.6g, 35.20 mmol) in dichloromethane (60 mL) was

-64added at 0°C. The resulting mixture was stirred at 25°C for 1 hour. The mixture was concentrated in vacuo and the obtained residue was purified by high performance liquid chromatography on reversed phase (eluent: CHjCN in water (0.1 % TFA) from 25% to 55%, v/v). The pure fractions were collected and the organic solvent was evaporated. The aqueous solution was adjusted to pH =7 with saturated aqueous NaHCOj. The mixture was extracted with dichloromethane (3 x 200 mL). The combined organic layers were dried over Na₂SO₄ and concentrated in vacuo. The obtained residue was suspended in water (10 mL) and the aqueous layer was lyophilized to dryness resulting in compound 100 (4.7 g). Method B; Rt: 4.70 min. m/z : 3872 (M+H)⁺ Exact mass:

386.1.

Compound 101 F (S)-tetrahydrofuran-3-amîne hydrochloride (5.17 g, 42 mmol) and NaOH (5 g, 126 mmol) were dissolved in THF (50 mL) and H₂O (50 mL). 5-(chlorosulfonyl)-2fluorobenzoic acid (10 g, 42 mmol) was added at 0°C. The mixture was stirred at 20°C for 4 hours. The mixture was washed with ethyl acetate (3 x 20 mL). The aqueous layer was separated and adjusted to ρΗ=3 with IN HCl. The aqueous layer was extracted with ethyl acetate (3 x 50 mL). The combined organic layers were washed with brine and dried over NajSCU The solvent was removed in vacuo resulting in (S)-2-fluoro-5(N-(tetrahydrofùran-3-yl)sulfamoyl)benzoic acid (2.1 g). (S)-2-fluoro-5-(N-(tetrahydrofuran-3-yl)sulfamoyl)benzoic acid (1 g, 3.457 mmol), 3,4-difluoroaniline (0.53 g,

4.15 mmol) and triethylamine (0.7 g, 6.9 mmol) were dissolved in DMF (400 mL) and HATU (1.57 g, 4.15 mmol) was added at 0°C. The mixture was next stirred at 20°C for 6 hours. The solvent was removed in vacuo and the obtained residue was purified by silica gel chromatography (eluent: petroleum ether: ethyl acetate=5:l) resulting in compound 101 (0.8 g). Method B; Rt: 4.15 min. m/z : 401.3 (M+H)⁺ Exact mass: 400.1 Synthesïs of 3-[[(3S)-tetrahydrofuran-3-yl]sulfamoyl]bcnzoic acid: (3S)-tetrahydroforan-3-amine hydrochloride (5.6 g, 45.3 mmol) and NaOH (5.2 g, 130 mmol) were dissolved in THF (50 mL) and H₂O (50 mL). 3-(chlorosulfonyl)benzoic acid (10 g, 45.325 mmol) was added at 0°C. The mixture was stirred at 20°C for 4 hours. The aqueous layer was separated and the pH was adjusted to 2 with IN HCL The mixture was washed with ethyl acetate (3 x 100 mL).The combined organic layers were concentrated in vacuo resulting in 3-[[(3S)-tetrahydrofuran-3yljsulfamoyljbenzoic acid (l 1.2 g).

A mixture of (S)-tctrahydrofùran-3-amine hydrochloride (11.2 g, 90.7 mmol) and NEt₃(50.5 mL, 362.6 mmol) in dry CH₂C1₂ (400 mL) was stirred for 5 minutes at 20° C. 3-(chlorosulfonyl)benzoic acid (20 g, 90.7 mmol) was added and the mixture was stirred ovemight at 20°C. The reaction mixture was washed with IN HCl (100 mL), the aqueous layer was extracted with dichloromethane (2 x 200 mL). The combined organic layers were dried over Na^SCL and the solvent was removed in vacuo, resulting in3-[[(3S)-tetrahydrofiiran-3-yl]sulfamoyl]benzoic acid (16.3 g). 3-[[(3S)-tctrahydrofuran-3-yl]sulfamoyl]benzoic acid (3 g, 11.058 mmol), 3-(difluoromethyl)-4-fluoroaniline (2.1 g, 13.3 mmol) and triethylamine (3.3 g, 33 mmol) were dissolved in DMF (400 mL). PyBrOP (132705-51-2,6.2 g, 13.3 mmol) was added at 0°C. The mixture was stirred at 50“C for 12 hours. The solvent was removed in vacuo and the obtained residue was purified by reversed phase high performance liquid chromatography (mobile phase: CHjCN in water (0.1% TFA) from 30% to 60%). The pure fractions were collected and neutralized with solid NaHCOj. The organic solvent was removed in vacuo and the formed precipitate was fîltered, washed with H₂O (5 mL) and dried under high vacuum. The obtained residue was suspended in water (5 mL) and lyophilized to dryness resulting in compound 102 (2.3 g). Method A; Rt: 5.32 min. m/z : 415.2 (M+H)⁺ Exact mass: 414.1.¹H NMR (400 MHz, DMSOAs) δ ppm 1.53 - 1.68 (m, 1 H) 1.82 - 1.99 (m, 1 H) 3.27 - 3.42 (m, 1 H) 3.51 - 3.90 (m, 4 H) 7.26 (t,>55 Hz, 1 H) 7.36 - 7.51 (m, 1 H) 7.80 (t, >7.8 Hz, 1 H) 7.92 - 8.00 (m, 1 H) 8.01 - 8.08 (m, 1 H) 8.08 - 8.15 (m, 2 H) 8.25 (d,>7.8 Hz, 1 H) 8.40 (s, 1 H) 10.75 (s, 1 H).

Compound 103

3-[[(3S)-tetrahydrofuran-3-yl]sulfamoyl]benzoic acid (400 mg, 1.47 mmol) was dissolved in DMF (0.5 mL) and CH₂C1₂ (10 mL). (COC1)₂ (223 mg, 1.76 mmol) was added at 0°C. The mixture was stirred at 20°C for 2 hours. The solvent was removed in vacuo and the obtained residue was co-evaporated with toluene (2x10 mL) resulting in crude 3-[[(3S)-tetrahydrofùran-3-yl]sulfamoyl]benzoyl chloride (400 mg).The crude product was used in the next step without purification. 3-[[(3S)-tetrahydrofûran-3-yl]

-66sulfamoyljbenzoyl chlonde (200 mg) was dissolved in dichloromethane (5 mL).

4-fluoro-3-methoxy-aniline (78 mg, 0.552 mmol) and triethylamine (167 mg, 165 mmol) were added at 0°C. The mixture was stirred ai 20°C for 2 hours, washed with H₂O (5 mL) and the waterlayer extracted with dichloromethane (3 x 10 mL). The combined organic layers were concentrated in vacuo. The obtained residue was purified by reversed phase high performance liquid chromatography (mobile phase: CHjCN in water (0.1 % TFA) from 30% to 60%). The pure fractions were collected and neutralized with solid NaHCOj. The organic solvent was removed in vacuo. The obtained prccipitate was filtered, washed with H₂O (5 mL) and dried under high vacuum. The residue was suspended in water (5 mL) lyophilized to dryness resulting in compound 103 (140 mg). Method A; Rt: 4,98 min. m/z : 395.2 (M+H)* Exact mass:

394.1

Prepared similarly as described for compound 103:

Method A; Rt: 5.10 min. m/z: 389.1 (M+H)⁺ Exact mass: 390.2

Compound 106

Method A; Rt: 5.18 min. m/z : 397.2 (M+H)⁺ Exact mass: 396.1 ^lH NMR (400 MHz, DMSO-</₆) δ ppm 1.54 - 1.69 (m, 1 H) 1.82 -1.98 (m, 1 H) 2.24 (s, 3 H) 3.35 - 3.40 (m, 1 H) 3.52 - 3.66 (m, 2 H) 3.66 - 3.83 (m, 2 H) 7.32 (t, J= 10.0 Hz, 1 H) 7.49 (t, >8.5 Hz, l H) 7.79 (t, >7.8 Hz, 1 H) 8.04 (d, >8.0 Hz, 1H)8.O7-

8.18 (m, 1 H) 8.23 (d, >7.8 Hz, l H) 8.39 (s, 1 H) 10.40 (br. s, l H)

Compound 107

3-[[(3S)-tetrahydrofuran-3-yl]sulfamoyl]benzoic acid (270 mg, 1.0 mmol) was dissolved in dichloromethane (5 mL). 3-methyl-4-methoxyaniline (165 mg, 1.2 mmol) and triethylamine ( 145 mg, 1.4 mmol) were added to the mixture at 20°C. The mixture was stirred at 20°C for 5 minutes. HATU (456 mg, 1.2 mol) was added and the mixture was further stined at 20°C for 8 hours. The solvent was removed in vacuo and the obtained residue was purified by high performance liquid chromatography (Column: Phenomenex Synergi Cl 8 150*20mm*5um.. A: H2Û+0.l%TFA B: MeCN from 30% to 60 % B in A). The product fractions were collected and the organic solvent was evaporated in vacuo. The aqueous layer was neutralized with saturated aqueous NaHCOj and extracted with dichloromethane (2x10 mL). The combine organic layers was dried over Na₂SO4 and concentrated in vacuo resulting in compound 107 (135 mg). Method A; Rt: 5.24 min. m/z : 391.3 (M+H)* Exact mass: 390.1

Compound 108

5-amino-2-fluono-phenol (234 mg, 1.84 mmol) and 3-[(3-methyloxetan-3-yl)sulfamoyljbenzoic acid (500 mg, 1.84 mmol) were dissolved in dichloromethane (8 mL). PyBrOP (132705-51-2, 1030 mg, 2,21 mmol) was added followed by drop wise addition of DIPEA (714 mg, 5.53 mmol) at 0°C. The mixture was stirred for 1 hour at 25°C. The mixture was washed with saturated aqueous citric acid (15 mL), saturated aqueous NaHCOj ( 15 mL) and brine and dried over Na₂SO4. The solvent was removed in vacuo. The obtained residue was purified by reversed phase préparative high-performance liquid chromatography (mobile phase: CHjCN in water (0.05% NH4HCO3) from 29% to 39%). The pure fractions were collected and the volatiles were removed in vacuo. The residual aqueous layer was lyophilized to dryness re sulting in compound 108 (60 mg). Method A; Rt; 4.47 min. m/z: 381.2 (M+H)* Exact mass:

380.1

Compound 109

-68Prepared similarly as descnbed for compound 108, using 4-fluoro-3-methoxy-aniline instead of5-amino-2-fluoro-phenoL Method A; Rt: 5.03 min. m/z: 395.2 (M+H)⁺ Exact mass: 394.1

Compound 110

DIPEA (2.85 g, 22.08 mmol) was added to a solution of 3-[(3-methyloxetan-3-yl)sulfamoyljbenzoic acid (3.0 g, 11.06 mmol) and HATU (4.20 g, 11.05 mmol) in DMF (100 mL) at 25°C. After 30 minutes, 3-bromo-4-fluoro-aniline (2.1 g, 11.05 mmol) was added to the solution. The reaction mixture was stirred at 25°C ovemight. The solvent was removed in vacuo and the obtained residue was purified by silica gel coiumn chromatography (gradient eluent: petroleum ether/ethyl acetate from 10/1 to 5/1). The pure fractions were collected and the solvent was removed in vacuo resulting in N-(3bromo-4-fluoro-phenyl)-3-[(3-methyloxetan-3-yl)sulfamoyl]benzamide (compound

160,2.5 g). A mixture of N-(3-bromo-4-fluoro-phenyl)-3-[(3-mcthyloxctan-3yl)sulfamoyl]benzamidc (0.3 g, 0.68 mmol), 4,4,5,5-tetramcthy 1-2-vinyl-1,3,2dioxaborolane (54.2 mg, 0.35 mmol), Pd (dppf) Cl₂ (50 mg, 0.068 mmol), KOAc (108 mg, 1.1 mmol) and Na₂CO₃ (100 mg, 0.94 mmol) in CHjCN (10 mL) and H₂O (2 mL) was heated by microwave irradiation for 30 minutes at 130°C under a N₂ atmosphère. The réaction mixture was filtered through Celite and the filter cake was washed with ethyl acetate (2x10 mL). The organic layer was separated from the filtrate, washed with brine and dried over Na₂SO₄. The solvent was removed in vacuo. The obtained residue was purified by reversed phase préparative high performance liquid chromatography (eluent: CH₃CN in H₂O (0.05% NH₃.H₂O) from 30% to 80%, v/v). The pure fractions were collected and the volatiles were removed in vacuo. The aqueous layer was lyophilized to dryness resulting in compound 110 (70 mg). Method B; Rt: 4.19 min. m/z : 391.3 (M+H)⁺ Exact mass: 390.1.

.OH

Compound 111

3-[(3-methyloxetan-3-yï)sulfamoyl]benzoic acid (3 g, 11.06 mmol), methyl 5-amîno-2 fluoro-benzoate (2.33 g, 13.2 mmol) and DIPEA (2.84 g, 22 mmol) were dissolved in

-69DMF (40 mL). HATU (5.02 g, 13.2 mmol) was added at 0°C. The mixture was stirred at 20°C for 2 hours. The solvent was removed in vacuo and the obtained residue was purified by silica gel column chromatography (eluent: petroleum ether: ethyl acetate=3:l) resultîng in methyl 2-fluoro-5-[[3-[(3-methyloxetan-3-yl)sulfamoyl]benzoyl]amino]benzoate (2.3 g). Methyl 2-fluoro-5-[[3-[(3-methyloxetan-3-yl)sulfamoyl]benzoyl]amino]benzoate (0.3 g, 0.71 mmol) was dissolved in THF (5 mL) and éthanol (5 mL). NaBHj (53 mg, 1.4 mmol) was added at 0°C. The mixture was stirred for 2 hours at 20°C. The solvent was removed in vacuo and the obtained residue was purified by reversed phase high performance liquid chromatography (mobile phase: CHjCN in water (0.1 % TFA) from 34% to 64%). The pure fractions were collected and neutralized with solid NaHCOj. The organic solvent was removed in vacuo. The precipitate was filtered, washed with H2O (5 mL) and dried under high vacuum. The residue was suspended in water (5 mL) and the aqueous layer was lyophilized to dryness resultîng in compound 111 (220 mg). Method A; Rt: 4.34 min. m/z : 395.3 (M+H)⁺ Exact mass: 394.1.

Compound 127 (2-fluoro-5-nitro-phenyl)methanol (4.3 g, 25.1 mmol) was dissolved in dichloromethane (50 mL). Diethylaminosulfur trifluoride (4.5 g, 27.9 mmol) was added drop wise to the mixture at -30°C. The mixture was stirred at 10° C for 4 hours. Methanol (10 mL) was added to the mixture and the mixture was further stirred at 10°C for 30 minutes. The mixture was washed with brine (30mL) and the aqueous layer was extracted with CH₂C12(2 x 30 mL). The combined organic layers were dried over Na₂SOj and concentrated in vacuo, resultîng in l-fluoro-2-(fluoromethyl)-4-nitrobenzene(3.9 g). A mixture of l-fluoro-2-(fluoromethyl)-4-nitro-benzene (3.1 g,

17.9 mmol), iron (4.0 g, 71.6 mmol) and methanol (30 mL) was stirred at 65° for 8 hours. The mixture was filtrated and the filtrate was concentrated in vacuo, resultîng in

4-fluoro-3-(fluoromethyl)anilÎne (1.5 g). 3-(chlorosulfonyl)benzoyl chloride (300 mg,

1.2 mmol) and triethylamine (150 mg, 1.5 mmol) were dissolved in dichlorométhane (20 mL). 4-fluoro-3-(fluoromethyl)aniline (175 mg, 1.22 mmol) was added to the mixture at 0° C. The mixture was stirred at 10°C for 30 minutes. The mixture was used to the next step without further purification.Triethylamine (152 mg, 1.5 mmol) and 3-methyl-3-oxetanamine (131 mg. 1.5 mmol) were added to the above obtained reaction mixture at 0° C. The mixture was stirred at 20° C for 1 hour. The solvent was removed m vacuo and the obtained residue was purified by reversed phase high performance liquid chromatography (Column: Gemini 250*20mm*5um.. A: H₂O+0.1%TFA B: MeCN. 27% to 57% B in A). The product fractions were collected and the organic solvent was removed in vacuo. The fraction was neutralized by saturated NaHCOj. The mixture was extracted with dichloromethane (3 x 20 mL) and the combined organic layer was dried over Na₂SO₄ and concentrated in vacuo, resulting in compound 127 (91.1 mg). Method A; Rt: 4,95 min. m/z : 397.3 (M+H)⁺ Exact mass:

396.1. 'H NMR (400 MHz, DMSO-Je) δ ppm 1.41 (s, 3 H) 4.14 (d, J=6.3 Hz, 2 H)

4.56 (d, >6.3 Hz, 2 H) 5.52 (d, >48 Hz, 2 H) 7.31 (t,>9.4 Hz, 1 H) 7.72 - 7.89 (m, 2 H) 7.92-7.97 (m, 1 H) 8.03 (d, >8.0 Hz, 1 H) 8.23 (d, >7.8 Hz, 1 H) 8.39 (s, 1 H)

8.55 (s, 1 H) 10.67 (s, 1 H).

Compound 112

Compound 123 (255 mg, 0.592 mmol) and Pd/C (50 mg) were stirred in methanol (25 mL) under a hydrogen atmosphère for 3 hours. The reaction mixture was fîltered, concentrated and the obtained residue dried in vacuo at 50°C resulting in compound 112 as a colorless resin.(174 mg). Method G; Rt: 1.57 min. m/z : 397.1 (M+H)⁺ Exact mass: 396.1. ’H NMR (400 MHz, DMSO-di) 8 ppm 1.65 -1.80 (m, 1 H), 1.91 - 2.04 (m, 1 H), 2.24 (d, >1.5 Hz, 3 H), 3.43 (dd, >9.0,4.6 Hz, 1 H), 3.55 - 3.79 (m, 3 H),

3.80 - 3.91 (m, 1 H), 7.14 (t, >9.2 Hz, 1 H), 7.45 - 7.57 (m, 2 H), 7.64 (dd, >7.0,2.4 Hz, 1 H), 7.85 - 8.02 (m, 2 H), 8.40 (d, >6.8 Hz, 1 H), 10.62 (s, 1 H)

Compound 113 ^r

3-methyloxetan-3-amine hydrochloride (210 mg, 1.7 mmol) andNaOH (204 mg,

5.1 mmol) were dissolved in 2-methyltetrahydrofùran (5 mL) and H₂O (5 mL). 5-chlorosulfonyl-2-methyl-benzoic acid (400 mg, 1.7 mmol) was added at 0°C. The mixture was stirred at 20°C for 4 hours. The aqueous layer was separated and adjusted to pH=3 by aq.HCl (lN).The mixture was extracted with ethyl acetate (3 x 100 mL). The combined organic layers were concentrated in vacuo resulting in 2-methyl-5[(3-methyloxetan-3-yl)sulfamoyl]benzoic acid (250 mg). 2-methyl-5-[(3-methyloxetan17200

3-yl)sulfamoyl]benzoic acid (250 mg, 0.876 mmol), 3-(difluoromethyI)-4-fluoroaniline (178 mg, 1.1 mmol) and DIPEA (232 mg, 1.8 mmol) were dissolved in DMF (5 mL). HATU (399 mg, 1.05 mmol) was added at 0°C. The mixture was stirred at 20°C for 2 hours. The solvent was removed in vacuo and the obtained residue was purified by reversed phase high performance liquid chromatography (mobile phase: CHjCN in water (0.1% TFA) from 34% to 64%). The pure fractions were collected and neutralized with solid NaHCOj. The organic solvent was removed in vacuo and the formed precipitate was fïltered, washed with H₂O (5 mL) and dried under high vacuum. The residue was suspende d in water (5 mL) and the aqueous layer was lyophilized to dryness resulting in compound 113 (220 mg). Method A; Rt: 5.28 min. m/z : 429,3 (M+H)* Exact mass: 428.1. *H NMR (400 MHz, DMSCMs) δ ppm 1.44 (s, 3 H) 2.47 (s, 3 H) 4.15 (d, >6.3 Hz, 2 H) 4.57 (d,>6.0 Hz, 2 H) 7.24 (t, >=54.5 Hz, 1 H) 7.40 (t, >9.5 Hz, I H) 7.56 (d,>8.0 Hz, I H) 7.71 - 7.98 (m, 3 H) 8.09 (d,>4.3 Hz, 1 H) 8.37 (br. s., I H) 10.74 (br. s„ I H)

Compound 114

3-(isopropylsuIfamoyl)benzoic acid (190 mg, 0.78 mmol) was dissolved in dichloromethane (5 mL). 3-fluoro-4-methoxyaniline (139 mg, 0.94 mmol) and triethylamine (112 mg, 1 mmol) were added to the mixture at 20°C. The mixture was stirred at 20°C for 5 minutes, HATU (358 mg, 0.94 mmol) was added to the mixture at 20°C. The mixture was stirred at 20°C for 8 hours. The solvent was removed in vacuo and the obtained residue was purified by high performance liquid chromatography (Column: Phcnomenex Synergi CI8 150*20mm*5um.. A: H₂O+0.1%TFA B: MeCN 30% to 60% B in A). The product fractions were collected and the organic solvent was evaporated. The aqueous layer was neutralized with saturated aqueous NaHCOj. The mixture was extracted with dichloromethane (2x10 mL). The combined organic layers were dried over Na₂SO₄ and concentrated in vacuo resulting in compound 114 (135 mg). Method A; Rt: 5.60 min. m/z: 367.2 (M+H)* Exact mass: 366.1

Compound 115

Prepared similarly as desribed for compound 127 using 4-fluoro-2,3-dimethyl-aniline

-72msteadof 4-fIuoro-3-(fIuoromethyl)aniline. Method A; Rt: 4.98 min. m/z : 393.3 (M+H)⁺ Exact mass: 392.1.

Compound 116

4-fluoro-3-methyl-aniline (9.04 g, 72.2 mmol) was added drop wise to a solution of 3-(chlorosulfonyl) benzoyl chloride (19.0g, 79.47 mmol) in toluene (300 mL) at 110°C. The résultant mixture was stirred at 110°C for 1 hour and allowed to cool to 20°C ovemight. The precipitate was filtered and recrystallized from dry toluene resulting in 3-[(4-fluoro-3-methyl-phenyl)cafbamoyl]benzenesulfonyl chloride (20 g). 3-[(4-fluoro3-methyl-phenyl)cafbamoyl]benzenesulfonyl chloride (15 g, 45.77 mmol) was added drop wise at 0°C to a solution of 2-aminopropan-l-ol (3,437 g, 45.77 mmol) and triethylamine (6,946 g) in THF (200 mL). The résultant mixture was stirred for 10 minutes and then allowed to warm to 20°C during 2 hours. The reaction mixture was quenched with IN HCl (50 mL). The mixture was extracted with dichloromethane (3 x 30 mL).The combined organic layers were washed with brine, dried over MgSO₄, filtered and concentrated in vacuo. The residue was purified by silica gel column chromatography (gradient eluent: petroleum ether / ethyl acetate from 100/1 to 50/50), resulting in N-(4-fluoro-3-methyl-phenyl)-3-[(2-hydroxy-l-methyl-ethyl)sulfàmoyl]benzamide (15.6 g). Diethyl diazene-l,2-dicarboxylate (4.91 g, 28.19 mmol) was added drop wise to a solution of N-(4-fluoro-3-methyl-phenyl)-3-[(2-hydroxy-l-methylethyl)sulfamoyl]benzamide (7.8 g, 21,29 mmol) and PPh₃ (6.14 g, 23.41 mmol) in THF (500 mL) at -70°C under Argon. The résultant mixture was stirred for 1 hour and then allowed to warm to 20°C ovemight The reaction mixture was quenched with IN HCl (300 mL). The mixture was extracted with dichloromethane (4 x 400 mL) and the combined organic layers were washed with brine, dried over MgSO«, filtered and concentrated in vacuo. The obtained residue was purified by silica gel column chromatography (gradient eluent: petroleum ether / ethyl acetate from 100/1 to 60/40) resulting in N-(4-fluoro-3-methyl-phenyl)-3-(2-methylaziridin-l -yl)sulfonyl-benzamide (6.5 g). A mixture ofN-(4-fluoro-3-methyl-phenyl)-3-(2-methylaziridin-l-yl)sulfonylbenzamide (300 mg, 0.861 mmol) and 1-methylpiperazine (862 mg, 8.61 mmol) in

1.4-dioxane (3 mL) was heated by microwave irradiation at 150°C for 30 minutes. The volatiles were removed in vacuo. The obtained residue was purified by silica gel column chromatography (gradient eluent: petroleum ether/ethyl acetate from 100/1 to 1/100). The pure fractions were collected and the solvent was removed in vacuo. The obtamed residue was purified by préparative high-pcrformance liquid chromatography (coiumn: Luna 150*30mm*5u, mobile phase: CHjCN in water (0,1%NH₄HCOj) from 44% to 74%). The pure fractions were collected, concentrated in vacuo and the residual aqueous solution was lyophilized to dryness resulting in compound 116 (250 mg). Method A; Rt: 4.26 min. m/z : 449.4 (M+H)⁺ Exact mass: 448.2

o.

Compound 117

Prepared simîlarly as desrîbed for compound 116 using morpholine instead of

1-methylpiperazine, Method A; Rt: 4,45 min. m/z : 436.3 (M+H)⁺ Exact mass: 435.2

Compound 118

To a stirred solution of 3,4-dïfluoro-2-methyl-anilÎne (369 mg, 2.6 mmol), 3-[[(3S)tetrahydrofùran-3-yl]sulfamoyl]benzoic acid (700 mg, 2.58 mmol) and N,Ndiisopropylethylamine(1.35 ml, 7.74 mmol) in DMF (10 mL), Pybrop (132705-51-2,

1,82 g, 3.9 mmol) was added at 0° C. The resulting mixture was stirred overnight at 18 °C. The mixture was concentrated in vacuo, ethyl acetate (15 mL) was added and the organic layer was washed with IN HCl (15 ml) and saturated aqueous NaHCOj (15 mL). After drying over Na₂SO₄ and concentration in vacuo, the crude residue was purified by reversed phase préparative high-performance liquid chromatography (eluent: CHjCN in H2O (0.05% NHj.H₂O) from 37% to 37%, v/v). The pure fractions were collected and the volatiles were removed in vacuo. The aqueous layer was lyophilized to dryness, resulting in compound 118 (238 mg). Method D; Rt: 5.01 min. m/z : 396.9 (M+H)⁺ Exact mass: 396.1

Compound 119

Prepared similarly as described for compound 127 using 4-fluoro-2,5-dimethyl-aniline instead of 4-fluoro-3-(fluoromethyl)aniline, and DIPEA instead of NEtî. Method A; Rt: 5.27 min. m/z: 393.3 (M+H)⁺ Exact mass: 392.1

A mixture of l-(2-pyridyl)propan-2-amine (207.8 mg, 1.53 mmol) and DIPEA (0.532 mL, 3.05 mmol) were dissolved in CH₂C1₂ (10 mL). 3-[(4-fluoro-3-methylphenyl)carbamoyl]benzenesulfonyl chloride (500 mg, 1.53 mmol) was added portion 10 wise at 0°C and the mixture was stirred at 0°C for 1 hour. The mixture was washed with saturated citric acid (10 mL), saturated aqueous NaHCOj (10 mL), brine and dried over Na₂SO₄. The solvent was removed in vacuo and the obtained residue was purified by silica gel column chromatography (gradient eluent: petroleum ether/ethyl acetate from 100/1 to I/I00).The pure fractions were collected and the solvent was removed in 15 vacuo. The obtained solid was suspended in water ( 10 mL) and acetonitrile ( 10 mL) and the solution was lyophilized to dryness resulting in compound 120 (550 mg). Method B; Rt: 3.36 min. m/z: 428,3 (M+H)⁺ Exact mass: 427.1. 'H NMR (400 MHz, DMSCMs) 6 ppm 0.95 (d,>6.5 Hz, 3 H) 2.26 (d, J= 1.5 Hz, 3 H) 2.69 (dd, >13.6,7.3 Hz, I H) 2.80 (dd, >13.6,7.0 Hz, I H) 3.64 - 3.74 (m, 1 H) 7.08 - 7.19 (m, 3 H) 7.5520 7.64 (m, 2 H) 7.64 - 7.71 (m, 2 H) 7.84 - 7.89 (m, I H) 7.89 - 7.95 (m, 1 H) 8.12 - 8.Ï7 (m, I H) 8.25 (t, >1.5 Hz, I H) 8.32 - 8.36 (m, 1 H) 10.45 (s, 1 H).

Compound 224

Compound 224 was prepared similarly as described for compound 223, using 1 -(4pyrîdyl)propan-2-amine instead of l-(2-pyridyl)propan-2-amine. Compound 224 was purified by préparative high-performance liquid chromatography (column: Luna 150*30mm*4u, mobile phase: CHjCN in water (0.05% NH₄HCOj) from 40% to 70%). Method A; Rt: 4.6 min. m/z: 428.3 (M+H)⁺ Exact mass: 427.1.

Synthesis of 5-chlorosulfonyl-2-methyl-benzoy! chloride and 3-lï4-fluoro-3-methylphenyl)carbamoyl]-4-methy!-bcnzenesul fony! chloride

-755-(chlorosulfonyl)-2-mcthylbenzoic acid (10 g, 42.61 mmol) was dissolved in dichloromethane (200 mL). N,N-dimethylformamide (166 pL, 2.13 mmol) was added and the mixture was stirred at room température under a nitrogen atmosphère. Oxalyl chloride ( 18.3 mL, 213 mmol) was added in four portions over one hour. The resulting mixture was stirred for one hour at room température. The mixture was concentrated în vacuo and co-evaporated twice using toluene (2 x 100 mL) yielding 5chlorosulfonyl-2-methyl-benzoyl chloride as a yellow oil which was used as such. 5chlorosulfonyl-2-methyl-benzoyI chloride_(10.7 g, 42.3 mmol) was dissolved în toluene (220 mL) and this was heated to reflux and stirred under a gentle flow of nitrogen.

4-fluoro-3-mcthylaniline (4.76 g, 38.1 mmol) în toluene (80 mL) was added drop wise using a syringe pump (0,8 mL / min). The resulting mixture was stirred for 30 minutes while heating was continued. Then the mixture was cooled to room température. A précipitation was formed and collected on a glass filter. The obtained solid was dried in vacuo at 55°C, yielding 3-[(4-fluoro-3-methyl-phenyl)carbamoyl]-4-methylbenzenesulfonyl chloride (10.4 g) as a solid which was used as such in the next step.

Compound 121

A solution of (S)-3-aminotetrahydrofùran tosylate (0.76 g, 2.93 mmol) and diisopropylethy lamine ( 1.26 mL, 7.31 mmol) in dichloromethane (10 mL) was added drop wise to a solution of 3-[(4-fluoro-3-mcthyl-phenyI)carf)amoyl]-4-methylbenzenesulfonyl chloride (1 g, 2.93 mmol) in dichloromethane (10 mL). The resulting mixture was stirred for 1 hour at room température. The mixture was quenched using HCl (aq / 14.6 mL, 14.6 mmol). The layers were separated and the water layer was extracted with dichloromethane (2 x 20 mL). The combined organics were concentrated in vacuo and purified using silica gel column chromatography (gradient elution: EtOAc-heptane 0:100 to 100:0). The desîred fractions were concentrated in vacuo and dried in vacuo at 55°C yielding compound 121 as a bright white solid. Method F; Rt:

0.90 min. m/z: 393.2 (M+H)⁺ Exact mass: 392.1. 'H NMR (400 MHz, DMSO-tU) δ ppm 1.58 - 1.69 (m, 1 H), 1.85 - 1.98 (m, 1 H), 2.24 (d, J=1.3 Hz, 3 H), 2.45 (s, 3 H),

3.38 (dd, J=8.8,4.4 Hz, 1 H), 3.53 - 3.65 (m, 2 H), 3.66 - 3.76 (m, 2 H), 7.13 (t, J=9.2 Hz, 1 H), 7.46 - 7.59 (m, 2 H), 7.66 (dd, J=7.0,2.2 Hz, I H), 7.75 - 7.87 (m, 2 H), 7.96 (br. s., 1 H), 10.46 (s, 1 H).

A solution of 3-mcthyl-3-oxetanamine hydrochloride (0.4 g, 3.22 mmol) and diisopropylethyl amine (1.26 mL, 7.31 mmol) in of dichloromethane (10 mL) was added drop wise to a solution of 3-[(4-fluoro-3-methyl-phenyl)carbamoyl]-4-methylbenzenesulfonyl chloride (1 g, 2.93 mmol) in dichloromethane(10 mL). The resulting mixture was stirred for 1 hour at room température. The mixture was quenched using HCl (aq ! 14.63 mL, 14.63 mmol). The layers were separated and the water layer was extracted using dichloromethane (2 x 20 mL). The combined organic layers were concentrated in vacuo and purified using column chromatography (gradient elution: EtOAc-heptane 0:100 to 100:0). The desired fractions were concentrated in vacuo and dried in a vacuum oven at 55°C yïelding compound 122 as a bright white solid. Method F; Rt: 0.90 min. m/z: 410.2 (M+NH,)⁺ Exact mass: 392.1,’H NMR (400 MHz, DMSOdô) S ppm 1.43 (s, 3 H), 2.19 - 2.29 (m, 3 H), 2.44 (s, 3 H), 4.14 (d, >6.4 Hz, 2 H),

4.56 (d, >6.2 Hz, 2 H), 7.13 (t, >9.1 Hz, 1 H), 7.42 - 7.57 (m, 2 H), 7.59 - 7.71 (m, 1 H), 7.74 - 7.90 (m, 2 H), 8.36 (s, 1 H), 10.46 (s, 1 H).

Compound 123 Cl

Compound 123 was prepared similarly as described for compound 121 starting from 5-chloro-3-chlorosulfonyl-2-fluoro-benzoic acid (commercial from Enamine EN30035191) via 5-chloro-3-chlorosulfonyl-2-fluoro-benzoyl chloride (’H NMR (400 MHz, CHLOROFORM-d) δ ppm 8.23 (dd, >5.4,2.8 Hz, 1 H), 8.37 (dd, >5.5,2.6 Hz, 1 H)). After silica gel column chromatography (gradient elution: EtOAc-heptane 10:90 to 100:0) compound 123 was crystallised by addition of H₂O to a hot iPrOH solution of compound 123, resulting in compound 123 as white solid (3153 mg). Method G; Rt:

1.81 min. m/z: 431.0 (M+H)⁺ Exact mass: 430.1. 'H NMR (400 MHz, DMSO-dô) δ ppm 1.65 - 1.79 (m, 1 H), 1.93 - 2.06 (m, 1 H), 2.25 (d, >1.8 Hz, 3 H), 3.44 (dd, >9.0,

4.4 Hz, 1 H), 3.62 (td, >8.0,5.9 Hz, 1 H), 3.69 (dd, >8.9,6.3 Hz, 1 H), 3.71 - 3.79 (m, 1 H), 3.84 - 3.98 (m, 1 H), 7.15 (t, >9.1 Hz, 1 H), 7.45 - 7.55 (m, 1 H), 7.61 (dd, >6.9,2.3 Hz, 1 H), 7.91 (dd, >5.7,2.6 Hz, 1 H), 8.07 (dd, J=5.2,2.8 Hz, 1 H), 8.57 (d, >6.8 Hz, 1 H), 10.68 (s, 1 H)

Compound 124

Compound 125 (167 mg,0.371 mmol) and Pd/C (25 mg) were stirred in methanol (19 mL) under hydrogen atmosphère during 80 minutes. The reaction mixture was filtered and concentrated. The obtained residue was purified by préparative SFC (Stationary phase: Chiralpak Diacel AD 30 x 250 mm), Mobile phase: CO₂, MeOH with 0.2% iPrNH₂), the desired fractions were collected, evaporated, dissolved in MeOH and evaporated again resulting in compound 124 (67 mg). Method G; Rt: 1.61 min. m/z: 430.0 (M+NH₄)⁺Exact mass: 412.1. *H NMR (400 MHz, DMSO-Je ) δ ppm 1.68-

1.83 (m, 1 H), 1.89 - 2.03 (m, 1 H), 224 (d, >1.5 Hz, 3 H), 3.45 (dd, >8.9,4.7 Hz, 1 H), 3.56 - 3.69 (m, 2 H), 6 3.70 - 3.86 (m, 2 H), 7.14 (t, >9.1 Hz, 1 H), 7.45 - 7.55 (m, 1 H), 7.60 - 7.69 (m, 2 H), 7.82 (dd, >7.6,1.7 Hz, 1 H), 8.09 (dd, >7.8,1.7 Hz, 1 H), 8.34 (s, 1 H), 10.62 (s, 1 H)

Compound 125

CI

Compound 125 was prepared similarly as described for compound 126 starting from

2,6-dichloro-3-chlorosulfonyl-benzoic acid instead of 3-chlorosulfonyl-2-methylbenzoic acid. Method G; Rt: 1.77 min. m/z: 464.0 (M+NH|)⁺ Exact mass: 446.0. 'HNMR(400 MHz, CHLOROFORM-d) δ ppm 1.75-1.86 (m, 1 H), 2.04-2.16(m, 1 H), 2.30 (d, >1.8 Hz, 3 H), 3.57 - 3.65 (m, 1 H), 3.66 - 3.76 (m, 2 H), 3.82 - 3.95 (m, 2 H), 5.45 (d, >7.5 Hz, 1 H), 7.01 (t, J=8.9 Hz, 1 H), 7.30 - 7.38 (m, 1 H), 7.47 - 7.56 (m, 2 H), 7.83 (s, 1 H), 8.05 (d, >8.6 Hz, 1 H).

Compound 126

3-ch!orosulfonyl-2-methyl-benzoîc acid (commercial from Enamine EN300-109516;

508.4 mg, 2.17 mmol) was dissolved in dichloromethane (50 mL). DMF (I drop) and oxalylchloridc (1375mg, 10.83 mmol) were added and the mixture was stirred for 4 hours under an inert atmosphère. The reaction mixture was concentrated resulting in 35 chlorosulfonyl-2-methyI-benzoyl chloride as a yellow oil (554 mg) which was used as such in the next step. ’H NMR (400 MHz, CHLOROFORM-/) δ ppm 2.92 - 3.01 (m, 3 H), 7.60 (t, >7.9 Hz, 1 H), 8.27 - 8.41 (m, 2 H). 4-Fluoro-3-methylaniline (227 mg,

1.98 mmol) dissolved in dichloromethane (10 mL) was added drop wise, over 5 minutes, to a solution of 3-chlorosulfonyl-2-methyl-benzoyl chloride (550 mg, 10 2.17 mmol) in toluene (50 mL) at reflux. The réaction mixture was refluxed for 30 minutes and next cooled in an icebath. A solution of (S)-3-aminotetrahydrofùran tosylate (564 mg, 2.17 mmol) and D1PEA (0.85 ml, 4.94 mmol) dissolved in dichloromethane (10 mL) was added and the obtained mixture was stirred for 30 minutes. The resulting mixture was washed with HCl (2 x 100 mL / IM aq), water (2 x 15 100 mL) and NaHCOj (2x100 mL / sat. aq). The organic layer was dried over MgSO₄, filtered and concentrated in vacuo. The obtained residue was purified using silica gel column chromatography (CfyCb-MeOH 100:0 to 90:10) and repurified by applying a gradient from 10 till 100% EtOAc in heptane. The product fractions were concentrated and dried ovemight in vacuo at 50°C yielding compound 126 as colourlcss oil (16.6 mg). MethodG; Rt: 1.65 min. m/z: 393.1 (M+H)* Exact mass: 392.1. ’HNMR (400 MHz, CHLOROFORM-/) δ ppm 1.73 - 1.87 (m, I H), 2.06 - 2.20 (m, 1 H), 2.30 (d, >1.8 Hz, 3 H), 2,69 (s, 3 H), 3.54 - 3.63 (m, 1 H), 3.65 - 3.78 (m, 2 H), 3.83 - 3.97 (m, 2 H), 4.99 (d, >8.1 Hz, 1 H), 7.01 (t, >8.9 Hz, 1 H), 7.31 - 7.44 (m, 2 H), 7.51 (dd, >6.7,2.5 Hz, 1 H), 7.58 - 7.69 (m, 2 H), 8.06 (dd, >8.0, 1.2 Hz, I H)

Procedure SI: A solution of 3-[(4-fluoro-3-methyl-phenyl)carbamoyl]benzencsulfonyl chloride (0.50 g, 1.52 mmol, I eq) in toluene (10 mL) was added to a flask containing an amine (1.1 eq). D1PEA (657 pL, 3.81 mmol, 2.5 eq) was added and the reaction mixture was stirred for I hour. Next, 1M HCl (5 mL) was added to the reaction mixture.

Procedure S2: A tube wascharged with 3-[(4-fluoro-3-methyl-phenyl)carbamoyl]benzenesulfonyl chloride (250 mg, 0.76 mmol) and an amine (1.1 eq) and CH2CI2 (5 mL) was added. The solution was stirred, DIPEA (329 pL, 1.9 mmol, 2.5 eq) was added and the mixture was further stirred for 30 minutes.Then, HCl (IM aq / 5 mL) 35 was added and the mixture was stirred for 5 minutes more.

Procedure S3: To a solution of 3-[(4-fluoro-3-mcthyl-phenyl)carbamoyl]bcnzenesulfonyl chloride (0.50 g, 1.52 mmol, 1 eq) and DIPEA (657 pL, 3.81 mmol, 2.5 eq) in

-79CH₂CI₂(10 mL), an amine (1.1 eq) was added. The reaction mixture was stirred for 1 hour. Ncxt, IM HCl (5 mL) was added to the reaction mixture.

Procedure S4: 3-[(4-fluoro-3-methyl-phenyl)carbamoyl]benzenesulfonyl chloride (250 mg, 0.76 mmol) and DIPEA (329 gL, 1.9 mmol, 2.5 eq) dissolved in CH₂C1₂(5 mL) were added to a tube containing an amine (1.1 eq). The reaction mixture was stirred for 3 hours. 1M HCl (5 mL) was added.

Workup Wl: A precipitate was formed. The precipitate was filtered ofT, rinced with diisopropylether and dried in a vacuum oven at 55 °C.

Workup W2: The organic layer was separated and concentrated in vacuo. The obtained residue was purified by silica gel column chromatography using a heptane to EtOAc gradient as eluent.

Workup W3: The layers were separated and the organic layer was loaded on a silica gel column for purification (with gradient elution: CH₂C12-methanol 100:0 to 97:3). Workup W4: The organic layer was separated and loaded on a silica gel column. The mixture was purified using gradient elution from heptane to EtOAc.

Compound 128

Synthesis following procedure S4 with 7-oxabicyclo[2.2.1]heptan-2-amine.

as amine, workup W4. Method F; Rt: 0.94 min. m/z: 422.1 (M+NH₄)⁺ Exact mass:

404.1.^]H NMR (400 MHz, DMSO-Je ) δ ppm 1.22 - 1.48 (m, 5 H), 1,68 (dd, J=12.5,

7.9 Hz, 1 H), 2.25 (d, J=1.8 Hz, 3 H), 3.25 - 3.29 (m, 1 H), 4,14 (d, J=4.8 Hz, 1 H), 4.44 (t, J=4.8 Hz, 1 H), 7.14 (t, J=9.2 Hz, 1 H), 7.54 - 7.63 (m, 1 H), 7.68 (dd, J=7.2,

2.3 Hz, 1 H), 7.74 - 7.80 (m, 1 H), 7.86 (d, J=6.8 Hz, 1 H), 7.98 - 8.03 (m, 1 H), 8.20 (dt, J=7.8,1.4 Hz, 1 H), 8.35 (t, J=1.5 Hz, 1 H), 10.46 (s, 1 H).

O'

Compound 129

Synthesis following procedure S3 with R-(+)-3-aminotetrahydrofuran toIuene-4sulfonatc as amine, workup W2.

Method F; Rt: 0.89 min. m/z: 396,1 (M+NH|)⁺ Exact mass: 378.1.¹ H NMR (400

MHz, DMSO-di ) ppm 1.56 - 1.65 (m, 1 H), 1.85 - 1.94 (m, 1 H), 2.25 (d, J=1.8 Hz, 3

H), 3.36 (dd, J=9.0,4.4 Hz, 1 H), 3.52 - 3.65 (m, 2 H), 3.65 - 3.73 (m, 1 H), 3.73 - 3.79 . (m, 1 H), 7.14 (t, >9.2 Hz, 1 H), 7.56 - 7.62 (m, 1 H), 7.67 (dd, J=7.0,2.3 Hz, 1 H),

7.78 (t, >7.8 Hz, 1 H), 7.99 - 8.05 (m, 1 H), 8.08 (bs, 1 H), 8.20-8.23(m, 1 H), 8.37 (t, >1.7 Hz, 1 H), 10.47 (s, 1 H), [a]o = + 5.8 (c 0.61 w/v %, MeOH)

Compound 130

Method F; Rt: 0.95 min. m/z: 424.2 (Μ+ΝΗ»)⁺ Exact mass: 406.1.

Synthesis following procedure S3 with racemic trans-2-aminocyclohexanol hydrochloride as amine, workup W2.

Compound 131

Synthesis following procedure S3 with (lS,2<S)-trans-2-amÎnocyclohexanol hydrochloride as amine, workup W2.

Method F; Rt: 0.95 min. m/z: 424.2 (M+NH₄)⁺ Exact mass: 406.1.

'H NMR (400 MHz, DMSO-de) 5 ppm 1.01 -1.23 (m, 4 H), 1.41 - 1.58 (m, 2 H), 1.59 -1.70 (m, 1 H), 1.71 - 1.83 (m, 1 H), 2.25 (d, >1.3 Hz, 3 H), 2.77 - 2.90 (m, 1 H), 3.15 - 3.27 (m, 1 H), 4.50 (d, >4.6 Hz, 1 H), 7.14 (t, >9.2 Hz, 1 H), 7.54 - 7.64 (m, 2 H), 7.64 - 7.69 (m, 1 H), 7.72 (t, >7.9 Hz, 1 H), 8.04 (d, >7.7 Hz, 1 H), 8.16 (d, >7.9 Hz, 1 H), 8.39 (s, 1 H), 10.43 (s, 1 H)

Compound 132

Synthesis following procedure S3 with racemic cis-2-aminocyclohexanol hydrochloride as amine, workup W2. Method F; Rt: 0.96 min. m/z: 424.1 (M+NH₄)⁺ Exact mass:

406.1. ’ll NMR (400 MHz, DMSO-de ) δ ppm 1.01 -1.26 (m, 4 H), 126 - 1.36 (m, 1 H), 1.38- 1.62 (m, 3 H), 2.25 (d, >1.8 Hz, 3 H), 3.03 - 3.14 (m, 1 H), 3.57 (br. s., 1 H),

4.52 (d, >4.2 Hz, 1 H), 7.14 (t, >9.1 Hz, 1 H), 7.46 (d, >7.9 Hz, 1 H), 7.56 - 7.62 (m, 1 H), 7.68 (dd, >7.0,2.6 Hz, 1 H), 7.73 (t, >7.8 Hz, 1 H), 8.05 (dt, >8.1,1.2 Hz, 1 H), 8.14 - 8.19 (m, 1 H), 8.39 (t, >1.7 Hz, 1 H), 10.43 (s, 1 H)

Compound 133

Synthesis following procedure S3 with trans-4-aminocyclohexanol hydrochloride as amine, workup W2.

Method F; Rt: 0.84 min. m/z: 424.2 (M+NH^)* Exact mass: 406.1.

¹ H NMR (400 MHz, DMSO-&) 8 ppm 1.01 - 1.31 (m, 4 H), 1.57 (d, J=10.3 Hz, 2 H),

1.69 (d, >12.5 Hz, 2 H), 2.25 (d, >1.8 Hz, 3 H), 2.84 - 3.01 (m, 1 H), 3.22 - 3.29 (m,

H), 4.46 (d, >4.4 Hz, 1 H), 7.14 (t, >9.1 Hz, 1 H), 7.53 - 7.64 (m, 1 H), 7.68 (dd, >7.0,2.2 Hz, 1 H), 7.72 - 7.79 (m, 2 H), 7.95 - 8.04 (m, 1 H), 8.18 (dt, >7.7,1.3 Hz, 1 H), 8.36 (t, >1.7 Hz, 1 H), 10.46 (s, 1 H)

Compound 134

Method F; Rt: 0.89 min. m/z: 424.2 (M+NH^)* Exact mass: 406.1.

Synthesis following procedure S3 with 3-amino-cyclohexanol as amine, workup W2. Compound 134 was separated in it’s isomers by préparative SFC (Stationary phase: Chiralpak Daicel IC 20 x 250 mm), Mobile phase: CO2, iPrOH with 0.4% iPrNîh), the desired fractions were collected, evaporated, dissolved in MeOH and evaporated again, yielding 134a, 134b, 134c, 134d. SFC Columns: ID-H 250 mm x 4.6 mm Flow: 3 ml/min Mobile phase: 25 % iPrOH (containing 0.2% iPrNH2) hold 18.0 min. Température: 30°C; Rt: 134 a (10.0 min), 134b (11.1 min), 134c (13.6 min), 134d (14.7 min). Cis: Enantiomers 134a and 134b N-(4-fluoro-3-methyl-phenyl)-3[[(I R,3S)-3-hydroxycyclohexyl]sulfamoyl]benzamide or N-(4-fIuoro-3-methylphenyl)-3-[[(lS,3R)-3-hydrDxycyclohcxyl]sulfamoyl]bcnzamide. ’H NMR (400 MHz, DMSO-Je ) 8 ppm 0.84 -1.14 (m, 4 H), 1.48 - 1.60 (m, 2H), 1.60-1.72 (m, 1 H), 1.72 - 1,82 (m, 1 H), 2.26 (d, >1.8 Hz, 3 H), 2.93 - 3.07 (m, 1 H), 3.20 - 3.30 (m, 1 H), 4.58 (d, >4.6 Hz, 1 H), 7.14 (t, >9.1 Hz, 1 H), 7.55 - 7.64 (m, 1 H), 7.69 (dd, >7.0,2.2 Hz, 1 H), 7.76 (t, >7.8 Hz, 1 H), 7.83 (br. s., 1 H), 7.96 - 8.06 (m, 1 H), 8.13 - 8.24 (m, 1 H), 8.38 (t, >1.7 Hz, 1 H), 10.47 (s, 1 H)

Trans: enantiomers 134c and 134d N-(4-fluoro-3-methyl-phenyl)-3-[[(lR,3R)-3 hydroxycyclohexyl]sulfamoyl]benzamide or N-(4-fluoro-3-mcthyl-phenyl)-3[[(lS,3S)-3-hydroxycyclohexyl]sulfamoyl]benzamide ’H NMR (400 MHz, DMSO-de ) 8 ppm 1.08 - 1.20 (m, 1 H), 1.25 - 1.42 (m, 4 H), 1.42 - 1.58 (m, 3 H), 2.25 (d, >1.8

-82Hz, 3 H), 3.36 - 3.45 (m, 1 H), 3.71 - 3.89 (m, 1 H), 4.38 (d, >3.5 Hz, 1 H), 7.14 (t, >9.1 Hz, 1 H), 7.51 (br. s., 1 H), 7.56 - 7.63 (m, 1 H), 7.69 (dd, >7.2,2.3 Hz, 1 H),

7.73 - 7.78 (m, 1 H), 7.97 - 8.05 (m, 1 H), 8.19 (dt, >7.9,1.2 Hz, 1 H), 8.37 (t, >1.7 Hz, 1 H), 10.47 (br. s., 1 H)

Compound 135

Synthesis following procedure S3 with2-oxa-6-azaspiro[3.3]heptane as amine, workup W2. Method F; Rt: 0.91 min. m/z: 389.1 (M-H)' Exact mass: 390.1. ’H NMR (400 MHz, DMSO-de ) δ ppm 2.26 (d, >1.8 Hz, 3 H), 3.95 (s, 4 H), 4.44 (s, 4 H), 7.15 (t, >9.2 Hz, 1 H), 7.57 - 7.65 (m, 1 H), 7.68 (dd, J=7.0,2.4 Hz, 1 H), 7.85 (t, >7.8 Hz, 1 H), 8.01 (dt, >8.0,1.3 Hz, 1 H), 8.28 - 8.38 (m, 2 H), 10.51 (s, 1 H).

Synthesis following procedure SI with (ll?,2S)-(+)-cis-l-aminoindan-2-ol as amine, workup Wl. Method G; Rt: 1.79 min. m/z: 439.0 (M-H)' Exact mass: 440.1.¹ H NMR (400 MHz, DMSO-de) δ ppm 2.25 (d, >1.8 Hz, 3 H), 2.72 (d, >15.0 Hz, 1 H), 2.93 (dd, >16.1,4.6 Hz, 1 H), 4.15 (qd, >4.7,1.8 Hz, 1 H), 4.69 (dd, >8.7,4.7 Hz, 1 H),

4.96 (d, >4.4 Hz, 1 H), 6.87 (d, >7.3 Hz, 1 H), 7.04 - 7.10 (m, 1 H), 7.10 - 7.21 (m, 3 H), 7.55 - 7.64 (m, 1 H), 7.68 (dd, >7.0,2.4 Hz, 1 H), 7.77 (t, >7.8 Hz, 1 H), 7.93 (d, >9.0 Hz, 1 H), 8.15 (dt, >8.1, 1.2 Hz, 1 H), 8.21 (dd, >7.7,1.5 Hz, 1 H), 8.48 (t, >1.7 Hz, 1 H), 10.44 (s, 1 H)

Synthesis following procedure S4 with (l$,21?)-2-ammotetralin-l-ol hydrochloride as amine, workup W4. Method F; Rt: 1.03 min. m/z: 472.2 (M+NH₄)⁺ Exact mass:

454.1. ‘H NMR (400 MHz, DMSO-Je ) δ ppm 1.35 - 1.46 (m, 1 H), 1.96 (qd, >11.8, 6.2 Hz, 1 H), 2.25 (d, >1.5 Hz, 3 H), 2.62 (ddd, >17.2,10.9,6.3 Hz, 1 H), 2.70 - 2.82 (m, 1 H), 3.34 - 3.45 (m, 1 H), 4.39 (br. s., 1 H), 5.29 (d, >5.7 Hz, 1 H), 7.04 (d, >6.8

Hz, 1 H), 7.09 - 7.24 (m. 4 H), 7.55 - 7.63 (m, 1 H), 7.62-7.70 (m, 2 H), 7.75 (t, >7.8 Hz, 1 H), 8.06-8.13 (m, 1 H), 8.19 (d, >8.1 Hz, 1 H), 8.43 (t, >1.5 Hz, 1 H), 10.44 (s, 1 H), [a]?: +66 ° (c 0.55 w/v %, DMF). DSC (From 30 to 300 °C at 10°C/min): 170°C.

Compound 138 ^OH

Synthesis following procedure SI with trans-(lS,2S)-2-aminocyclopcntanol hydrochloride as amine, workup W1. Method F; Rt: 0.88 min. m/z: 410.4 (M+NH₄)⁺Exact mass: 392.1. ’ H NMR (400 MHz, DMSO-de) δ ppm 1.16 - 1.29 (m, 1 H), 1.29 -

1.40 (m, 1 H), l .50 (quîn, >7.4 Hz, 2 H), 1.61 - 1.78 (m, 2 H), 2.25 (d, >1.8 Hz, 3 H),

3.16 - 3.26 (m, 1 H), 3.74 - 3.82 (m, 1 H), 4.67 (d, >4.4 Hz, 1 H), 7.14 (ζ J=9.2 Hz, 1 H), 7.55 - 7.63 (m, 1 H), 7.65 - 7.72 (m, 2 H), 7.75 (t, >7.8 Hz, 1 H), 7.98 - 8.04 (m, 1 H), 8.18 (dt, >7.9,1.3 Hz, 1 H), 8.36 (t, >1.7 Hz, 1 H), 10.45 (s, 1 H)

Compound 139 ^OH

Synthesis following procedure SI with cis-(l/ï,2S)-2-aminocyclopentanol hydrochloride as amine, workup Wl. Method F; Rt: 0.92 min. m/z: 410.1 (M+NH₄)⁺Exact mass: 392.1.¹ H NMR (400 MHz, DMSO-de) δ ppm 125 -1.51 (m, 4 H), 1.51 -

1.67 (m, 2 H), 225 (d, >1.5 Hz, 3 H), 321 - 3.28 (m, 1 H), 3.72 - 3.79 (m, 1 H), 4.63 (d, >4.0 Hz, 1 H), 7.14 (ζ J=9.2 Hz, 1 H), 7.42 (d, >8.1 Hz, 1 H), 7.55 - 7.63 (m, 1 H), 7.68 (dd, >7.3,2.4 Hz, 1 H), 7.73 (t, >7.8 Hz, 1 H), 8.06 (dt, >8.1,1.2 Hz, 1 H),

8.17 (d, >8.1 Hz, 1 H), 8.40 (t, >1.5 Hz, 1 H), 10.43 (s, 1 H)

Compound 172 ^OH

Synthesis following procedure S2 with cis-(15,2Æ)-2-aminocyclopentanol hydrochloride as amine.The formed precipitate was collected on a glassfilter and rinsed with CH2CI2 (2x5 mL). The precipitate was further purified using silica gel column chromatography (gradient elutîon; EtOAc-heptane 0:100 to 100:0). Drying in vacuo at 55°C resulted in compound 172 as abright white powder. Method G; Rt: 1.65 min. m/z: 392.9 (M+H)⁺ Exact mass: 392.1. DSC (From 30 to 300 ^qC at 10°C/min):145 °C.

-84Compound 173

Synthesis following procedure S4 (reaction time= 20 hours instead of 3 hours) with trans-(l/ï,2/ï)-2-aminocyclopentanol as amine, workup W4. Method F; Rt: 0.87 min. m/z: 410.1 (M+NH<)⁺ Exact mass: 392.1.

Compound 140

Synthesis following procedure SI with l,l-dioxothiolan-3-amine hydrochloride as amine, workup Wl. Method F; Rt: 0.85 min. m/z: 444.2 (M+NH₄)* Exact mass: 426. L ¹H NMR (400 MHz, DMSO-de) δ ppm 1.90 - 2.04 (m, 1 H), 2.16 - 2.24 (m, 1 H), 2.25 (d, >1.8 Hz, 3 H), 2.81 (dd, >13.4,7.0 Hz, 1 H), 3.08 (ddd, >13.1,9.1,7.5 Hz, 1 H), 3.15 - 3.26 (m, 2 H), 3.94 - 4.06 (m, 1 H), 7.15 (t, >9.2 Hz, 1 H), 7.55 - 7.63 (m, 1 H),

7.68 (dd, >7.2,2.3 Hz, 1 H), 7.79 (t, >7.8 Hz, 1 H), 8.01 - 8.07 (m, 1 H), 8.23 (dt, >7.7,1.3 Hz, 1 H), 8.38 (t, >1.7 Hz, 1 H), 8.40 (br. s., 1 H), 10.48 (s, 1 H)

Synthesis following procedure S4 with 2-aminoindan-l-ol hydrochloride as amine, workup W4. Method F; Rt; 0.98 and 1.01 min. m/z: 458.1 (M+NH<)⁺ Exact mass: 440.1. Compound 141 was separated in it’s isomers by préparative SFC (Stationary phase: Chiralcel Diacel OD 20 x 250 mm), Mobile phase: CO2, MeOH with 0.2% iPrNH2), the desired fractions were collected, evaporated, dissolved in MeOH and evaporated again. SFC, Column: OD-H (Diacel) 250 mm x 4.6 mm

Flow: 5 mL/min, Mobile phase: 30% MeOH (containing 0.2% iPrNH2) hold 4.00 min, up to 50% in 1 min and hold 2.00 min @ 50% Température: 40°C.Rt: 141a (1.8 min), 141b (2.1 min), 141c (2.5 min), 141d (2.7 min).

141a, 141c: N-(4-fluoro-3-methyl-phenyl)-3-n(lS,2S)-l-hydroxyindan-2-yl]sulfamoyljbenzamide or N-(4-fluoro-3-mcthyl-phcnyl)-3-[[(IR,2R)-l-hydiOxyindan-2yljsulfamoyljbenzamide. 'H NMR (400 MHz, DMSO-i/_e ) δ ppm 2.25 (d, >1.5 Hz, 3 H), 2.43-2.55 (m, 1 H), 2.83 (dd, >15.7,7.8 Hz, I H), 3.59 - 3.70 (m, 1 H), 4.83 (d,

-85>6.8 Hz, 1 H), 5.58 (br. s., 1 H), 7.03 - 7.27 (m, 5 H), 7.56 - 7.65 (m, 1 H), 7.68 (dd, >7.0,2.4 Hz, 1 H), 7.78 (t, >7.8 Hz, 1 H), 8.05 - 8.11 (m, 1 H), 8.16 (br. s., 1 H), 8.22 (d, >8.1 Hz, 1 H), 8.43 (t, >1.7 Hz, 1 H), 10.47 (br. s., 1 H) Method F; Rt: 0.98 m/z:

458.3 (M+NH₄)⁺ Exact mass: 440.1.

141b, 141d: N-(4-fluoro-3-methy!-phenyl)-3-[[(17î,2S)-l-hydroxyindan-2yljsulfamoyljbenzamide or N-(4-fluoro-3-methyl- phenyl)-3-[[( 1 S,2R)-l-hydroxyindan2-yl]sulfamoyl]benzamide. ^JH NMR (600 MHz, ACETONE-de, -14 °C) δ ppm 2.25 (d, >1.9 Hz, 3 H), 2.80 - 2.90 (m, 2 H), 3.94 - 3.99 (m, 1 H), 4.72 (d, >5.3 Hz, 1 H), 4.87 (d, >3.8 Hz, 1 H), 6.96 (d, >5.0 Hz, 1 H), 7.08 (t, >9.2 Hz, 1 H), 7.14 - 7.19 (m, 2 H), 7.21 (td, >7.3,1.2 Hz, 1 H), 7.29 (d, >7.3 Hz, 1 H), 7.65 - 7.70 (m, 1 H), 7.74 (dt, >6.8,3.1 Hz, 1 H), 7.79 (t, >7.8 Hz, 1 H), 8.19 (ddd, >7.8,1.8, 1.1 Hz, 1 H), 8.27 (ddt, >7.8,1.8,0.9,0.9 Hz, 1 H), 8.54 (q, >1.6 Hz, 1 H), 10.09 (s, 1 H) Method F; Rt: 1.00 m/z: 458.2 (M+NH₄)⁺ Exact mass: 440.1.

Compound 142

Synthesïs following procedure S4 with (17ï,2/î)-2-amino-l-phenyl-propan-l-ol as amine, workup W4. Method F; Rt: 1.00 min. m/z: 460.1 (M+NH₄)⁺ Exact mass:

442.1. ’H NMR (400 MHz, DMSO-</₆) δ ppm 0.76 (d, >6.8 Hz, 3 H), 2.25 (d, > 1.3 Hz, 3 H), 3.37 - 3.46 (m, 1 H), 4.56 (d, >4.6 Hz, 1 H), 5.41 (br. s., 1 H), 7.14 (t, >9.2 Hz, 1 H), 7.18 - 7.23 (m, 1 H), 7.23 - 7.32 (m, 4 H), 7.49 (br. s„ 1 H), 7.56 - 7.64 (m, 1 H), 7.64 - 7.72 (m, 2 H), 7.88 - 7.96 (m, 1 H), 8.15 (d, >7.9 Hz, 1 H), 8.31 (t, >1.5 Hz, 1 H), 10.42 (s, 1 H).

Compound 143

Synthesïs following procedure SI with (l/?,2S)-(-)-norcphcdrinc as amine, workup WI. Method F; Rt: 1.01 min. m/z: 460.1 (M+NH0⁺ Exact mass: 442.1.¹ H NMR (400 MHz, DMSO-de ) δ ppm 0.79 (d, >6.8 Hz, 3 H), 2.25 (d, >1.8 Hz, 3 H), 3.33 3.37 (m, 1 H), 4.48 (t, J=4.6 Hz, 1 H), 5.42 (d, >4.6 Hz, 1 H), 7.10 - 7.27 (m, 6 H),

7.55 - 7.63 (m, 1 H), 7.64 - 7.71 (m, 2 H), 7.78 (d, >8.4 Hz, 1 H), 7.91 (dt, >8.2,1.2 Hz, 1 H), 8.12 - 8.18 (m, 1 H), 8.30 (t, >1.7 Hz, I H), 10.42 (s, 1 H)

Synthesis following procedure SI with (15,2Æ)-(+)-norephedrine as amine, workup Wl. Method F; Rt: 1.01 min. m/z: 460.2 (M+NH₄)* Exact mass: 442.1.

*H NMR (400 MHz, DMSO-dk) δ ppm 0.79 (d, >6.8 Hz, 3 H), 2.25 (d, >1.8 Hz, 3 H),

3.32 -3.38 (m, 1 H),4.48 (t, >4.6 Hz, 1 H), 5.42 (d,>4.8 Hz, 1 H), 7.10-7.27(m,

H), 7.56 - 7.63 (m, 1 H), 7.65 - 7.71 (m, 2 H), 7.78 (d, >8.4 Hz, 1 H), 7.89 - 7.94 (m,

H), 8.15 (dt, >7.8, 1.3 Hz, I H), 8.30 (t, >1.7 Hz, 1 H), 10.42 (s, 1 H)

Compound 145

Synthesis following procedure S4 with 3-aminocyclopentanol as amine, after completion, the reaction mixture was directly loaded on a silica gel coiumn for purification, using a heptane to EtOAc gradient yielding compound 145 as a 83 (145a, 145b): 17 (145c, 145d) mixture of diastereomers. Method F; Rt: 0.82 and 0.86 min. m/z: 410.2 (M+NH₄)⁺ Exact mass: 392.1. Compound 145 was separated in ît’s isomers by préparative SFC (Stationary phase: Chiralpak Diacel AD 30 x 250 mm), Mobile phase: CO₂, MeOH with 0.4% iPrNHj), the desired fractions were collected, evaporated, dissolved in MeOH and evaporated again yielding compound 145a (238 mg) and 145b (236 mg) and a mixture of compound 145c and 145d. The mixture of 145c and 145d was further purified by Préparative SFC (Stationary phase: Chiralpak Diacel AD 30 x 250 mm), Mobile phase: CO2, EtOH with 0.4% iPrNH₂), the desired fractions were collected, evaporated, dissolved in MeOH and evaporated again yielding 145c (29 mg) and 145d (27 mg). 145a and 145b: N-(4-fluoro-3-mcthyl-phenyl)-3[[(lÆ,3S)-3-hydroxycyclopentyl]sulfamoyl]bcnzamide or N-(4-fluoro-3-mcthylphenyl)-3-[[(15,3Æ)-3-hydroxycyclopentyl]sulfamoyl]bcnzamide.

Method F; Rt: 0.85 min. m/z: 410.2 (M+NHj)* Exact mass: 392.1. ’H NMR (400 MHz, DMSO-J₆) 5 ppm 1.21 (ddd, >13.3,7.8, 6.1 Hz, 1 H), 1.36 1.64 (m, 4 H), 1.84 - 1.95 (m, 1 H), 2.25 (d, >1.1 Hz, 3 H), 3.37 - 3.47 (m, 1 H), 3.85 -

3.96 (m, 1 H), 4.25-5.00 (IH, br. s), 7.14 (t, >9.2 Hz, 1 H), 7.35-7.75 (IH, br. s), 7.54 7.63 (m, 1 H), 7.68 (dd, >7.0, 2.2 Hz, 1 H), 7.75 (t, >7.8 Hz, 1 H), 8.01 (d, >7.9 Hz, 1 H), 8.19 (d, >7.7 Hz, 1 H), 8.36 (s, 1 H), 10.46 (br. s., 1 H)

145c and 145d: N-(4-fluoro-3-mcthyl-phenyl)-3-[[(15,3S)-3-hydroxycyclopentyl]sulfamoyljbenzamide or N-(4-fluoro-3-methyl-phenyl)-3-[[( lÆ,3/î)-3-hydroxycyclo

-87pentyl]sulfamoyl]benzamide. Method F; Rt: 0.82 min. m/z: 410.2 (M+NHi) Exact mass: 392.1.

'H NMR (400 MHz, DMS0-</₆ ) 5 ppm 1.17 - 1.35 (m, 2 H), 1,41 (ddd, >13.4, 8.0,

5.7 Hz, 1 H), 1.56 (ddd, >13.2,7.3,2.6 Hz, 1 H), 1.69 - 1.83 (m, 2 H), 2.25 (d, >1.8 Hz, 3 H), 3.59 - 3.72 (m, 1 H), 3.99 - 4.09 (m, 1 H), 4.43 (d, >3.5 Hz, 1 H), 7.14 (t, >9.2 Hz, 1 H), 7.55 - 7.63 (m, 1 H), 7.68 (dd, >7.0,2.2 Hz, 1 H), 7.73 - 7.84 (m, 2 H),

7.96 - 8.02 (m, 1 H), 8.20 (dt, >7.9,1.2 Hz, 1 H), 8.36 (t, >1.7 Hz, 1 H), 10.48 (br. s.,

H) 145a: [«]□ : +5.2 ⁰ (c 0.56 w/v%, DMF); 145b: [a]”: -5.4 ⁰ (c 0.60w/v%, DMF); 145c: [a]o : -3.5 ° (e 0.46 w/v %, DMF); 145d: [a]?: +2.5 °(c 0.44 w/v %, DMF)

Compound 146

Synthesis following procedure S2 with 6-oxa-2-azaspiro[3.4]octane oxalatc as amine, after completion, the reaction mixture was directly loaded on a silica gel column for purification, using a heptane to EtOAc gradient yielding compound 146, Method F; Rt: 0.93 min. m/z: 422.3 (M+NH₄)⁴ Exact mass: 404.1.¹ H NMR (400 MHz, DMSO-dô) ppm 1.81 (t, >6.9 Hz, 2 H), 2.26 (d, >1.8 Hz, 3 H), 3.46 (s, 2 H), 3.57 (t, >6.9 Hz, 2 H), 3.72 - 3.80 (m, 4 H), 7.15 (t, >9.1 Hz, 1 H), 7.58 - 7.64 (m, 1 H), 7.69 (dd, >7.0, 2.2 Hz, 1 H), 7.87 (t, >7.8 Hz, 1 H), 8.04 (dt, >8.0,1.3 Hz, 1 H), 8.32 - 8.41 (m, 2 H), 10.53 (s, 1 H).

Compound 147

Synthesis following procedure S2 with 6-oxa-l-azaspiro[3,3]heptane as amine, after completion, the reaction mixture was directly loaded on a silica gel column for purification, using a heptane to EtOAc gradient yielding compound 147. Method F; Rt: 0.92 min. m/z: 408.2 (M+NH,)⁴ Exact mass: 390.1. ¹H NMR (400 MHz, DMSO-</₆ ) δ ppm 2.25 (d, >1.8 Hz, 3 H), 2.53 (t, >7.3 Hz, 2 H), 3.73 (t,>7.4 Hz, 2 H), 4.53 (d, >7.9 Hz, 2 H), 5.01 (d, >7.9 Hz, 2 H), 7.15 (t,>9.1 Hz, 1 H), 7.56 - 7.64 (m, 1 H),

7.68 (dd, >7.0,2.2 Hz, l H), 7.82 (t, >7.8 Hz, 1 H), 8.05 - 8.11 (m, 1 H), 8.29 (dt, >7.8, 1.3 Hz, 1 H), 8.40 (t, >1.7 Hz, 1 H), 10.51 (s, 1 H)

Compound 148

Synthesis following procedure S4 with (S>-(+)-I-cyclohexylethylamine as amine, workup W4. Method F; Rt: 1.23 min. m/z: 436.2 (M+NH.»)⁺ Exact mass: 418.2

Compound 149 F

Synthesis following procedure S4 with 4,4-difluorocyclohexylamine as amine, workup W4. Method F; Rt: 1,06 min. m/z: 444.5 (M+NHj)* Exact mass: 426.1.

Compound 150

Synthesis following procedure S4 with 3-butcn-2-amîne, hydrochloride as amine, workup W4. Method F; Rt: 1.01 min. m/z: 380.3 (M+NHi)⁺ Exact mass:

362.1. *H NMR (400 MHz, DMSO-d^) δ ppm 1.03 (d, >6.8 Hz, 3 H), 2,25 (d, J-1.8 Hz, 3 H), 3.74 - 3.87 (m, 1 H), 4.87 (dt, J= 10.5.1.4 Hz, 1 H), 5.00 (dt, J= 17.3,1.4 Hz, 1 H), 5.61 (ddd, >17.3,10.5,6.1 Hz, 1 H), 7.14 (t, J=9.2 Hz, 1 H), 7.55 - 7.63 (m, 1 H), 7.68 (dd, J=7.2,2.3 Hz, 1 H), 7.74 (t, >7.8 Hz, I H), 7.93 (d, >7.9 Hz, 1 H), 7.96 8.01 (m, 1 H), 8.18 (dt, >7.7, 1.3 Hz, 1 H), 8.35 (t, >1.7 Hz, 1 H), 10.45 (s, 1 H).

Synthesis following procedure S4 (stirred for 20 hours instead of 3 hours) with ($)-(+)2-amino-3-methyIbutane as amine, workup W4. Method F; Rt: 1.11 min. m/z: 396.2 (M+NHj)⁺ Exact mass: 378.1. 'H NMR (400 MHz, CHLOROFORM-d) 6 ppm 0.81 (d, >6.8 Hz, 6 H), 0.95 (d, >6.8 Hz, 3 H), 1.57 - 1.67 (m, l H), 2.28 (d, >1.8,3 H), 3.13 - 3.28 (m, 1 H), 4.85 (d, >8.6 Hz, 1 H), 6.98 (t, J=9.0 Hz, 1 H), 7.36 - 7.46 (m, 1 H),

7.49 - 7.57 (m, 1 H), 7.61 (t, >7.8 Hz, 1 H), 8.00 (dt, >7.9,1.5 Hz, 1 H), 8.12 (dt, >7.9, 1.5 Hz, 1 H), 8.25 (s, I H), 8.39 (t, >1.9 Hz, 1 H).

Synthesis following procedure S4 (stirred for 20 hours instead of 3 hours) with ( 1 Æ)-l cyclopropylethylamine as amine, workup W4.¹ H NMR (400 MHz, CHLOROFORMd) δ ppm-0.05 - 0.05 (m, 1 H), 0.09-0.16 (m, 1 H), 0.20 - 0.36 (m, 1 H), 0.38 - 0.51 (m, 1 H), 0.69-0.81 (m, 1 H), 1.13 (d, >6.6 Hz, 3 H), 2.27 (d, >1.8 Hz, 3 H), 2.63 - 2.85 (m, 1 H), 5.10 (d, >6.8 Hz, 1 H), 6.98 (t, >8.9 Hz, 1 H), 7.37-7.45 (m, 1 H), 7.52 (dd, >6.6,2.4 Hz, 1 H), 7.60 (t, >7.8 Hz, 1 H), 7.98-8.02 (m, 1 H), 8.08-8.13 (m, 1 H),

8.25 (s, 1 H), 8.38 (t, >1.7 Hz, 1 H). Method F; Rt: 1.07 min. m/z: 394.2 (M+NH₄)⁺Exact mass: 376.1.

Synthesis following procedure S4 (stirred for 20 hours instead of3 hours) with (1Æ)-1cyclopropylethylamine as amine, workup W4. The obtained residue was recrystallised from disopropylether/acetonitrile. The precipitate was collected and dried în vacuo at 55°C, resulting in compound 174. ’H NMR (400 MHz, DMSO-de) δ ppm -0.11 - -0.01 (m, 1 H), 0.07 - 0.23 (m, 2 H), 0.29 - 0.38 (m, 1 H), 0.70 - 0.82 (m, 1 H), 0.99 (d, >6.6 Hz, 3 H), 2.21 - 2.30 (m, 3 H), 2.66 (quin, >6.8 Hz, 1 H), 7.14 (t, >9.1 Hz, 1 H), 7.56 - 7.64 (m, 1 H), 7.68 (dd, >7.0,2.4 Hz, 1 H), 7.75 (t, >7.8 Hz, 1 H), 7.85 (br. s., 1 H),

7.93 - 8.07 (m, 1 H), 8.18 (d, >7.9 Hz, 1 H), 8.37 (t, >1.7 Hz, 1 H), 10.46 (br. s., 1 H)

Compound 153

Synthesis following procedure S4 (stirred for 20 hours instead of 3 hours) with 3-amino-l-phenylbutane as amine, workup W4. Method F; Rt: 1.19 min. m/z: 458.2 (M+NH₄)⁺ Exact mass: 440.2. ’H NMR (400 MHz, CHLOROFORM-d) δ ppm 1.06 (d, >6.6 Hz, 3 H), 1.62 - 1.76 (m, 2 H), 2.25 (d, >1.8 Hz, 3 H), 2.44 - 2.64 (m, 2 H),

3.30 - 3.43 (m, 1 H), 5.05 (d, >8.4 Hz, 1 H), 6.96 (t, >8.9 Hz, 1 H), 7.00-7.04 (m, 2 H), 7.09 - 7.17 (m, 1 H), 7.17 - 7.25 (m, 2 H), 7.36-7,42 (m, 1 H), 7.50 (dd, >6.8,2.4

Hz, 1 H), 7.57 (t, J=7.8 Hz, 1 H), 7.95 (m, J=7.8,1 H), 8.10 (m, J=7.8 Hz, 1 H), 8.25 (s, 1 H), 8.37 (t, J=1.5 Hz, 1 H)

3-[(4-fluoro-3-methyl-phenyl)cafbamoyl]benzenesulfonyl chloride (500 mg,

1.53 mmol) and D1PEA (657 gL, 3.8 mmol, 2.5 eq) dissolved in CH2CI2 (15 mL) were added to a tube containing 3-amino-l-Boc-3-mcthyl-azetidine (1.1 eq). The reaction mixture was stirred for 20 hours. 1M HCl (5 mL) was added and the mixture was stirred for 5 minutes. The organic layer was separated and toaded on a silica gel column. The mixture was purified using gradient élut ion from heptane to EtOAc, resultîngincompound 154 (721 mg). MethodF;Rt: Lit min.m/z:478.2 (M+H)* Exact mass: 477.2.

Compound 155

Prepared as described for compound 154 using l-Boc-3-aminopiperidîne instead of

3-anuno-l-Boc-3-mcthyl-azetidine. Method F; Rt: 1.13 min. m/z: 492.1 (M+H)* Exact mass: 491.2.

Compound 156

Prepared as described for compound 154 using (+/-)-3-amino-l-N-Boc-pynOlidine instead of 3-amino-l-Boc-3-methyl-azetîdine. Method F; Rt: 1.08 min. m/z: 478.2 (M+H)* Exact mass: 477.2 'H NMR (400 MHz, CHLOROFORM-d) δ ppm 1.36 (s, 9 H), 1.71 - 1.92 (m, 1 H), 1.92-2.15 (m, 1 H), 2.28 (d, >1.8 Hz, 3 H), 3.10-3.24 (m, t H), 3.24-3.44 (m, 3 H), 3.81 - 3.94 (m, t H), 5.50 - 6.00 (m, 1 H), 6.98 (t, >9.0 Hz, 1 H), 7.40 - 7.48 (m, 1 H), 7.52 - 7.71 (m, 2 H), 7.93-8.03 (m, 1 H), 8.04 - 8.17 (m, 1 H), 8.31 (br. s., 1 H), 8.45 - 8.88 (m, 1 H).

Compound 154 (721 mg, 1.51 mmol) was dissolved in CH2CI2 (10 mL) and HCl (6M in iPrOH, 2.5 mL) was added. The mixture was stirred ovemight and the volatiles were removed in vacuo, resulting in N-(4-fluoro-3-methyl-phenyl)-3-[(3-mcthylazctidin3-yl)sulfamoyl]benzamidc hydrochloride as a white solid (0.57 g). To N-(4-fluoro-3methyl-phenyl)-3-[(3-methylazetidin-3-yl)sulfamoyl]benzamide hydrochloride (150 mg) in CH2CI2 (10 mL), DIPEA (263 pL, 1.5 mmol) and methyl chloroformate (44 pL, 0.57 mmol) were added. The mixture was concentrated under a gentle flow of nitrogen at 55°C until only 2 mL remained. This residue was purified using silica gel column chromatography (gradient elution: EtOAc-heptanc 0:100 to 100:0). The desired fractions were concentrated under reduced pressure and the obtained product was dried in a vacuum oven at 55°C yielding compound 157 (74.2 mg) as a bright white powder. Method F; Rt: 0.93 min. m/z: 436.1 (M+H)⁺ Exact mass: 435.1. ‘H NMR (400 MHz, DMSO-de) δ ppm 1.36 (s, 3 H), 2.25 (d, >1.5 Hz, 3 H), 3.52 (s, 3 H), 3.56-3.68 (m, 2 H), 3.83-3.93 (m, 2 H), 7.14 (t, J = 9.2 Hz, 1 H), 7.57 - 7.62 (m, 1 H), 7.68 (dd, >6.8,

2.4 Hz, I H), 7.77 (t, J=7.9 Hz, 1 H), 8.01 (m, >7.9 Hz, 1 H), 8.21 (m, J=7.9 Hz, 1 H), 8.37 (t, >1.5 Hz, 1 H), 8.48 (bs, I H), 10.49 (s, 1 H)

Prepared similarly as described for compound 157, starting from compound 156 instead of compound 154, via intermediate N-(4-fluoro-3-methyl-phenyl)-3-(pyrrolidin-3-ylsulfamoyl)benzamide hydrochloride. Method F; Rt: 0.91 min. m/z: 436.2 (M+H)⁺Exact mass: 435.1. *H NMR (400 MHz, DMSO-de) δ ppm 1.61-1.77 (m, 1 H), 1.80-

1.98 (m 1 H), 2.25 (d, >1.5 Hz, 3 H), 3.00-3.12 (m, 1 H), 3.14 - 3.27 (m, 1 H), 3.26 -

3.39 (m, 2 H), 3.50-3.58 (m, 3 H), 3.67 - 3.76 (m, 1 H), 7.14 (t, J=9.2 Hz, 1 H), 7.57 7.63 (m, 1 H), 7.68 (dd, J=7.2,2.3 Hz, 1 H), 7.78 (t, >7.8 Hz, I H), 7.97 - 8.04 (m, I H), 8.04 - 8.18 (m, 1 H), 8.18 - 8.25 (m, 1 H), 8.37 (t, >1.5 Hz, 1 H), 10.48 (s, 1 H)

Compound 159

Prepared similarly as described for compound 157, starting from compound 155 instead of compound 154, via intermediate N-(4-fluoro-3-methyl-pheny!)-3-(3-pipcridylsulfamoyl)benzamide hydrochloride. Method F; Rt: 0.96 min, m/z: 467.1 (M+NH₄)⁺Exact mass: 449.1. The racemic compound 159 was separated by Préparative SFC (Stationary phase: Chiralpak Daicel IC 20 x 250 mm), Mobile phase: CO₂, MeOH with 0.2% iPrNH₂), the desired fractions were collected, evaporated, dissolved in methanol and evaporated again, resulting in enantiomer 159a and 159b.

Columns: ID-H (Daicel) 250 mm x 4.6 mm; Flow: 3 mL/min; Mobile phase: 20% EtOH (containing 0.2% iPrNH₂) hold 15.00 min; Température: 30°C ; Rt: 9.6 min (159a), Rt: 11.0 min (159b)

Method B; Rt: 4 min. m/z: 443.1 (M+H)⁺ Exact mass: 442.0 ’H NMR (400 MHz, DMSO-de) S ppm 1.41 (s, 3 H) 4.14 (d, J= 6.3 Hz, 2 H) 4.56 (d, J=6.0 Hz, 2 H) 7.42 (t, J=8.8 Hz, I H) 7.74 - 7.82 (m, 2 H) 8.04 (s, 1 H) 8.15 - 8.24 (m, 2 H) 8.37 (t, J=l .5 Hz, 1 H) 8.54 (br. s, 1 H) 10.67 (br. s, 1 H).

l-pyridin-4-yl-cthylamine (220 mg, 1.8 mmol) and 3-[(4-fluoro-3-methyl-phenyl)carbamoyijbenzenesulfonyl chloride (500 mg, 1.53 mmol) were dissolved in CH₂C1₂(10 mL). DIPEA (6.2 mmol) was added at 0°C and the mixture was stirred at 25°C for 4 hours. The mixture was washed with water (20 mL) and the aqueous layer was extracted with CH₂C1₂ (3 x 20 mL). The combined organic layers were washed with brine and dried over Na₂SO₄. The solvent was removed in vacuo and the obtained residue was purified by reversed phase high performance liquid chromatography (mobile phase: CHjCN in water (0.1% TFA) from 30% to 60%).

-93The pure fractions were collected and neutralized with solid NaHCOj. The organic solvent was removed in vacuo and the formed precipitate was filtered, washed with H₂O (5 mL) and dried under high vacuum. The obtained residue was suspended in water (5 mL) and the aqueous layer was lyophilized to dryness, resulting in compound

161 (410 mg). Method A; Rt: 4.34 min. m/z: 414.3 (M+H)⁺ Exact mass: 413.1. ’H NMR (400 MHz, DMSO-7,) δ ppm 1.23 (d, 7=7.0 Hz, 3 H) 2.26 (d, 7= t .5 Hz, 3 H)

4.34 - 4.50 (m, l H) 7.15 (t, 7=9.3 Hz, 1 H) 7.20 - 7.24 (m, 2 H) 7.56 - 7.66 (m, 2 H)

7.68 (dd, 7=7.0,2.3 Hz, l H) 7.86 (m, 7=7.8 Hz, 1 H) 8.13 (m, 7=7.8 Hz, 1 H) 8.26 (t, 7=1.3 Hz, l H) 8.32 - 8.39 (m, 2 H) 8.55 (d, 7=8.3 Hz, 1 H) 10.41 (s, 1 H).

Compound 162

Prepared similarly as described for compound 161, using l-(3-pyridyl)ethanamine instcad of l-pyridin-4-yl-ethylamine. Method D; Rt: 5.16 min. m/z: 414.3 (M+H)* Exact mass: 413.1.

Compound 163 ^X

Prepared similarly as described for compound 161, using l-(2-pyridyl)cthanammc insteadof l-pyridin-4-yl-ethylamine. Method A; Rt: 4.60 min. m/z: 414.3 (M+H)* Exact mass: 413.1.

Compound 164 ^sX

Prepared similarly as described for compound 161, using l-(l-methyl-4piperidyl)ethanamine insteadof l-pyridin-4-yl-ethylamine. MethodB; Rt: 3.35 min. m/z: 434.4 (M+H)* Exact mass: 433.2.

Compound 165

-94Prepared similarly as described for compound 161, using 4-morpholinobutan-2-amine instead of l-pyridÎn-4-yl-ethylamine. Method B; Rt: 3.33 min. m/z: 450.3 (M+H)⁺Exact mass: 449.2.

Compound 166

Prepared similarly as described for compound 161, using (Æ)-l-phenylethanamine instead of l-pyridin-4-yl-ethylamine. The impure compound was purified by préparative high-performance liquid chromatography (column: Luna 150*30mm*5u, mobile phase: CHjCN in water (0.1% NH₄HCOj) from 40% to 70%, flow rate: 35 ml/min). Method B; Rt: 4.45 min. m/z: 413.3 (M+H)⁺ Exact mass: 412.1. [a]”: + 55° (c 0.12 w/v, methanol).

Compound 167

Prepared similarly as described for compound 166, using(S)-l-phenylethanamine instead of (A)-l-phcnylethanamine. Method B; Rt: 4.45 min. m/z: 413.3 (M+H)⁺ Exact mass: 412.1. [«]» : - 57° (c 0.12 w/v, methanol).

Compound 168 *—%

Synthesis following procedure S4 (20 hours reaction time instead of 3 hours) with 2-aminoindane as amine, workup W4. The obtained residue was rccrystalliscd from Diisopropylether/acetonitrile, resulting in compound 168. Method F; Rt: 1.14 min. m/z:

442.2 (M+NHt)* Exact mass: 424.1. 'H NMR (400 MHz, DMSO-J_s) δ ppm 2.25 (d, >1.8 Hz, 3 H), 2.72 (dd, >15.6,7.0 Hz, 2 H), 2.96 (dd, >15.8, 7.5 Hz, 2 H), 3.95 (quin, >7.3 Hz, 1 H), 7.08 - 7.17 (m, 5 H), 7.57 - 7.63 (m, 1 H), 7.68 (dd, >6.9,2.3 Hz, I H), 7.79 (t, >7.8 Hz, 1 H), 8.03 - 8.12 (m, 1 H), 8.13 - 8.28 (m, 2 H), 8.41 (t, >1.7 Hz, 1 H), 10.49 (br. s., 1 H)

Prepared similarly as described for compound 166, using l-phenylpropan-2-amine instead of (Æ)-l-phenylethanamine. Method B; Rt: 4.60 min. m/z: 427.3 (M+H)⁺ Exact mass: 426.1.

#	T¹ Rr^Ny	Amine used	Synthetic/ work up Procedure	LC-MS method	Rt (min.)	[M+NIÏ4 for [M+Hf	Exact mass
170		2-cyclopropylcthanaminc	S4/W4	H	8.63	377.1	376.1
171	y	4-anunolctrahydroruran-3-ol	S4/W4	F	0.79	412.1	394.1
175	QA OH	(1R,2R)-1amino-2,3· dihydro-lHinden-2-ol	S4*/W4	F	0.97	458.1	440.1
176	QA OH	(iS,2S)-lAmino-2,3dihydro-lH- indcn-2-ol	S4*/W4	F	1.01	458.1	440.1
177	ΌΗ	(iS^RH-)-Cisl-amino-2· indanol	S4*/W4	F	0.97	458.4	440.1
178	OH y	(1R.2RJ-2amin<Metra!in-lol hydrochloride	S4*/W4	F	1.01	472.2	454.1

#		Amine used	Synthetic/ work up Procedure	LC-MS method	Rt (min.)	[M+NH, \|*or 1Μ+ΗΓ	Exact mass
179	«A 1	4-Amino-lmethylpyrrolÎdin-2-one	S4*/W4	F	0.81	406.1	405.1
180	o^tr 1	5-Amino-lmethylpiperidin-2-one	S4*/W4	F	0.81	420.2	419.1
181	1	3-Amino-lmclhylpynOlidi n-2-one	S4/W4	F	0.84	423.1	405.1
182	H rfV _ZN-J Boc	3-Amino-l-Nboc-azctidine	S4*/W4	F	1.06	481.2	463.2
183		l-(trifluon> methy1)cyclopropanamine	S4*/W4	F	1,03	434.1	416.1

S4*: reaction time 20 hours instcad of 3 hours

Compound 175. 'H NMR (400 MHz, DMSO-da) δ ppm 2.25 (d, J=1.5 Hz, 3 H), 2.62 (dd, J= 15.7, 6.5 Hz, 1 H), 3.07 (dd, J= 15.7, 6.7 Hz, 1 H), 4.11 (quin, >6.2 Hz, 1 H),

4.50 (dd, J=7.9, 6.2 Hz, 1 H), 5.14 (d, >5.7 Hz, 1 H), 6.92 (d, J=7.5 Hz, 1 H), 7.06 -

7.24 (m, 4 H), 7.55 - 7.65 (m, 1 H), 7.69 (dd, J=7.0,2.4 Hz, 1 H), 7.77 (t, J=7.8 Hz, 1 H), 8.05 - 8.15 (m, 1 H), 8.19 - 8.26 (m, 1 H), 8.31 (d, J=8.4 Hz, 1 H), 8.47 (t, J=1.7 Hz, 1 H), 10.45 (s, 1 H)

Compound 178. ^lH NMR (400 MHz, DMSO-d$) δ ppm 1.51-1.72 (m, 1 H), 1.86 10 1.99 (m, 1 H), 2.22 - 2.31 (m, 3 H), 2.60-2.74 (m, 1 H), 2.74 - 2.85 (m, 1 H), 3.26 -

3.41 (m, 1 H), 4.38 (t, >6.2 Hz, 1 H), 5.32 - 5.39 (m, 1 H), 6.96 - 7.09 (m, 1 H), 7.11 -

7.21 (m, 3 H), 7.28 - 7.37 (m, 1 H), 7.51 - 7.65 (m, 1 H), 7.69 (dd, J=7.0,2.4 Hz, 1 H), 7.72 - 7.82 (m, 2 H), 8.05 - 8.12 (m, 1 H), 8,17 - 8.24 (m, 1 H), 8.43 (t, >1.7 Hz, 1 H), 10.48 (s, 1 H)

Compound 179. 'H NMR (400 MHz, DMSO-da) δ ppm 1.99 (dd, >5.1,16.7 Hz, 1 H),

2.25 (d, >1.8 Hz, 3 H), 2.35 (dd, >8.4,16.7 Hz, 1 H), 2.66 (s, 3 H), 3.10 (dd, >10.1, 4.6 Hz, 1 H), 3.47 (dd, >10.3,7.3 Hz, 1 H), 3.80-3.92 (m, 1 H), 7.14 (t, J=9.2 Hz, 1 H), 7.53 - 7.63 (m, 1 H), 7.68 (dd, >7.0,2.2 Hz, 1 H), 7.74 - 7.86 (m, 1 H), 7.97 - 8.08 (m, 1 H), 8.15 - 8.32 (m, 2 H), 8.37 (s, 1 H), 10.48 (s, 1 H). Racemic compound 179 was separated in enantiomers 179a and 179b by Preparative SFC (Stationary phase:

‘ Chiralpak Diacel AD 30 x 250 mm), Mobile phase: CO₂, ÎPrOH with 0.4% iPrNH₂) The collected fractions were concentrated in vacuo resulting in compound 179a and 179b. Columns: AD-H (diacel) 250 mm x 4.6 mm; Flow: 5 mL/min; Mobile phase: 30% iPrOH (containing 0.2% iPrNH₂) hold 4.00 min, up to 50% in 1 min and hold 2.00 min @ 50%; Température: 40°C Rt: 2.2 min (179a); 2.9 min (179b). 179a: +6.1 ⁰ (589 nm, c 0.6225 w/v %, MeOH, 20 °C). 179b: -6.1 ⁰ (589 nm, c 0.506 w/v %, MeOH, 20°C).

Compound 180. ’H NMR (400 MHz, DMSO-de) δ ppm 1.55 - 1.79 (m, 2 H), 2.01 2.36 (m, 5 H), 2.68 (s, 3 H), 3.06 (dd, >12.3,6.8 Hz, 1 H), 3.25 - 3.30 (m, 1 H), 3.46 -

3.58 (m, 1 H), 7.14 (t, >9.1 Hz, 1 H), 7.52 - 7.63 (m, 1 H), 7.64 - 7.71 (m, 1 H), 7.78 (t, >7.8 Hz, 1 H), 8.01 - 8.09 (m, 1 H), 8.11 - 8.27 (m, 2 H), 8.39 (t, >1.7 Hz, 1 H), 10.47 (s, 1 H)

Compound 181. ’H NMR (400 MHz, DMSO-de) δ ppm 1.59 (dq, > 12.4,9.3 Hz, 1 H),

1.93 - 2.16 (m, 1 H), 2.25 (d, J=1.5 Hz, 3 H), 2.69 (s, 3 H), 3.06 - 3.24 (m, 2 H), 4.00 (ζ >9.1 Hz, 1 H), 7.14 (t, >9.2 Hz, 1 H), 7.54 - 7.64 (m, 1 H), 7.65 - 7.71 (m, 1 H), 7.74 (t, >7.8 Hz, 1 H), 7.99 - 8.09 (m, 1 H), 8.25 (br. s, 1 H), 8.11 - 8.20 (m, 1 H), 8.44 (t, >1.7 Hz, 1 H), 10.42 (s, 1 H).

Compound 182.¹H NMR (400 MHz, DMSO-de) δ ppm 1.12 -1.52 (m, 9 H), 2.26 (d, >1.3 Hz, 3 H), 3.40-3.60 (m 2 H), 3.80-4.00 (m, 2 H), 4.02 - 4.19 (m, 1 H), 7.15 (t, >9.2 Hz, 1 H), 7.57 - 7.66 (m, 1 H), 7.70 (dd, >7.0,2.2 Hz, 1 H), 7.80 (t, >7.8 Hz, 1 H), 8.01 (m, >8.1 Hz, 1 H), 8.26 (m, >7.9 Hz, 1 H), 8.38 (t, >1.0 Hz, 1 H), 8.51 (d, >8.4 Hz, 1 H), 10.50 (s, 1 H).

Compound 183. ’H NMR (400 MHz, CHLOROFORM-d) δ ppm 1.19 -1.43 (m, 4 H), 2.28 (d, >1.8 Hz, 3 H), 5.74 (br. s., 1 H), 6.99 (t, >8.8 Hz, 1 H), 7.37 (m, >8.4,3.7 Hz, 1 H), 7.45 - 7.54 (m, 1 H), 7.64 (t, >7.8 Hz, 1 H), 7.88 (br. s., 1 H), 8.03 (m, >8.1 Hz, 1 H), 8.10 (m, >7.9 Hz, 1 H), 8.29 - 8.38 (m, 1 H)

HO'

Compound 184

Synthesis following procedure S4 with 3-aminocyclobutanol as amine, 1 hour reaction time instead of 3 hour, workup W4. Method F; Rt: 0.81 min. m/z: 396.2 (M+NH₄)⁺ Exact mass: 378.1. SFC: Columns: Diacel AD-H (250 mm x 4,6 mm); Flow: 5 mL/min Mobile phase: 30% MeOH (containing 0.2% iPrNH₂) hold 4.00 min, up to 50% in 1 min and hold 2.00 min at 50%; Température: 40°C; Rt: 184a (2.5

-98mm), 184b (3.4 min). The diastercomenc mixture of compound 184 was separated m diastereoisomers (Prep SFC (Stationary phase: Chiralpak Diaccl AD 30 x 250 mm), Mobile phase: CO₂, MeOH with 0.4% iPrNH₂). The obtained fractions were concentrated under reduced pressure and dried in vacuo at 55°C, resulting in compound

184a and 184b.

Compound 184a

'H NMR (600 MHz, DMSO-de) δ ppm 1.84 - 1.91 (m, 2 H), 1.92 -1.98 (m, 2 H), 2.25 (d, >1.8 Hz, 3 H), 3.77 (quin, >6.9 Hz, 1 H), 4.10 - 4.14 (m, 1 H), 4.93 (d, J=4.9 Hz, 1 H), 7,14 (t, >9.2 Hz, 1 H), 7.59 (ddd, >8.8,4.6,2.7 Hz, 1 H), 7,68 (dd, >7.1,2.7 Hz, 1 H), 7.76 (t, >7.8 Hz, 1 H), 7.96 (ddd, >7.8,1.9,1.1 Hz, 1 H), 8.06 (br. s., 1 H),

8.20 (dt, >7.8,1.5 Hz, 1 H), 8.33 (t, >1.8 Hz, 1 H), 10.49 (br. s., 1 H).

Compound 184b

*H NMR (600 MHz, DMSO-de) δ ppm 1.54 - 1.60 (m, 2 H), 2.19 - 2.24 (m, 2 H), 2.25 (d, >1.8 Hz, 3 H), 3.09 - 3.19 (m, 1 H), 3.62 - 3.68 (m, 1 H), 5.00 (d, >5.6 Hz, 1 H), 7.14 (t, >9.2 Hz, 1 H), 7.59 (ddd, >8.5,4.5,2.8 Hz, 1 H), 7.68 (dd, >7.0,2.2 Hz, I H), 7.75 (t, >7.8 Hz, 1 H), 7.97 (ddd, >7.8,1.9,1.0 Hz, 1 H), 8.02 (br. s., 1 H), 8.19 (ddd, >7.8, 1.8,1.1 Hz, 1 H), 8.34 (t, >1.6 Hz, 1 H), 10.48 (s, 1 H)

Compound 185

Prepared similarly as described for compound 157, starting from compound 182 instead of compound 154, via intermediate 3-(azetidin-3-ylsulfamoyl)-N-(4-fluoro-3-methylphenyl)benzamide hydrochloride. Method F; Rt: 0.89 min. m/z: 439.2 (M+NHi)⁺Exact mass: 421.1.^lH NMR (400 MHz, DMSO-de) δ ppm 2.25 (d, >1.8 Hz, 3 H), 3.45-3.60 (m, 5 H), 3.85-4.05 (m, 2 H), 4.07 - 4.17 (m, 1 H), 7.15 (t, >9.1 Hz, 1 H),

7.53 - 7.64 (m, 1 H), 7.65 - 7.71 (m, 1 H), 7.78 (t, >7.8 Hz, 1 H), 7.94 - 8.03 (m, 1 H), 8.23 (m, >7.9 Hz, 1 H), 8.33 (t, >1.7 Hz, 1 H), 8.44 - 8.63 (br. s, 1 H), 10.49 (s, 1 H).

3-(isopropylsuIfamoyl)benzoic acid (250 mg, L03 mmol), 4-fluoro-3,5-dimethylaniline(157mg, I.I3 mmol) andDIPEA(398 mg,3.08 mmol) weremixed in acetonitrile (10 mL) at room température under a nitrogen atmosphère. HATU (430 mg, I.I3 mmol) wasadded andthe mixture was stirredovemight. EtOAc (100mL) was added and the mixture was washed with IM HCl, sat NaHCOj and brine. After drying over MgSO₄ and évaporation to dryness in vacuo, the obtained residue was crystallized from MeOH (10 mL) to provide a white solid (216 mg). Method F; Rt: L04 min. m/z: 382.2 (M+NH₄)⁺ Exact mass: 364.1.¹H NMR (400 MHz, DMSO-d^) δ ppm

0.96 (d, >6.6 Hz, 6 H), 2.23 (d, >2.0 Hz, 6 H), 3.23 - 3.29 (m, 1 H), 7.48 (d, >6.6

Hz, 2 H), 7.66 - 7.80 (m, 2 H), 7.95 - 8.04 (m, 1 H), 8.18 (d, >7.9 Hz, I H), 8.35 (t, >1.7Hz, IH), 10.37(s, 1 H).

Compound 187

Br

A solution of 2-fluoro-6-methylbenzoic acid (10 g, 0.0649 mol) in HOAc (300 mL) was stirred on a water-bath containing a bit of ice. At ~ 15°C, HNOj (65%, 32.7 mL) was added dropwise. After addition, H₂O (30 mL) was added slowly. After addition, 20 Br₂ (3.7 mL) was added dropwise. A solution of silver nitrate (14.33 g, 0.0844 mol) in

H₂0 (100 mL) was added dropwise over a period of 30 minutes. After addition, the reaction mixture was stirred at room température for 3 hours 30 minutes. The reaction mixture was poured into H₂O (850 mL), and EtOAc (300 mL) was added. The mixture was stirred vigorously for 5 minutes. Both upper liquid layers were dccantcd from a 25 residue. The separated water layer was combined with the residue, and extracted with

EtOAc. Both upper liquid layers were dccanted from the residue. The separated water layer was combined with the residue, and extracted again with EtOAc. The organic layers were combined, washed with satured NaCl and dried with Na₂SO₄, filtered off, evaporated, and co-evaporated with toluene. The obtained solid residue was stirred in a 30 small amount of diisopropylether, filtered off, washed with diisopropylether, resulting

in 3-bromo-6-fIuoro-2-mcthyl-bcnzoic acid (4 g).The fïltrate was evaporated. The residue was stirred in heptane, filtered off, washed with heptanes (3x), and dried at 50°C in vacuo, resulting in a mixture of bromo-6-fluoro-2-mcthyl-benzoïc acid and 2fluoro-6-methylbenzoic acid (12 g, 1/0.4 ratio). 3-bromo-6-fluoro-2-mcthyl-bcnzoic acid (4 g, 0.0172 mol) was added portionwise to stirring chlorosulfonic acid (25 mL). The resulting solution was stirred at 115°C for 2 hours, left standing at room température ovemight and next stirred at 115°C for 3 hours more. The reaction mixture was allowed to reach room température, and added dropwise to a stirring mixture of crushed ice (150 g) and H₂O (50 mL). The product was extracted with EtOAc (2 x).

The combined organic layers were washed with brine, dried with Na₂SO₄, filtered off, and evaporated, resulting in a crude mixture containing 5-bromo-3-chlorosulfonyl-2fluoro-6-methyl-benzoic acid (4.4 g) (Na₂CO₃,1.407 g, 0.0133 mol) was dissolved in water (25 mL). A solution of (S)-3-aminotetrahydrofiiran (2.312 g, 0.0265 mol) in THF (20 mL) was added, and the reaction mixture was cooled to 0°C on an ice-bath. A solution of crude 5-bromo-3-chlorosulfony[-2-fluoro-6-methyl-benzoic acid (4.4 g) in THF (30 mL) was added dropwise at 0°C. After addition, the réaction mixture was stirred at 0°C for 1 hour, and at room température for 2 hours. The mixture was concentrated till ~ 35 mL rcmained, then left standing for 70 hours. The solid was filtered offand washed with H₂O (2x). The fïltrate was washed with Et₂O. The separated waterlayer was acidified with IN HCl (30 mL), and the product was extracted with 2-MeTHF. The separated waterlayer was acidified further till pH ~ 2 and extracted with 2-MeTHF. The organic layer was washed with brine, dried with Na₂SO₄and filtered, resulting in crude 5-bromo-2-fluoro-6-methyl-3-[[(3S)-tetrahydrofuran-3yljsulfamoyljbenzoic acid (6.5 g). To a stirring solution of crude 5-bromo-2-fluoro-625 methyl-3-[[(3S)-tetrahydrofuran-3-yl]sulfamoyl]benzoic acid (1.3 g) in CH₃CN (30 mL ) under N₂-atm triethylamine (1.42 mL, 0.0102 mol ), 3,4-difluoroaniline (0.446 mL,

4.42 mmol ) and HATU (1.55 g, 4.08 mmol ) were successively added. The reaction mixture was stirred at room température for 16 hours. The volatiles were evaporated and the obtained residue was purified by silica gel chromatography (heptane-EtOAc

100/0 to 0/100 ], resulting in compound 187 (0.45 g).An impure fraction was further purified by Préparative HPLC (Stationary phase: RP XBridge PrepC18 OBD10pm,30x 150mm), Mobile phase: 0.25% NH₄HCO₃ solution in water, CH₃CN), resulting in more compound 187 (0.048 g) Method F; Rt: 1.06 min. m/z: 491.0 (M-H)' Exact mass:492.0. ’H NMR (400 MHz,

DMSO-î/î) δ ppm 1.66 - 1.76 (m, I H), 1.94 - 2.05 (m, 1 H), 2.41 (s, 3 H), 3.43 (dd, >8.9,4.5 Hz, 1 H), 3.58 - 3.65 (m, 1 H), 3.68 (dd, >8.9,6.3 Hz, 1 H), 3.71 - 3.78 (m, 1 H), 3.83 - 3.92 (m, 1 H), 7.36 - 7.42 (m, 1 H), 7.43 - 7.52 (m, 1 H), 7.85 (ddd, >12.8,

7.5,2.4 Hz, 1 H), 8.02 (d, >6.8 Hz, 1 H), 8.55 (s, t H), 11.09 (s, 1 H)

-101-

Compound 188

Compound 187 (0.45 g, 0.912 mmol ) was dissolved in MeOH (20 mL) and THF (30 mL). To the resulting solution, tricthylamïne (0.254 mL, 1.82 mmol) was added and the mixture was stirred with 10% Pd/C (0.2 g) under hydrogen atmosphère at room température. After 3 hours, the catalyst was filtered off over dicalite, and washed with MeOH (3x) and THF (Ix). The volatiles were removed in vacuo and the obtained residue was dissolved in hot MeOH (10 mL) and hot H2O (10 mL) was added. The volume was concentrated till ~ 15 mL, and left standing for 1 hour. The precipitated product was filtered off, washed with H2O (3x), and dried at 50°C in vacuo, resulting in compound 188 (245 mg). Method F; Rt: 0.93 min. m/z: 413.2 (M-H)' Exact mass:

414.1.” F NMR (377 MHz, DMSO-dô) δ ppm -143.7 - -143.2 (m, 1 F), -137.1 - -136.5 (m, 1 F), -114.8 (d, >7.9 Hz, 1 F).¹H NMR (400 MHz, DMSO-di) δ ppm 1.66 1.77 (m, 1 H), 1.91 - 2.03 (m, 1 H), 2.39 (s, 3 H), 3.43 (dd, >9.0,4.6 Hz, 1 H), 3.57 -

3.70 (m, 2 H), 3.70 - 3.77, (m, I H), 3.78 - 3.86 (m, 1 H), 7.35 (d, >8.1 Hz, 1 H), 7.39 - 7.52 (m, 2 H), 7.79 (t, >7.8 Hz, 1 H), 7.87 (ddd, >12.9,7.5,2.1 Hz, 1 H), 8.32 (br. s., 1 H), 11.00 (s, 1 H).

Compound 189

Compound 189 was prepared similarly as described for compound 188, using 4-fluoro3-methyIaniline instead of 3,4-difluoroaniline. Method F; Rt: 0.94 min. m/z: 409.2 (ΜΗ)’ Exact mass:410.1. ”FNMR (377 MHz, DMSO-dé) δ ppm -122.40 (dtd, >9.3,4.6, 4.6,2.1 Hz, 1 F), -114.96 (d, >7.2 Hz, 1 F). ‘H NMR (400 MHz, DMSO-/₆) δ ppm 1.67 - 1.77 (m, 1 H), 1.92 - 2.03 (m, 1 H), 2.24 (d, >1.5 Hz, 3 H), 2.38 (s, 3 H), 3.43 (dd, >8.8,4.6 Hz, 1 H), 3.58 - 3.64 (m, 1 H), 3.65 - 3.70 (m, I H), 3.70 - 3.77 (m, 1 H), 3.78 - 3.86 (m, 1 H), 7.14 (dd, >9.1 Hz, 1 H), 7.34 (d, >8.1 Hz, 1 H), 7.45 - 7.53 (m, 1 H), 7,63 (dd, >7.0,2.4 Hz, 1 H), 7.77 (dd, >7.9 Hz, I H), 8.30 (br. s., 1 H), 10.72 (s, I H). Difïerential scanning calorimetry From 30 to 300 °C at 10°C/min:

Peakat 157.0’C

Compound 190

Br

NajCOj (1.60 g, 0.0151 mol) was dissolved in water (25 mL). A solution of 3methyloxetan-3-amîne (2.63 g, 0.0302 mol) in THF (20 mL) was added, and the reaction mixture was cooled to 0°C on an ice-bath. A solution of crude 5-bromo-3chlorosulfonyl-2-fIuoro-6-methyl-benzoic acid (5 g) in THF (30 mL) was added dropwise at 0°C. After addition, the reaction mixture was stirred vigorously at 0°C for

30 minutes, and at room température for 2 hours. The organic volatiles were evaporated, and the remaining - 30 mL was washed with Et₂O (50 mL). The separated waterlayer was acidified with IN HCl (40 mL), and the product was extracted with 2MeTHF (2x). The combined organic layers were washed with brine, dried with Na₂SO₄, filtered off, evaporated, and co-evaporated with CHjCN, resulting in crude 5-bromo-2-fluoro-6-methyl-3-[(3-methyloxctan-3-yl)sulfamoyl]benzoîc acid (3.6 g)To a solution of crude 5-bromo-2-fIuoro-6-mcthyI-3-[(3-mcthyloxctan-3yl)sulfamoyl]bcnzoic acid(0.72 g, 0.00188 mol) in CHjCN(15 mL)underN₂-atm was successively added NEtj (0.786 mL, 0.00565 mol ), 4-fluoro-3-methylaniline (0,313 g, 0,00245 mol), and HATU (0.86 g, 0.00226 mol ). The reaction mixture was stirred at room température for 20 hours. More 4-fIuoro-3-methylaniline (0.1g) and HATU (0.3 g) were added, and the reaction was continued for 20 hours. The volatiles were evaporated. The residue was purified by silica gel Chromatography (heptaneEtOAc 100/0 to 0/100). The desired fractions were combined and evaporated. The residue was stirred in diisopropylether, filtered off, washed with diisopropylether (3x), and dried at 50°C, resulting in compound 190 (0.38 g), m/z: 486.9 (M-H)' Exact mass:488.0. ^l9FNMR(377MHz,DMSO-d<s)5ppm-122.15--121.89(m, 1 F),-116.05 (d, >6.4 Hz, 1 F). *H NMR (400 MHz, DMSO-J₆) 5 ppm 1.47 (s, 3 H), 2.25 (d, >1.5 Hz, 3 H), 2.40 (s, 3 H), 4.22 (d, >6.6 Hz, 2 H), 4.62 (d, >6.4 Hz, 2 H), 7.16 (dd, >9.2 Hz, 1 H), 7.44 - 7.51 (m, 1 H), 7.61 (dd, >6.9,2.3 Hz, 1 H), 8.01 (d, >6.8 Hz, 1 H),

8.86 (br. s., 1 H), 10.81 (s, 1 H)

Synthesis of2-fluoro-6-mcthyl-3-lï3-methyloxetan-3-yDsulfamoyl1benzoic acid

-103A solution of 5-bromo-2-fluoro-6-mcthyl-3-[(3-mcthyloxetan-3-yl)sulfamoyl]bcnzoic acid (0.9 g) and triethylamine(0.98 mL, 7.1 mmol) in MeOH (30 mL) was stirred with Pd/C 10% (0.1 g) at room température under a hydrogen atmosphère. After the calculated amount of hydrogen was taken up, the catalyst was fïltered off. The filtrate was concentrated in vacuo, and co-evaporated with CH3CN. The obtained residue containing 2-fluoro-6-methyl-3-[(3-methyloxetan-3-yl)sulfamoyl]benzoic acid was used as such. Method F; Rt: 0.38 min. m/z: 302.0 (M-H)* Exact mass:303.1

Compound 191

Triethy lamine (0.206 mL, 0.00149 mol ) was added to a stirring mixture of 2-fluoro-6methyl-3-[(3-methyloxetan-3-yl)sulfamoyl]benzoic acid (0.15 g, 0.000495 mol ) and CHjCN ( 10 mL ) under Nj-atm. To the resulting solution was added HATU (0.207 g, 0.545 mmol). After stirring for 5 minutes, 5-amino-2-fluorobenzonitrile, (79.9 mg, 0.569 mmol ) was added, and the reaction mixture was stirred at room température for 20 hours. The reaction was next continued at 50°C for 4 hours. The volatiles were evaporated and the obtained residue was dissolved in CH2CI2 (2.5 mL) and purified by silica gel Chromatography (heptane-EtOAc 100/0 to 0/100) followed by repurification with CH2C12-MeOH 100/0 to 98/2 as eluent. The desired fractions were combined and evaporated, and co-evaporated with EtOAc. The residue was dried fiirthcr at 50°C in vacuo, resulting in compound 191 (63 mg). Method F; Rt: 0.88 min. m/z: 420.1 (M-H)‘ Exact mass:421.1. *H NMR (400 MHz, DMSO-de) d ppm 1.46 (s, 3 H), 2.40 (s, 3 H),

4.19 (d, J=6.6 Hz, 2 H), 4.62 (d, J=6.2 Hz, 2 H), 7.36 (d, >8.1 Hz, 1 H), 7.58 (t, >9.1 Hz, 1 H), 7.80 (t, >7.9 Hz, 1 H), 7.96 (ddd, >9.1,4.8,2.8 Hz, 1 H), 8.22 (dd, >5.7, 2.6 Hz, 1 H), 8.64 (s, 1 H), 11.16 (s, 1 H). ^,?F NMR (377 MHz, DMSO-de) δ ppm 115.10 (d, >7.9 Hz, 1 F), -113.61 (dt, >8.9,5.2 Hz, 1 F).

Synthesis of3-chloro-4.5-difluoro-aniline

3-chloro-4,5-difluorobenzoic acid (commercial from astatech, 25.5 g, 0.132 mol ) was dissolved in tert-butyl alcohol (200 mL) at 50°C. EtîN (20.2 mL, 0.146 mol ) was added. Diphenylphosphoryl azide, 30.0 mL, 0.139 mol ) was added slowly, and the reaction mixture was stirred and refïuxed for 18 hours. The volatiles were evaporated, and co-evaporated with EtOAc. The residue was stirred in Et_zO (300 mL)/Sat. NaHCOj (300 mL) /H2O (50 mL) for 15 minutes. The separated organic layer was dried with

-104MgSO₄, fîltered off, and evaporated. The solid residue was stirred in dusopropylether (20 mL), fîltered off, washed with diisopropylether (3 x) and dried at 50°C, resulting in tert-butyi N-(3-chloro-4,5-difluoro-phenyl)carbamate (8.5 g), The filtrate was concentrated in vacuo. The residue was stirred in CH2CI2 (20 mL) + heptanes (20 mL), fîltered off, washed with CH₂Cl₂-heptane 1/1 (2x) and heptanes (2x), and dried at 50°C in vacuo, resulting in more tert-butyi N-(3-chloro-4,5-difluoro-phenyl)carbamate, 11.8 g), tert-butyi N-(3-chloro-4,5-difluoro-phenyI)carbamate (8.5 g, 0.0322 mol) was added portion wise to stirring HCl (40 mL, 0.16 mol, 4 M in dioxane). The mixture was stirred at room tempertaure for 2 hours, then left standing for 65 hours. Stirring was continued for another2 hours. The formed precipitate was fîltered off, washed with dioxane (4x) and dried at 50°C in vacuo, resulting in 3-chloro-4,5-difluoro-aniline hydrochloride (5.95 g). A mixture of 3-chloro-4,5-difluoro-aniline hydrochloride (1 g, 0.005 mol), NaOH (IM in H₂0,10 mL, 0.01 mol) and toluene (15 mL) was stirred at room température for 1 hour. The separated organic layer was dried with MgSO_4lfîltered off, and evaporated. The obtained 3-chIoro-4,5-difluoro-aniline (0.81 g) was used as such.

Compound 192 ci

Compound 192 was prepared similarly as described for compound 191, using 3-chloro-

4,5-difluoro-aniline hydrochloride instead of 5-amino-2-fluorobenzonitrile.^l9F NMR (377 MHz, DMSO-dô)d ppm-144.93 (br.s., 1 F),-134.02--133.17 (m, 1 F),-115.09 (d, >7.9 Hz, 1 F). ‘H NMR (400 MHz, DMSO-&) δ ppm 1.45 (s, 3 H), 2.38 (s, 3 H),

4.18 (d, J=6.4 Hz, 2 H), 4.61 (d, >6.2 Hz, 2 H), 7.35 (d, >8.1 Hz, 1 H), 7.71 - 7.83 (m, 3 H), 8.64 (br. s., 1 H), 11.14 (br. s., 1 H). Method F; Rt: 1.05 min. m/z: 447.1 (ΜΗ)* Exact mass:448.0.

Compound 193

Oxalyl chloride ( 12.3 mL, 0.143 mol) was added dropwise to a stirring solution of 5bromo-3-chlorosulfonyl-2-fluoro-6-methyl-benzoic acid (9.5 g) and DMF (0.111 mL)

in CH2CI2 (100 mL). After addition, the reaction mixture was stirred at room température for 2 hours and 30 minutes. The volatiles were removed in vacuo, and coevaporated with toluene. The obtained residue contaînîng 5-bromo-3-chlorosulfonyl-2fluoro-6-methyl-benzoyl chloride was used as such. A solution of 5-bromo-35 chlorosulfonyl-2-fluoro-6-methyI-benzoyI chloride ( l .75 g) in toluene (20 mL) was stirred at reflux under N2-flow. A solution of 3-chIoro-4,5-difluoroaniline (0.818 g, 0.005 mol) în toluene (10 mL) was added dropwîse. After addition, the reaction mixture was refluxed for 45 minutes, then allowed to reach room température, and left standing for 18 hours. A precipitate (0.51 g) was fîltered off, washed with toluene (2 x), and dried at 50°C in vacuo. (Æ)-l,l,l-trifluoro-2-propylamine (0.181 g, 0.0016 mol ) was dissolved in CHjCN (5 mL ) under N2-atm. 5-bromo-3-[(3-chIoro-4,5-difluorophenyl)carbamoy!]-2-fluoro-4-methyl-benzenesulfonyI chloride (0.51 g) was added, then DIPEA (0.461 mL, 0.00267 mol). The mixture was stirred in a sealed tube at 80°C for 20 hours. The reaction mixture was allowed to reach room température, and left standing for 2 hours. The mixture was fîltered and the filtrate was evaporated. The residue was dissolved in CH2CI2 (2 mL), and purified by silica gel chromatography [heptane-EtOAc 100/0 to 0/100 ]. The fractions containing the desired compound were combined and evaporated, and co-evaporated with EtOH, resulting in crude 5-bromoN-(3 -chloro-4,5-difluoro-pheny l)-2-fluoro-6- methy l-3-[ [( I R)-2,2,2-trifluo ro-1 -methy ΙΣΟ ethyl]sulfamoyl]benzamide (0.12 g).To a solution of 5-bromo-N-(3-chloro-4,5difluoro-phenyl)-2-fluoro-6-methyl-3-[[(IR)-2,2,2-trifluoro-l-methylethyl]sulfamoyl]benzamide (0.1 g) in EtOH (11 mL ) was added H2O (3.5 mL ), then K₂CO₃ aq. sat. sol., (1.25 mL) and next Palladium(0)tetrakis(triphenylphosphinc (26.1 mg, 0.023 mmol). The mixture was stirred I50°C by microwave irradiation for 45 minutes. The reaction mixture was combined with a similar reaction mixture starting from 20 mg 5-bromo-N-(3-chIoro-4,5-difluoro-phenyl)-2-fluoro-6-methyl-3-[[(lR)-

2,2,2-trifluoro-l-methyI-ethyl]sulfamoyl]benzamide) allowed to reach room température and left standing for 15 minutes. The upper layer was isolated by means of a séparation fùnnel, and evaporated. The obtained residue was purified by silica gel chromatography (heptane-EtOAc 100/0 to 0/100, also Cï^Ch-MeOH 100/0 to 98/2), followed by séparation by préparative HPLC (Stationary phase: RP Vydac Denali Cl8 - 10pm, 200g, 5cm), Mobile phase: 0.25% NH4HCO3 solution in water, CHjCN), resulting in compound 193 (11.4 mg). Method F; Rt: 1.17 min. m/z: 473.0 (M-H)' Exact mass:474.0. *H NMR (400 MHz, DMSOAe) δ ppm 1.17 (d, >6.8 Hz, 3 H), 2.38 (s, 3 H), 4.00-4.15 (m, 1 H), 7.35 (d, >8.4 Hz, l H), 7.71 - 7.78 (m, 2 H), 7.82 (t, >7.8

Hz, 1 H), 9.00 (br. s., 1 H), 11.13 (s, I H). ¹⁹FNMR (377 MHz, DMSO-de) d ppm -

145.3 to -144.5 (m, 1 F), -134.4 to -132.8 (m, I F), -114.9 (br. s., 1 F), -76.0 (d, >7.2 Hz, 3 F).

-106-

Compound 194

2-fluoro-6-methyl-3-[(3-methy!oxetan-3-yl)sulfamoyl]benzoic acid (0.15 g, 0.473 mmol) was dîssolved in DMF (5 mL) and triethylamine (0,2 mL) and HATU (233 mg, 0.61 mmol) were added to the reaction mixture. The reaction mixture was stirred for 10 minutes and 3,4-diiluoroaniline (123 mg, 0.945 mmol) was added. The reaction mixture was stirred at room température for 42 hours. The reaction mixture was poured into ice water (50 mL). The mixture was extracted with Me-THF (3 x 20 mL). The combined organic extracts were washed with brine, dried (Na₂SO₄) and concentrated. The residue was purified using silica gel column chromatography (ethyl acetate in heptane from 0 to 100% and methanol in dichloromethane from 0 to 2%) to afford compound 194 (79 mg) as a white powder which was dried in vacuum oven ovemight. Method F; Rt: 0.94 min. m/z: 413.2 (M-H) Exact mass: 414.1. *H NMR (400 MHz, DMSO-dfi) S ppm 1.45 (s, 3 H), 2.39 (s, 3 H), 4.18 (d, >6.6 Hz, 2 H), 4.62 (d, >6.2 Hz, 2 H), 7.35 (d, >8.1 Hz, 1 H), 7.39 - 7.51 (m, 2 H), 7.79 (t, >7.8 Hz, 1 H), 7.87 (ddd, >12.9,7.4,2.0 Hz, 1 H), 8.64 (br. s., I H), 11.00 (s, 1 H)

Compound 195

Compound 195 (98 mg) was prepared similarly as described for compound 194, using 3-chloro-4-fluoroaniline instead of 3,4-difluoroaniline. Method F; Rt: 0.99 min. m/z: 429.1 (M-H) Exact mass:430.1. 'H NMR (400 MHz, DMSO-d«) δ ppm 1.45 (s, 3 H),

2.39 (s, 3 H), 4.18 (d, >6.4 Hz, 2 H), 4.62 (d, >6.2 Hz, 2 H), 7.35 (d, >8.1 Hz, 1 H),

7.45 (t, >9.0 Hz, l H), 7.60 (ddd, >9.0,4.3,2.5 Hz, l H), 7.79 (t, >7.9 Hz, l H), 8.02 (dd, >6.8,2.6 Hz, l H), 8.63 (br. s., 1 H), 10.99 (s, l H)

Compound 196

F

Sodium carbonate (2.07 g, 19.48 mmol) was dissolved in distilled water (30 mL). To this was added (S)-3-aminotetrahydrofùran (3.4 g, 38.97 mmol) at once followed by THF (30 mL). The obtained solution was stirred and cooled in an ice bath. 35 (chlorosulfonyl)-2,6-difluorobenzoic acid (5 g, 19.48 mmol) was dissolved in THF (40 mL) and this was added drop wise to the stirring solution. The resultîng mixture was stirred for 30 minutes while cooling was continued. Then the mixture was stirred for 3 hours at room température. The mixture was concentrated in vacuo until only water remained. Water (20 mL) was added and the mixture was acidified with HCl (1M / aq;

40 mL). This was extracted using Me-THF (3 x 50 mL). The combined organics were washed with of brine (50 mL), dried on Na2SO4, filtered and concentrated in vacuo yielding 2,6-difluoro-3-[[(3S)-tetrahydrofuran-3-yl]sulfamoyl]benzoic acid as a yellow powder (5.9 g). Method F, Rt: 0.33 min. m/z : 306.0 (M-H)'Exact mass: 307.0.2,6difluoro-3-[[(3S)-tetrahydrofuran-3-yl]sulfamoyl]benzoic acid (1 g, 2.99 mmol) was dissolved in N,N-dimethylformamidc (5 mL). HATU (1.42 g, 3.74 mmol) was added followed by diisopropylethylamine (1.55 mL, 8.98 mmol). The resultîng mixture was stirred for 30 minutes at room température. Then, 3,4-difluoroaniline (0.77 g, 5.99 mmol) was added. The resultîng mixture was stirred for 24 hours and next poured in water (50 mL) and extracted using Me-THF (3 x 50 mL). The combined organics were washed with brine, dried on Na₂SO4, filtered and concentrated in vacuo. The obtained residue was purified by silica gel column chromatography using gradient elution from heptane to EtOAc. (100:0 to 0:100). The desired fractions were concentrated in vacuo and dried in a vacuum oven at 55°C for 24 hours yielding compound 196. Method F, Rt: 0.92 min. m/z : 417.1 (M-H)‘ Exact mass: 418.1. *H NMR (400 MHz, DMSO-<7₆) 8 ppm 1.64 - 1.79 (m, 1 H), 1.92 - 2.07 (m, 1 H), 3.43 (dd, J=9.0,4.6 Hz, I H), 3.56 3.79 (m, 3 H), 3.80 - 3.92 (m, 1 H), 7.32 - 7.43 (m, 1 H), 7,44 - 7.54 (m, 2 H), 7.84 (ddd, J= 12.7,7.4,2.5 Hz, 1 H), 8.01 (td, >8.6,6.2 Hz, 1 H), 8.49 (br. s., 1 H), 11.21 (br. s., 1 H)

Compound 197 to 201 were prepared as described for compound 196, using the corresponding aniline instead of 3,4-difluoroaniline: .

Compound 197

-108-

4-fluoro-3-methylaniline was used as aniline. *H NMR (400 MHz, DMSO-di) δ ppm 1.64 - 1.76 (m, 1 H), 1.91 - 2.05 (m, 1 H), 2.25 (d, >1.8 Hz, 3 H), 3.42 (dd, >8.9,4.7 Hz, 1 H), 3.56 - 3.78 (m, 3 H), 3.79 - 3.88 (m, 1 H), 7.16 (t, J=9.1 Hz, 1 H), 7.41 - 7.51 (m, 2 H), 7.60 (dd, >7.0,2.2 Hz, 1 H), 7.97 (td, >8.6,6.2 Hz, 1 H), 8.49 (br. s, 1 H),

10.93 (s, 1 H). Method F, Rt: 0.93 min. m/z : 413.2 (M-H)- Exact mass: 414.1

Compound 198

3-bromo-4-fluoroaniline was used as aniline. Method G, Rt: 1.74 min. m/z : 478.8 (ΜΗ)' Exact mass: 480.0.¹H NMR (400 MHz, DMSO-d«) δ ppm 1.67 - 1.77 (m, 1 H),

I. 93 - 2.05 (m, 1 H), 3.43 (dd, J=9.0,4.6 Hz, 1 H), 3.57 - 3.78 (m, 3 H), 3.80 - 3.89 (m,

H), 7.43 (t, >8.7 Hz, 1 H), 7.49 (m, >8.7, 8.7 Hz, 1 H), 7.61 (ddd, >9.0,4.4, 2.6 Hz, 1 H), 8.00 (td, >8.6,6.2 Hz, 1 H), 8.11 (dd, >6.3,2.5 Hz, 1 H), 8.49 (br. s., 1 H),

II. 19 (br. s., 1 H)

Compound 199

5-amino-2-fluorobenzonitrile was used as aniline

Method G, Rt: 1.56 min. m/z : 423.9 (M-H)' Exact mass: 425.1.¹H NMR (400 MHz, DMSO-cU) δ ppm 1.65-1.80 (m, 1 H), 1.94 - 2.06 (m, 1 H), 3.43 (dd, >9.0,4.6 Hz, 1 H), 3.57 - 3,78 (m, 3 H), 3.80 - 3.91 (m, 1 H), 7.49 (t, >8.5 Hz, 1 H), 7.59 (t, >9.1 Hz, 1 H), 7.94 (ddd, >9.2,4.8,2.6 Hz, 1 H), 8.02 (td, >8.6,6.2 Hz, 1 H), 8.19 (dd, >5.7,

2.9 Hz, I H), 8.50 (br. s., 1 H), 11.37 (br. s., 1 H).

Compound 200

-109-

4-fluoro-3-(trifluoromethyl)aniIine was used as aniline

Method F, Rt: 1.02 min. m/z : 467.1 (M-H)- Exact mass: 468.1. 'HNMR (400 MHz, DMSO-Je) δ ppm 1.72 (ddt, >12.6,7.2,5.6,5.6 Hz, 1 H), 1.93 - 2.08 (m, 1 H), 3.43 (dd, >9.0,4.6 Hz, 1 H), 3.58 - 3.79 (m, 3 H), 3.80 - 3.91 (m, 1 H), 7.49 (t, >8.4 Hz, 1 H), 7.58 (t, >9.7 Hz, 1 H), 7.93 (s, 1 H), 8.02 (td, >8.6, 6.2 Hz, 1 H), 8.16 (dd, >6.4, 2.6 Hz, 1 H), 8.50 (br. s., 1 H), 11.35 (br. s., 1 H)

3-chloro-4-fluoroaniline was used as aniline.

Method F, Rt: 0.97 min. m/z: 433.1 (M-H)- Exact mass: 434.0. *H NMR (400 MHz, DMSO-Je) δ ppm 1.72 (ddt, >12.5,7.2,5.6, 5.6 Hz, 1 H), 1.92 - 2.12 (m, 1 H), 3.43 (dd, >8.8,4.6 Hz, 1 H), 3.55 - 3.79 (m, 3 H), 3.80 - 3.91 (m, 1 H), 7.35 - 7.52 (m, 2 H), 7.53 - 7.67 (m, 1 H), 7.90 - 8.12 (m, 2 H), 8.49 (br. s., 1 H), 11.20 (br. s., 1 H)

Compound 202 and 203 were prepared similarly as described for compound 196, using isopropyl amine instead of (S)-3-aminotetrahydrofuran and for compound 203, using 3(trifluoromethyl)aniline instead of 3,4-difluoroaniline.

Compound 202

Method G, Rt: 1.80 min. m/z : 388.9 (M-H)- Exact mass: 390.1.

¹H NMR (400 MHz, DMSO-di) δ ppm 1.03 (d, >6.6 Hz, 8 H), 3.34 - 3.46 (m, 1 H),

7.36 - 7.53 (m, 3 H), 7.84 (ddd, >12.7,7.4,2.5 Hz, 1 H), 8.00 (td, >8.6, 6.2 Hz, 1 H),

8.09 (br. s., 1 H), 11.20 (br.s., 1 H)

-110Compound 203

'F

F

Method G, Rt: 1.82 min. m/z : 421.1 (M-H)- Exact mass: 422.1.¹ HNMR (400 MHz, DMSO-de) 5 ppm 1.04 (d, J=6.6 Hz, 6 H), 3.34 - 3.46 (m, 1 H), 7.47 (t, J=8.6 Hz, 1 H), 7.54 (d, >7.9 Hz, 1 H), 7.65 (t, >7.9 Hz, 1 H), 7.87 (d, >8.4 Hz, 1 H), 8.01 (td, >8.6, 6.2 Hz, 1 H), 8.11 (d, >7.5 Hz, 1 H), 8.15 (s, 1 H), 11.32 (s, 1 H).

Compound 204

Compound 204 (0.19 g) was prepared starting from compound 190 (0.34 g), similar as described for the conversion of compound 187 to compound 188. Compound 204 was crystallised from Et₂O, filtered ofT, washed with 3x Et2Û, and dried at 50°C in vacuo. Method F; Rt: 0.94 min. m/z: 409.1 (M-H)' Exact mass:410.1. *H NMR (400 MHz, DMSO-Je) δ ppm 1.46 (s, 3 H), 2.24 (d, > 1.8 Hz, 3 H), 2.38 (s, 3 H), 4.18 (d, >6.6 Hz, 2 H), 4.62 (d, >6.2 Hz, 2 H), 7.14 (dd, >9.1 Hz, 1 H), 7.33 (d, >8.1 Hz, 1 H),

7.45 - 7.53 (m, 1 H), 7.63 (dd, >7.0,2.2 Hz, 1 H), 7.77 (t, >7.9 Hz, 1 H), 8.61 (br. s., 1 H), 10.72 (s, t H).

Compound 205

3-(tert-butylsulfamoyl)-2-fluoro-6-methyl-benzoic acid was prepared similarly as described for 2-fluoro-6-methyl-3-[(3-methyloxetan-3-yl)sulfamoyl]benzoic acid, using tert-buty lamine instead of 3-methyloxetan-3 -amine. Compound 205 was prepared similar as described for compound 194, using 4-fluoro-3-methylaniline instead of 3,4difluoroaniline and starting from 3-(tert-butylsulfamoyl)-2-fluoro-6-methyl-benzoic acid instead of 2-fluoro-6-methyl-3-[(3-methyloxetan-3-yl)sulfamoyl]benzoic acid. Method F; Rt: 1.08 min. m/z: 395.2 (M-H)' Exact mass: 396.1.‘H NMR (400 MHz, DMSO-de) δ ppm 1,16 (s, 9 H), 2.24 (d, >1.8 Hz, 3 H), 2.37 (s, 3 H), 7.14 (t, >9.2

Hz, 1 H), 7.30 (d, >8.1 Hz, 1 H), 7.50 (ddd, >9.0,4.7,2.3 Hz, 1 H), 7.64 (dd, >6.9,

2.3 Hz, 1 H), 7.73 - 7.84 (m, 2 H), 10.70 (br. s, 1 H).

Compound 206

Compound 206 was prepared similar as described for for compound 194, starting from 3-(tert-butylsulfamoyl)-2-fluoro-6-methy!-benzoic acid instead of 2-fluoro-6-methyl-3[(3-methyloxetan-3-yI)sulfamoyl]benzoic acid. Method F; Rt: 1.08 min. m/z: 399.1 (ΜΗ)' Exact mass:400.1. ‘H NMR (400 MHz, DMSO-de) δ ppm 1.16 (s, 9 H), 2.31 (s, 3

H), 7.32 (d, >8.1 Hz, 1 H), 7.40 - 7.51 (m, 2 H), 7.76 - 7.82 (m, 2 H), 7.88 (ddd, >13.0,7.5,2.4 Hz, 1 H), 10.97 (br. s., 1 H)

Synthesis of 6-ch1oro-2-fluoro-3-lï3-methy1oxetan-3-yl)sulfamoyllbenzoic acid and 2chloro-6-fluoro-3-[(3-methyloxetan-3-yDsulfamoyl]benzoic acid

2-chloro-6-fluorobenzoic acid (2 g, 11.46 mmol) was treated with chlorosulfonic acid (10 mL, 150.44 mmol) and this was heated to 100°C and stirred for 5 hours. The resulting mixture was cooled to room température and added dropwise to ice-water (1 liter). This was then extracted using dichloromethane (2 x 500 mL). The combined organics were dried on Na₂SO4, filtered and concentrated in vacuo yielding an isomeric mixture of 2-chloro-3-chlorosulfonyl-6-fluoro-benzoic acid and 6-chloro-3ch!orosulfonyl-2-fluoro-benzoic acid (3.1 gram) as a slightly yellow powder which was used as such.Method F, Rt: 0.47 min and 0.49 min. m/z : 270.9 (M-H)- Exact mass:

271.9. Sodium carbonate (1.21 g, 11.4 mmol) was dissolved in distilled water (22 mL).

To this was added 3-methyl-3-oxetanamine ( 1.19 g, 13.68 mmol) at once followed by

THF (20 mL). The obtained solution was stirred and cooled in an ice bath. An isomeric mixture of 2-chloro-3-chlorosulfonyl-6-fïuoro-benzoic acid and 6-chloro-3chlorosulfonyl-2-fluoro-benzoic acid (3.1 g, 11.4 mmol) was dissolved in THF (30 mL) and this was added drop wise to the stirring solution. The resulting mixture was stirred for 30 minutes while cooling was continued. Then, the mixture was stirred for 3 hours at room tcmpcrature.The mixture was concentrated in vacuo untill only water remained. Then water (20 mL) was added and the mixture was acidified with HCl (46 mL, 1M / aq). This was extracted using Me-THF (3 X 50 mL), The combined organics were dried on Na₂SO4, filtered and concentrated in vacuo. The residue was purified, and isomers

-112wcrc separated using préparative HPLC (Stationary phase: Uptisphere Cl8 ODB lOgm, 200g, 5cm), Mobile phase: 0.25% NH4HCO3 solution in water, MeOH), yielding 6-chloro-2-fluoro-3-[(3-methyloxetan-3-yl)sulfamoyl]benzoic acid as a white powder. Method G, Rt: 0.40 min. m/z : 322.0 (M-H)* Exact mass: 323.0.1H NMR (400 MHz, DMSO-d ) ppm 1.42 (s, 3 H), 4.15 (d, J=6.6 Hz, 2 H), 4.61 (d, >5.9 Hz, 13 H), 7.29 (dd, >8.5,0.8 Hz, 1 H), 7.36 - 7.73 (m, 5 H).

and 2-chloro-6-fluoro-3-[(3-methyloxetan-3-yl)sulfamoyl]benzoic acid as a white powder. Method G, Rt: 0.34 min. m/z : 321.9 (M-H)' Exact mass: 323.0

Compound 207 to 210 were prepared similarly as described for compound 196 using 6chloro-2-fluoro-3-[(3-mcthyloxetan-3-yl)sulfamoyl]benzoic acid instead of 2,6difluoro-3-[[(3S)-tetrahydrofiiran-3-yl]sulfamoyl]benzoic acid and the corresponding aniline instead of 3,4-difluoroaniline.

Compound 207

Using 5-amino-2-fluorobenzonitrile as aniline. Method F, Rt: 0.92 min. m/z : 440.0 (M H)* Exact mass: 441.0. ’H NMR (400 MHz, DMSO-î/₆) 5 ppm 1.46 (s, 2 H), 4,21 (d, >6.4 Hz, 2 H), 4.61 (d, >6.2 Hz, 2 H), 7.59 (t, >9.1 Hz, 1 H), 7.66 (d, >8.8 Hz, 1 H), 7.89 - 7.99 (m, 2 H), 8.18 (dd, >5.6,2.8 Hz, 1 H), 8.93 (br. s, 1 H), 11.37 (br. s., 1 H)

Compound 208

F

Using 4-fluoro-3-(trifluoromethyl)aniline as aniline. Method F, Rt: 1.06 min. m/z : 483 (M-H)* Exact mass: 484.0. ’H NMR (400 MHz, DMSO-i/_e) δ ppm 1.46 (s, 2 H), 4.20 (d, >6.2 Hz, 2 H), 4.61 (d, >6.2 Hz, 2 H), 7.58 (t, >9.9 Hz, 1 H), 7.66 (d, >8.6 Hz, 1 H), 7.94 (m, >8.1,8.1 Hz, 2 H), 8.07 - 8.25 (m, 1 H), 8.91 (br. s, 1 H), 11.34 (br. s., 1 H)

-113Compound 209

Using 3,4-difluoro-5-methyl-aniline as aniline. Method F, Rt: 1.03 min. m/z : 447.1 (M-H)' Exact mass: 448.1.¹H NMR (400 MHz, DMSO-Λ) δ ppm 1.45 (s, 3 H), 2.30 (d, >2.0 Hz, 3 H), 4.20 (d, >6.4 Hz, 2 H), 4.61 (d, >6.2 Hz, 2 H), 7.32 (m, >5.9 Hz, 1 H), 7.54 - 7.69 (m, 2 H), 7.91 (t, >8.3 Hz, 1 H), 8.92 (br. s, 1 H), 11.09 (br. s, 1 H)

Compound 210

Using 3-chloro-4,5-difluoro-aniline hydrochloride as aniline. Method F, Rt: 1.07 min. m/z : 467.0 (M-H)‘ Exact mass: 468.0. ’H NMR (400 MHz, DMSO-Λ) δ ppm 1.45 (s, 3 H), 4.20 (d, >6.6 Hz, 2 H), 4.60 (d, >6.2 Hz, 2 H), 7.64 (d, >8.6 Hz, 1 H), 7.67 7.79 (m, 2 H), 7.93 (t, >8.1 Hz, 1 H), 9.08 (br. s, 1 H), 11.34 (br. s„ 1 H)

Compound 211

Compound 211 was prepared similarly as described for compound 196 using 2-chloro-

6-fluoro-3-[(3-methyloxetan-3-yl)sulfamoyl]benzoic acid instead of 2,6-difluoro-3[[(35)-tetrahydrofùran-3-yl]sulfamoyl]benzoic acid. Method F, Rt: 0.94 min. m/z : 433.1 (M-H)' Exact mass: 434.0. ’H NMR (400 MHz, DMSO-Λ) δ ppm 1,46 (s, 3 H),

4.20 (d, >6.6 Hz, 2 H), 4.62 (d, >6.4 Hz, 2 H), 7.30 - 7.43 (m, 1 H), 7.43 - 7.54 (m, 1 H), 7.61 (t, >8.6 Hz, 1 H), 7.84 (ddd, >12.7,7.4,2.3 Hz, 1 H), 8.17 (dd, >9.0,5.9 Hz, 1 H), 8.75 (br. s, 1 H), 11.18 (br. s, 1 H).

-114-

2-bromo-6-fluoro-3-[(3-mcthyloxctan-3-yl)sulfamoyl]bcnzoic acid and 6-bromo-2fIuoro-3-[(3-nicthyloxetan-3-yl)sulfanioyl]benzoic acid were prepared similarly as described for 2-chloro-6-fluoro-3-[(3-mcthyloxetan-3-yl)sulfamoyl]benzoic acid and 6· chloro-2-fluoro-3-[(3-methyloxetan-3-yl)sulfamoyl]benzoic acid, starting from 2bromo-6-fluorobenzoic acid instead of 2-chloro-6-fluorobenzoic acid.

Compound 212

Compound 212 was prepared similarly as described for compound 196 using 2-bromo-

6-fIuoro-3-[(3-mcthyloxetan-3-yl)sulfamoyl]benzoic acid instead of 2,6-difluoro-3[[(3S)-tetrahydrofùran-3-yl]sulfamoyl]benzoic acid and 4-fluoro-3(trifluoromcthyl)aniline instead of 3,4-difluoroaniline. ’ H NMR (400 MHz, DMSO-de) δ ppm 1.48 (s, 3 H), 4.20 (d, J=6.6 Hz, 2 H), 4.64 (d, J=6.2 Hz, 2 H), 7.57 (t, >9.7 Hz, l H), 7.65 (t, >8.6 Hz, 1 H), 7.93 (dt, >8.4,3.7 Hz, 1 H), 8.08 - 8.31 (m, 2 H), 8.70 (br. s., 1 H), 11.29(br. s., 1 H).

Compound 213 to 216 were prepared similarly as described for compound 196 using 6bromo-2-fluoro-3-[(3-mcthyloxetan-3-yl)sulfamoyl]benzoic acid instead of 2,6difluoro-3-[[(3S)-tetrahydrofuran-3-yl]sulfamoyl]benzoic acid the corresponding aniline instead of 3,4-difluoroaniline.

Compound 213

Br

Using 4-fluoro-3-mcthylaniline as aniline. Method F, Rt: 0.99 min. m/z: 473.0 (M-H)* Exact mass: 474.0. ’H NMR (400 MHz, DMSO-de) δ ppm 1.46 (s, 3 H), 2.25 (d, >1.5 Hz, 3 H), 4.20 (d, >6.4 Hz, 2 H), 4.62 (d, >6.2 Hz, 2 H), 7.16 (t, >9.1 Hz, 1 H), 7.42 - 7.52 (m, 1 H), 7.60 (dd, >7.0,2.4 Hz, 1 H), 7.68 - 7.93 (m, 2 H), 8.65 (br. s, 1 H),

10.82 (br. s, 1 H).

Compound 214

-115-

Using 5-amino-2-fIuorobenzonitriïe as aniline. Method F, Rt: 0.92 min. m/z : 484.0 (ΜΗ)' Exact mass: 485.0. ‘H NMR (400 MHz, DMSO-de) δ ppm 1.39 - 1.55 (m, 3 H),

4.20 (d, >6.6 Hz, 2 H), 4.61 (d, J=6.4 Hz, 2 H), 7.59 (t, J=9.1 Hz, 1 H), 7.77 - 7.89 (m, 2 H), 7.95 (ddd, J=9.2,4.8,2.8 Hz, 1 H), 8,18 (dd, J=5.7,2.6 Hz, 1 H), 8.90 (br. s, 1 H), 11.34(br. s., 1 H).

Compound 215

Using 4-fluoro-3-(trifluoromethyl)aniline as aniline. Method F,Rt: 1.07 min. m/z : 527.0 (M-H)' Exact mass: 528.0. 'H NMR (400 MHz, DMSO-de) δ ppm 1.46 (s, 3 H),

4.20 (d, J=6.6 Hz, 2 H), 4.61 (d, >6.2 Hz, 2 H), 7.58 (t, J=9.8 Hz, 1 H), 7.74 - 7.89 (m, 2 H), 7.90 - 7.98 (m, 1 H), 8.16 (dd, >6.3,2.5 Hz, 1 H), 8.84 (br. s, 1 H), 11.31 (br. s., IH).

Compound 216

F

Using 3,4-difluoro-5-methyl-anîline as aniline. Method F, Rt: 1.03 min. m/z : 491,0 (M-H)' Exact mass: 492.0. *H NMR (400 MHz, DMSO-de) δ ppm 1.46 (s, 3 H), 2.30 (d, >1.8 Hz, 3 H), 4.20 (d, >6.6 Hz, 2 H), 4.61 (d, >6.4 Hz, 2 H), 7.32 (m, >5.7 Hz, 1 H), 7.61 (ddd, >12.3,6.9,2.6 Hz, 1 H), 7.72 - 7.89 (m, 2 H), 8.86 (br. s., 1 H), 11.07 (br. s, 1 H).

Compound 217

-116-

A solution of 3-(difluoromethyl)-4-fluoro-aniline (1.02 mL, 8.58 mmol) in dry toluene (10 mL) was added dropwise (over 15 min) to a refluxing solution of 5chloro-3-chlorosulfonyl-2-fluoro-benzoyl chloride (2500 mg, 8.576 mmol) in dry toluene (100 mL). After the addition, the reaction mixture was left to stir at reflux for 1 h. The reaction mixture was left to cool to room température under nitrogen atmosphère while stirring.The brown solution containing 5-chloro-3-[[3-(difluoromethyl)-4-fluorophenyl]carbamoyl]-2-fluoro-benzenesulfonyl chloride was used without further purification. 3-methyl-3-oxetanamine (580 mg, 6.66 mmol) was added dropwise to the above solution at room température. Et₃N (2.10 mL 15.14 mmol) was then added dropwise to the reaction mixture and the reaction mixture was stirred at room température for 45 minutes. The solvent was evaporated and the residue was taken up in EtOAc. HCl (0.5 N, 30 mL) was added to the réaction mixture and the layers were separated. The organic layer was washed again with NaOH (0.5 N, 30 mL).

The organic layer was dried on MgSO₄ and was evaporated. The obtained residue was purified by silica gel column chromatography (eluent: CHzChîMeOH 100:0 -> 95:5), resulting in compound 217 ( 1.8 g).¹H NMR (360 MHz, DMSO-de) δ ppm 1.45 (s, 3 H) 4.23 (d, >6.2 Hz, 2 H) 4.63 (d, J=6.2 Hz, 2 H) 7.27 (t, J=54.3 Hz, 1 H) 7.43 (t, >9.7 Hz, 1 H) 7.83 (dt, >8.1,4.0 Hz, 1 H) 7.95 (dd, >5.9,2.6 Hz, 1 H) 8.04 (dd, >6.0,2.4 Hz, 1 H) 8.13 (dd. >5.3,2.7 Hz, 1 H) 8.98 (s, 1 H) 10.98 (s, 1 H) Method F, Rt: 1.03 min. m/z : 465.1 (M-H)' Exact mass: 466.0.

Compound 218

Pd/C (10%) (716 mg) was suspended in a solution of compound 217 (345 mg, 0.673 mmol) and Et₃N (0.467 mL) in MeOH (100 mL) at room température under nitrogen atmosphere.The reaction mixture was next stirred at room température under an

-117atmosphere of hydrogen until one équivalent of hydrogen was absorbe d.The reaction mixture was filtered on decalite and the solvent was evaporated.The obtained residue was purified by silica gel column chromatography (CHîClî'.MeOH 100:0 -> 95:5) resulting in compound 218 (206 mg) as a white solid, dried in vacuo at 50 °C. ’H NMR (360 MHz, DMSO-de ) δ ppm 1.44 (s, 3 H) 4.19 (d, J=6.6 Hz, 2 H) 4.63 (d, >6.2 Hz, 2 H) 7.26 (t, >54.3 Hz, 1 H) 7.42 (t, J=9.5 Hz, 1 H) 7.52 (t, >7.7 Hz, 1 H)

7.86 (dd, >8.1,3.7 Hz, 1 H) 7.93 - 8.01 (m, 2 H) 8.06 (dd, >6.4, 2.4 Hz, 1 H) 8.77 (s, 1 H) 10.92 (s, 1 H). Method F, Rt: 0.92 min. m/z : 431.1 (M-H)* Exact mass: 432.1.

Compound 219

F

Compound 219 (828 mg), was prepared similar as described for compound 217 and 218. Using 4-fluoro-3-(trifluoromethyl)aniline instead of 3-(difluoromethyl)-4-fluoroaniline. Method F, Rt: 1.00 min. m/z : 449.1 (M-H)* Exact mass: 450.1.

^lH NMR (360 MHz, DMSO-de) δ ppm 1.44 (s, 3 H) 4.19 (d, >5.9 Hz, 2 H) 4.62 (d, >6.2 Hz, 2 H) 7.53 (t, >7.9 Hz, 1 H) 7.57 (t, >9.9 Hz, 1 H) 7.94 - 8.02 (m, 3 H) 8.20 (dd, >6.4, 2.7 Hz, 1 H) 8.78 (s, 1 H) 11.02 (s, 1 H).

Compound 220

Compound 220 was prepared similar as described for compound 217 and 218, using (S)-3-aminotetrahydrofuran instead of 3-mcthyl-3-oxctanaminc. Method F, Rt: 0.90 min. m/z :431.1 (M-H)‘ Exact mass: 432.1. ’H NMR (360 MHz, DMSO-de) δ ppm

1.66 - 1.77 (m, 1 H) 1.91 - 2.03 (m, 1 H) 3.43 (dd, >8.8,4.8 Hz, 1 H) 3.57 - 3.70 (m, 2 H) 3.70 - 3.78 (m, 1 H) 3.79 - 3.90 (m, 1 H) 7.26 (t, >54.2 Hz, 1 H) 7.42 (t, >9.5 Hz,

H) 7.53 (t, >7.7 Hz, 1 H) 7.81 - 7.88 (m, 1 H) 7.94 - 8.00 (m, 2 H) 8.07 (dd, >6.4,

2.4 Hz, 1 H) 8.45 (d, >6.6 Hz, 1 H) 10.92 (s, 1 H).

Compound 221

-118-

Compound 221 was prepared similar as described for compound 217 and 218, using 2methylpropan-2-amine instead of 3-methyl-3-oxetanamine, and 4-fluoro-3-methylaniline instead of 3-(difluoromethyl)-4-fluoro-anÎline Method F, Rt: 1.06 min. m/z : 381.2 (M-H)* Exact mass: 382.1.1 H NMR (360 MHz, DMSO-de) 6 ppm 1.15 (s, 9 H) 2.24 (d, > 1.5 Hz, 3 H) 7.15 (t, >9.1 Hz, 1 H) 7.47 (t, >7.7 Hz, 1 H) 7.43 - 7.55 (m, 1 H) 7.65 (dd, >7.0,2.6 Hz, 1 H) 7.87 (ddd, >7.8,6.1,1.8 Hz, 1 H) 7.93 (s, 1 H) 7.90-7.99 (m, 1 H) 10.63 (s, 1 H).

Compound 243

Compound 243 was prepared similar as described for compound 217 and 218, using tert-butylamine instead of 3-methyl-3-oxetanamine. Method G, Rt: 1.76 min. m/z :

417.1 (M-H)'Exact mass: 418.1. 'HNMR(360 MHz, DMSO-de)6 ppm 1.15 (s, 9 H)

7.41 (t, >9.7 Hz, 1 H) 7.26 (t, >54.5 Hz, 1 H) 7.49 (t, >7.7 Hz, 1 H) 7.85 (ddd, >8.6,

4.4.3.1 Hz, 1 H) 7.88 - 8.01 (m, 3 H) 8.08 (dd, >6.2,2.6 Hz, 1 H) 10.90 (s, 1 H).

Compound 222

Compound 222 was prepared similar as described for compound 221, using 3-methyl3-oxetanamine instead of 2-methylpropan-2-amine. Method F, Rt: 0.91 min. m/z :

395.1 (M-H)* Exact mass: 396.1.¹ H NMR (360 MHz, DMSO-de) 5 ppm 1.44 (s, 3 H) 2.24 (d, >1.5 Hz, 3 H) 4.19 (d, >6.6 Hz, 2 H) 4.62 (d, >6.2 Hz, 2 H) 7.15 (t, >9.3 Hz, 1 H) 7.46 - 7.55 (m, 2 H) 7.63 (dd, >7.0,2.6 Hz, 1 H) 7.88 - 7.99 (m, 2 H) 8.75 (s, 1 H) 10.65 (s, 1 H).

-119-

Compound 223

3-methyloxolan-3-amine hydrochloride (165.9 mg, 1.2! mmol) was added to a solution of 3-[(4-fluoro-3-methyl-phenyÎ)carbamoy!]benzenesulfonyl chloride (499 mg, 1.096 mmol) in dry CH2CI2 (20 mL) at room température. EtjN (381 pL) was then added dropwise to the reaction mixture and the reaction mixture was stirred at room température for 1 hour.The reaction mixture was diluted with EtOAc (250 mL). HCl 0.5 N (50 mL) was added and the layers were separated. The organic layer was washed again with NaOH 0.5 N (30 mL). The organic layer was dried on MgSO₄ and was evaporated. The obtained residue was purified t by silica gel column chromatography (CH₂C12:MeOH 100:0->95:5) and by préparative HPLC (Stationary phase: RP XBridge Prep C18 OBD-10pm,30xl50mm), Mobile phase: 0.25% NH4HCO3 solution in water, MeOH) resulting in compound 223 (257 mg) as a white solid after drying in vacuo at 50°C. Method F, Rt: 0.93 min. m/z : 391.2 (M-H)' Exact mass: 392.1.¹ H NMR (360 MHz, DMSO-de) ppm 1.17 (s, 3 H) 1.72 (dt, >12.8,7.7 Hz, 1 H) 2.14 (ddd, >12.8, 7.1, 6.0 Hz, 1 H) 2.25 (d, >1.8 Hz, 3 H) 3.30-3.40 (m, 1 H) 3.61 - 3.77 (m, 3 H) 7.15 (t, >9.3 Hz, 1 H) 7.55 - 7.64 (m, 1 H) 7.69 (dd, >7.0,2.2 Hz, 1 H) 7.75 (t, >7.9 Hz, 1 H) 8.04 (d, >8.0 Hz, 1 H) 8.10 (br. s., 1 H) 8.18 (dt, >7.7, 1.3 Hz, 1 H) 8.39 (t, >1.6 Hz, 1 H) 10.49 (br. s., 1 H).

Compound 225

3-[(4-fluoro-3-methyl-phenyl)carbamoyl]benzenesulfonyl chloride (0.5 g, 1.53 mmol) and (Æ)-l,l,l-trifluoro-2-propylamine (0.38 g, 3.36 mmol) were dissolvedin of dichloromethane (10 mL). Then diisopropylethylamine (0.66 mL, 3.81 mmol) was added and the resulting mixture was stirred for two hours. Then IM HCl (5 mL) was added and the organic layer was separated, loaded on silica and subjected to silica gel column chromatography using gradient elution from heptane to EtOAc. (100:0 to 0:100). The desired fractions were concentrated in vacuo and dried in a vacuum oven at 55°C for 24 hours compound 225 (233 mg) as a white powder. Method F, Rt: 1.05 min.

-120m/z : 403.1 (M-H)' Exact mass: 404.1. HNMR (400 MHz, DMSO-<L$) δ ppm 1,01 (d, >6.8 Hz, 3 H), 2.25 (d, >1.8 Hz, 3 H), 4.06 - 4.22 (m, 1 H), 7.15 (t, >9.2 Hz, 1 H),

7.51 - 7.63 (m, 1 H), 7.67 (dd, >7.2,2.3 Hz, 1 H), 7.78 (t, >7.8 Hz, 1 H), 8.00 - 8.10 (m, 1 H), 8.16 - 8.28 (m, 1 H), 8.40 (t, >1.7 Hz, 1 H), 8.66 (br. s„ 1 H), 10.46 (s, 1 H).

Compound 226

Compound 226 (416 mg) was prepared as described for compound 225, using ($)l,l,l-trifluoro-2-propylaminc insteadof(R)-l,l,l-trifluon>-2-propylamine. Method F, Rt: 1.05 min. mfz : 403.1 (M-H)' Exact mass: 404.1.

Compound 227

Compound 227 (444 mg) was prepared similarly as described in synthetic procedure S3 (using 2,2-difluoroethylamine as amine), workup W4. Method F, Rt: 0.93 min. m/z :

371.1 (M-H)’ Exact mass: 372.1.¹ HNMR (400 MHz, DMSO-d« ) δ ppm 2.25 (d, >1.8 Hz, 3 H), 3.26 (td, >15.8,3.7 Hz, 2 H), 6.00 (tt, >55.2,3.5 Hz, 1 H), 7.14 (t, >9.0 Hz, 1 H), 7.52 - 7.62 (m, 1 H), 7.63 - 7.70 (m, 1 H), 7.77 (t, >7.9 Hz, 1 H), 7.96

- 8.06 (m, 1 H), 8.14 - 8.25 (m, 1 H), 8.30-8.45 (m, 2 H), 10.46 (s, 1 H)

Compound 228

Compound 228 (238 mg) was prepared similarly as described in synthetic procedure S3

-121(usrng 2,2-difluoroethylamine as amine), workup W4, followed by préparative HPLC (SunFire Prep C18 OBD-10gm,30xl50mm). Mobile phase (0.25% NH4HCO3 solution in water, MeOH). Method F, Rt: 0.97 min. m/z : 389.1 (M-H)' Exact mass: 390.1. ¹H NMR (400 MHz, DMSO-d«) Ô ppm 2.25 (d, >1.8 Hz, 3 H), 3.74 (q, J=9.5 Hz, 2 H), 7.15 (t, >9.2 Hz, 1 H), 7.48 - 7.62 (m, 1 H), 7.64 - 7.71 (m, 1 H), 7.77 (t, J=7.8 Hz, 1 H), 7.94 - 8.10 (m, 1 H), 8.20 (m, J=8.1 Hz, 1 H), 8.37 (t, J=1,7 Hz, 1 H), 8.49 - 9.15 (bs, 1 H), 10.45 (s, 1 H)

Compound 229

Compound 243 (239 mg) was prepared similar to synthetic procedure S2 (using 3,3difluoro-cyclopentanamine as amine), workup W4. Method F, Rt: 1.03 min. m/z : 411.2 (M-H)Exact mass: 412.1. ^,HNMR(400MHz,DMSO-d_<î) δ ppm 1.50-1.165 (m, 1 H), 1.81 - 2.04 (m, 3 H), 2.04 - 2.23 (m, 2 H), 2.25 (s, 3 H), 3.63 - 3.76 (m, 1 H), 7.14 (t, >9.1 Hz, 1 H), 7.59 (dt, >8.1,3.9 Hz, 1 H), 7.65 - 7.72 (m, 1 H), 7.78 (t, >7.8 Hz, 1 H), 8.02 (d, >7.9 Hz, 1 H), 8.14 (d, >6.8 Hz, 1 H), 8.22 (d, >7.7 Hz, 1 H), 8.37 (s, 1 H), 10.47 (s, 1 H).

Compound 230

2-mcthyl-3-fiiroic acid (4.2 g, 32.6 mmol) was dissolved in CH2CI2 (100 mL) and cooled with an ice-bath to -5°C. Then chlorosulfonîc acid (10.85 mL, 163.2 mmol) was added dropwise at a rate of 0.250 mL/min. The reaction mixture was allowed to warm to room température and stirred ovemight. The reaction mixture was quenched on ice and extracted with 2-MeTHF. The organic layer was washed with brine, dried over MgSOi and evaporated to dryness yielding crude 5-chlorosulfonyl-2-methylfuran-3-carboxylic acid (420 mg) as a brown oil. 5-chlorosulfonyI-2-mcthykfuran-3carboxylic acid (420 mg) was dissolved in CH2CI2 (10 mL). Hunig'sbase (0.64 mL,

3.74 mmol) and isopropylamîne (0.478 mL, 5.61 mmol) were added and the reaction mixture was stirred ovemight at room température. The volatiles were removed under reduced pressure and the residue was used as such in the next step. The above residue

-122- was dissolved m CHiCb (20 mL), 4-fluoro-3-methylaniline(228 mg, 1.82 mmol), HATU (830 mg, 2.18 mmol) and N,N-diisopropylethylamine (0.94 mL, 5.46 mmol) were added and the reaction mixture was stirred for 30 minutes. The volatiles were removed under reduced pressure and the residue was purified on silica using a heptane to EtOAc gradient resulting in compound 230 (174 mg) as a white powder. Method F, Rt: 1.00 min. m/z : 353.1 (M-H)‘ Exact mass: 354.1.¹H NMR (400 MHz, DMSO-de) δ ppm 1.03 (d, >6.4 Hz, 6 H), 2.23 (s, 3 H), 2.64 (s, 3 H), 3.35 - 3.43 (m, 1 H), 7.11 (t, >9.2 Hz, 1 H), 7.53 (dd, >7.9,4.0 Hz, 1 H), 7.59 - 7.69 (m, 1 H), 7.72 (s, 1 H), 8.06 (d, >5.5 Hz, 1 H), 9.87 (s, 1 H).

Compound 231

3-methyl-3-oxctanamine hydrochloride (302.6 mg, 2.45 mmol) and Hunig's base (1.15 mL, 6.68 mmol) dissolved in CH2CI2 (2 mL) were added to a solution of methyl 5(chlorosulfonyl)-2-furoate (thermo scientific, 500 mg, 2.23 mmol) in CH2CI2 (10 mL). The reaction mixture was stirred ovemight at room température. The volatiles were removed under reduced pressure and the obtained residue was used as such.

The residue was dissolved in THF (10 mL). LiOH (60.2 mg, 2.514 mmol), dissolved in H2O (! mL), was added to the reaction mixture, MeOH (1 mL) was added and this was stirred ovemight at room température. The volatiles were removed under reduced pressure and the residue was dissolved water (25 mL). 1M HCl (2.5 mL) was added and then 2-MeTHF (50 mL) was added. The aqueous layer was removed and the organic layer was washed with brine (50 mL), The organic layer was dried over MgSO₄₍ filtered and evaporated to dryness yielding an oil which was used as such in the next step. The oil and HATU (573 mg, 1.51 mmol) were stirred in C^CLfS mL) and 4-fluoro-3-methylaniline (157.3 mg,1.26 mmol) and N,N-diisopropylethylamine (0.65 mL, 3.77 mmol) were added. The reaction mixture was stirred ovemight at room température. The volatiles were removed under reduced pressure and the residue was purified on silica using a heptane to EtOAc gradient followed by by préparative HPLC (Stationary phase: RP Vydac Dcnali Cl 8 - 10gm, 200g, 5cm), Mobile phase: 0.25% NH4HCO3 solution in water, CHjCN), the desired fractions were collected, evaporated, dissolved in MeOH and evaporated agaîn. This fraction was triturated in MeOH (4 mL), filtered and dried in the oven yielding compound 231 (305 mg) as a white solid. Method F, Rt: 0.89 min. m/z: 367.1 (M-H)‘ Exact mass: 368.1.¹H NMR (400 MHz,

-123-

DMSO-cU) δ ppm 1.53 (s, 3 H), 2.24 (d, >1.8 Hz, 3 H), 4.21 (d, >6.6 Hz, 2 H), 4.61 (d, >6.2 Hz, 2 H), 7.14 (t, J=9.2 Hz, 1 H), 7.26 (d, >3.7 Hz, 1 H), 7.50 (d, >3.7 Hz, 1 H), 7.51 - 7.57 (m, 1 H), 7.60 (dd, >7.0,2.4 Hz, 1 H), 8.92 (s, 1 H), 10.34 (s, 1 H).

Compound 232 to 239 were prepared by slow addition of an aniline to a refluxing toluene solution of a 3-chlorosulfonylbenzoyl chloride dérivative, followed by reaction with an amine in the presence of a base like NEtj or DIPEA, as described above.

	Structure	Aniline	Amine	3-chforosulfonyt benzoyl chloride dérivative
232	A	4-nuoro-3methylaniline	3-mcthy!-3oxetanamine	2-chIcro-5(chlorosulfonyl)bcn zoy! chloride
233	AA	4-fiuoro-3(trifluorometh yljaniline	3-methyl-3oxetanamine	2-chloro-S(chlorosulfonyl)ben zoyl chloride
234	A <3	3,4diûuoroaniline	3-mcthy!-3oxetanamine	2-chlcro-5- (chlorosulfonyl) benzoyl chloride
235		3(difluorometh yl)-4-fluoroaniline	3-methyl-3- oxetanamine	2-chloro-5- (chlorosulfonyt) benzoyl chloride
236		4-fIuoro-3methylaniline	(S>3aminotetrahydro furan tosylate	5’Chlorosulfonyl-2fluorobcnzoyl chloride
237		4-fIuoro-3mcthylaniline	W-3aminotetrahydro furan tosylate	2-bromo-5chlorosulfonylbenzoyl chloride
238	aa	4-fluoro-3(trifluorometh yl)aniline	3-methyl-3oxetanamine	5-chlorosulfonyl-2methylbenzoyl chloride

-124-

	Structure	Aniline	Amine	3-cblon>su!fonyl benzoyl chloride derivattve
239		4-fluon>3methytaniline	(S te 3hi	)trahydrofuranamine /drochloridc	3 -chIorosulfonyl-4fluorobenzoyl chloride
Compound	LC method	Rt (min)	m/z (M-H)'	Exact mass
232	G	1.67	410.8	412.1
233	G	1.83	464.9	466.0
234	G	1.68	414.9	416.0
235	G	1.69	446.9	448.1
236	F	0.90	395.1	396.1
237	F	0.93	457.1	458.0
238	F	1.03	445.1	446.1
239	G	1.64	394.9	396.1

Compound	’h-nmr
232	* H NMR (360MHz, DMSO-de ) δ ppm 10.67 (s, 1 H), 8.57 (s, 1 H), 7.96 - 7.88 (m, 2 H), 7.84 - 7.79 (m, 1 H), 7.62 (dd, J = 2.6, 7.0 Hz, 1 H), 7.54 - 7.46 (m, 1 H), 7.15 (t, J = 9.1 Hz, 1 H), 4.56 (d, J = 6.2 Hz, 2 H), 4.17 (d, J = 6.2 Hz, 2 H), 2.24 (d, J = 1.8 Hz, 3 H), 1.43 (s, 3 H)
233	’ H NMR (360MHz, DMSO-de ) δ ppm 1.44 (s, 3 H) 4.18 (d, >6.6 Hz, 2 H) 4.57 (d, >6.0Hz, 2 H) 7.57 (t, >9.9 Hz, I H) 7.85 (d, >8.4 Hz, 1 H) 7.91 - 7.98 (m, 2 H) 8.02 (d, >2.2 Hz, 1 H) 8,20 (dd, >6.2,2.6 Hz, I H) 8.58 (s, 1 H) 11.06 (s, IH)
234	'H NMR (360 MHz, CHLOROFORM-d) δ ppm 1.64 (s, 3 H) 4.37 (d, >6.5Hz, 2 H) 4.66 (d, >6.5 Hz, 2 H) 5.74 (s, 1 H) 7.09 7.24 (m, 2 H) 7.59 (d, >8.2 Hz, 1 H) 7.70 (ddd, >11.8,7.0,2.4 Hz, 1 H) 7.88 (dd, >8.4,2.2 Hz, I H) 8.19 (d, >2.2 Hz, I H) 8.30 (s,l H)
235	¹H NMR (360MHz, DMSO-de ) δ ppm 1.44 (s, 3 H) 4.18 (d, >6.2 Hz, 2 H) 4.57 (d, >6.2 Hz, 2 H) 7.26 (t, >54.2 Hz, 1 H) 7.36 - 7.46 (m, 1 H) 7.84 (d, >8.4 Hz, 2 H) 7.91 (d, >2.2 Hz, 1 H) 8.00 (d, >2.2 Hz, 1 H) 8.03 - 8.10 (m, 1 H) 8.58 (s, I H) 10.95 (s, 1 H)

-125-

Compound	’H-NMR
236	’ H NMR (400 MHz, DMSO-de) δ ppm 1.57- 1.70 (m, 1 H), 1.87 - 2.04 (m, 1 H), 2.25 (d, J=1.0 Hz, 3 H), 3.38 (m, 1 H), 3.54 - 3.81 (m, 4 H), 7.15 (t, J=9.1 Hz, 1 H), 7.47 - 7.56 (m, 1 H), 7.57 - 7.72 (m, 2 H), 7.95-8.20 (ddd, J=8.6,4.6,2.4 Hz, 1 H), 8.06 - 8.19 (m, 2 H), 10.60 (s, 1 H)
237	’ H NMR (400 MHz, DMSO-de) δ ppm 1.60 - 1.70 (m, 1 H), 1-89 - 2.00 (m, 1 H), 2.24 (d, J=1.6 Hz, 3 H), 3.38 (dd, >8.9,4.4 Hz, 1 H), 3.55-3.62 (m, 1 H), 3.63 - 3.67 (m, 1 H), 3.68-3.72 (m, 1 H), 3.73 - 3.80 (m, 1 H), 7.14 (t, J=9.3 Hz, 1 H), 7.49 (ddd, >8.9,4.4, 2.8 Hz, 1 H), 7.63 (dd, >6.9,2.4 Hz, 1 H), 7.80 (dd, >8.3,2.2 Hz, 1 H), 7.89 (d, >2.4 Hz, 1 H), 7.97 (d, >8.5 Hz, 1 H), 8.12 (br. s., 1 H), 10.63 (s, 1 H)
238	¹H NMR (360MHz, DMSO-de ) δ ppm 1.42 (s, 3 H) 2.46 (s, 3 H) 4.14 (d, >6.2 Hz, 2 H) 4.56 (d, >6.2 Hz, 2 H) 7.51 - 7.59 (m, 2 H) 7.84 (dd, >8.1,1.8 Hz, 1 H) 7.89 (d, >1.8 Hz, 1 H) 7.95 8.02 (m, 1 H) 8.24 (dd, >6.6,2.6 Hz, 1 H) 8.42 (s, 1 H) 10.87 (s, IH)
239	¹H NMR (400 MHz, DMSO-de) δ ppm 1.65 - 1.74 (m, 1 H), 1.90 - 2.00 (m, 1 H), 2.25 (d, > 1.5 Hz, 3 H), 3.41 (dd, >8.9,4.7 Hz, 1 H), 3.57 - 3.77 (m, 3 H), 3.83 - 3.91 (m, 1 H), 7.14 (dd, >9.2 Hz, 1 H), 7.54 - 7.61 (m, 110,7.61 - 7.69 (m, 2 H), 8.29 (ddd, >8.5, 4.6,2.3 Hz, 1 H), 8.40 (dd, >7.0,2.2 Hz, 1 H), 8.44 (br. s., 1 H), 10.47 (s, 1 H)

Difïerential scanning calorimetrv From 30 to 300 °C at 10°C/min: Compound 232; Peak at 169.6 °C

Optical rotation:

Compound 236: [«]□ = - 5.83 (c 0.67 w/v %, MeOH).

Compound 240

o

SOCb (20.1 mL, 277.2 mmol) was added slowly to water (125 mL) cooled to 5 °C, maintaîning the température between 4 and 7 °C (addition took about 1.5 hour). The solution was then kept stirring ovemight while the température was allowed to slowly reach room température. Copper(I) chloride (76.6 mg, 0.774 mmol) was then added to the solution and it was cooled to -10 °C (dry îce/acetone bath), (resulting in solution A). In another flask cooled to 0 °C, HCl (37% in H₂O,65 mL) was added dropwise to 3-amino-5-fluorobenzoic acid (10 g, 64.46 mmol), keeping the température below 20 °C. This slurry was cooled to -10 ’C (dry îce/acetone bath) and a solution of sodium nitrite (4.803 g, 69.62 mmol) in H₂O (20 mL) was added very slowly (1 drop/5 sec) to the slurry, keeping the température below -5°C.

After addition, the orange mixture was allowed to warm to -2 °C for 5 min before cooling back to -15 °C (solution B). Solution B was then added portîonwise (plastic pipette) to solution A, cooled to -10 °C. After addition (~30 min), the reaction mixture was stirred at 0 °C for 2 h. The resulting orange solid was filtered and rinsed with water (2 x 25 mL) resulting in 3-chlorosulfonyl-5-fluoro-benzoic acid as an orange solid (dried at 35 °C in vacuo). EtjN (1.22 mL, 8.8 mmol) was slowly added to a solution of 3-chlorosulfonyl-5-fluoro-benzoic acid (525 mg, 2.2 mmol) in dry CH₂C1₂ (10 mL). Isopropylamine (198 pL, 2.42 mmol) was then added dropwise at room température to the reaction mixture.The reaction mixture was stirred at room température for 30 min.The brown reaction mixture was diluted with CH₂C1₂ and water. HCl IN was added to pH 2. The layers were separated and the aqueous layer was extracted twice with CH₂Cl₂.The organic layer was dried on MgSOi, filtered, and evaporated resulting in 3-fluoro-5-(isopropylsulfamoyl)benzoic acid as an orange solid, which was used without further purification. HATU (356.7 mg, 0.94 mmol) was added to a solution of crude 3-fluoro-5-(isopropylsulfamoyl)benzoic acid (190 mg), 4-fluoro-3-methylaniline (78.3 mg, 0.625 mmol) and N,N-diisopropylethylamine (326.8 pL, 1.88 mmol) in CH₂Cl₂ (30 mL)at room température. The mixture was stirred at room température for 1 h. The reaction mixture was diluted with CH₂C1₂, washed with HCl 0.5 N, filtered on Extrelut NT3 and evaporated. The obtained residue was purified by coiumn chromatography on silica gel (Grâce Resolv 12g, eluent: CH₂Cl₂:MeOH 100:0 -> 95:5) resulting in compound 240 (136 mg) as a white solid, dried at 50 °C in vacuo. Method G, Rt: 1.87 min. m/z: 366.9(M-H)* Exact mass: 368.1.’H NMR (360 MHz, DMSO-Λ) δ ppm 0.97 (d, J=6.2 Hz, 6 H) 2.25 (d, J=1.5 Hz, 3 H) 3.30-3.39 (m, IH), 7.16 (t, J=9.3 Hz, 1 H) 7.55 - 7.62 (m, 1 H) 7.67 (dd, >7.1,2.4 Hz, IH) 7.83 (dt, >8.0,

1.9 Hz, 1 H) 7.88 (d, >7.0 Hz, 1 H) 8.08 (dt, >9.3,1.7 Hz, 1 H) 8.22 (s, 1 H) 10.52 (s,

H).

Compound 241

-127F

Compound 241 was prepared similarly as described for compound 240 using (S)-3aminotetrahydrofuran tosylate instead of isopropy lamine. Method G, Rt: 1.70 min. m/z:

394.9 (M-H)’ Exact mass: 396.1. *H NMR (360 MHz, DMSO-dô) d ppm 1.55 -1.67 (m, 1 H) 1.93 (dq, >12.8,7.4 Hz, 1 H) 2.25 (d, >1.8 Hz, 3 H) 3.37 (dd, >9.0,4.2 Hz, 1 H) 3.55 - 3.75 (m, 3 H) 3.75 - 3.85 (m, 1 H) 7.16 (t, >9.1 Hz, 1 H) 7.56 - 7.62 (m, 1 H) 7.67 (dd, >7.3,2.6 Hz, 1 H) 7.82 - 7.88 (m, 1 H) 8.08 - 8.13 (m, 1 H) 8.20 - 8.25 (m, 2 H) 10.53 (s, 1 H).

Compound 242

Compound 237 (400 mg, 0.87 mmol) was dissolved in a mixture of DMF (2.5 mL) and N-mcthylpyrrolidine (0.12 mL) containing Copper(l)iodide (45.43 mg, 0.24 mmol) and

2,2-difluoro-2-fluorosulfonyl acetic acid methylester (0.21 g, 1.09 mmol).

The resulting mixture was stirred at room température for 2 hours. An extra amount of

2,2-difluoro-2-fluorosulfonyl acetic acid methylester (0.21 g, 1.09 mmol) was added and the mixture was stirred at 60°C for 1 hour. The mixture was stirred at 60°C for 18 hours. Saturated ammonium chloride solution (10 mL) was added to the reaction mixture. Then this was extracted using EtOAc (3 x 15mL). The combined extracts were dried on Na₂SO₄, filtered and concentrated in vacuo. The obtained residue was purified using column chromatography on silica (gradient elution: ethylacetate: heptane from 0 to 100%). Ail desired fractions were combined and concentrated under reduced pressure and then dried at 50°C in a vacuum oven ovemight yïelding compound 242 (314 mg) as a white powder. Method G, Rt: 1.73 min. m/z: 445.0 (M-H)' Exact mass:

446.1.

Blologlcal exemples - anti-HBV activity of compounds of Formula (I) The anti-HBV activity was measured using a stable transfected cell line, HepG22.15. This cell line was described to secrete relatively consistent high levels of

HBV virion partie les, which hâve been shown to cause both acutc and chrome infection and disease in chimpanzees.

For the antiviral, assay cells were treated twice for three days with serially diluted compound in 96-well plates in duplicate. After 6 days of tretament the antiviral activity was determined by quantification of purified HBV DNA from sccretcd virions using realtimc PCR and an HBV spécifie primer set and probe.

Cytotoxicity of the compounds was tested in HepG2 cells using CelITiter-Blue, with the same incubation period and dose range as in the HepG2.2.15 assay.

The anti HBV activity was also measured using the HepG2.117 cell line, a stable, inducibly HBV producing cell line, which replicates HBV in the absence of doxicycline (Tet-off System). For the antiviral assay, HBV réplication was induced, followed by a treatment with serially diluted compound in 96-well plates in duplicate. After 3 days of treatment, the antiviral activity was determined by quantification of intracellular HBV

DNA using realtime PCR and an HBV spécifie primer set and probe. Cytotoxicity of the compounds was tested using HepG2 cells, incubated for 4 days in the presence of compounds. The viability of the cells was assessed using a Resazurin assay. Results are displayed in Table 1.

Table I.

STRUCTURE	Co. No.	IIepG2 2.15 EC50 (μΜ)	HepG2 6 days CCSO (μΜ)	HepG2 117 EC50 (μΜ)	IIcpG2 4 days CCSO (μΜ)
	1	0.93		1.67	>100
<J	2	0.47		0.56	32.7

-129-

STRUCTURE	Co. No.	lkpG2 2.15 EC50 (μΜ)	IkpG2 6 days CC50ftiM)	IkpG2 117 EC50 (μΜ)	IkpG2 4 days CC50 (μΜ)
	3	2.10		3.05	>100
	4	0.96		0.93	>100
Ο'ί’χ/Α	5	0.83		0.90	57.7
ο4^Ν“0 F—G Λ— NH —/ Ο	6			0.58	>25
^F3Xr^Hv^iO	7	0.66	-	0.56	11.4

-13»-

STRUCTURE	Co. No.	HepG2 2.15 ECSO (uM)	HepG2 6 days CC50 (μΜ)	HepG2 117 ECSO (μΜ)	IIepG2 4 days CC50 (μΜ)
Ο—ι ^FY> ο ο	8	1.18		2.03	>100
HO Ο	9	0.54		1.36	>100
λ xt^f>^dxj «	10	0.75		3.63	40.3
/-A/fe î XX Cr o^'Qor^'	11	0.10		0.42	19.6
/>A'feÂ Δ CT	12	0.11		1.51	13.3

-131-

STRUCTURE	Co. No.	HepG2 2.15 EC50 (μΜ)	IIcpGÎ 6 days CC50 (μΜ)	IIepG2 117 EC50 (μΜ)	HepG2 4 days CC50 (uM)
F a? î Xy	13	1.99		15.31	13.8
F a./? Xy^F<7 qyir	14	0.09		0.36	11.7
F A ώ CT <nQC tC~^^F	15	0.28		0.78	10.1
/ΆΑα xt CT o^Qr tr^	16	1.21		2.8	10.3
Cv ? jÔ ci^-Aj	17	0.56		2.65	>100

STRUCTURE	Co. No.	HcpG2 2.15 EC50 (μΜ)	ITepG2 6 days CC50 (μΜ)	HepG2 117 EC50 (μΜ)	IkpG2 4 days CC50 (μΜ)
, p	18	0.78	51.6	1.30	>50
^aôcA	19	0.66	42.5	0.60	>25
O 0 ΗΝ-Ό AA	20	0.50	>25	1.00	79.6
	21	0.60	27.2	0.76	41.1
CM _ s xx A¹	22	0.52	>25

-133-

STRUCTURE	Co. No.	IIcpGl 2.15 EC50 (μΜ)	HcpG2 6 days CC50(pM)	IIcpG2 117 EC50 (μΜ)	IIepG2 4 days CC50 (μΜ)
°κΧ'	23	0.66	17.0	1.30	19.6
F ΛΊ 0	24	0.79	>25
A, ï°	25	0.80	>25	1.02	>6.25
av°/_c	26	1.04	>25
^ZqA·⁰'·	27	1.13	>25

STRUCTURE	Co. No.	HepG2 2.15 EC50 (μΜ)	IIepG2 6 dayj CC50 (μΜ)	HepG2 117 EC50(pM)	HepG2 4 days CC50 —(μΜ)
	28	1.24		2.28	52.5
^?A, τΌ' a	29	1.39	>25
CX+jl- 0--1T Y,,	30	1.67	>25
CU^prⁿY> ^{H 0} ° AA	31	2.23	16.4
0 V— NH CH -p <C a o—	32	2.59	9.9	4.58	>25

-135-

STRUCTURE	Co. No.	HepG2 2.15 EC50 (μΜ)	ücpG2 6 days CC50 (μΜ)	HepG2 Π7 EC50 (μΜ)	HepG2 4 days CC50 (μΜ)
°ΎΑ) ? %ΧΑχΧ rvV T T j Ο ^{0 0}	33	3.56	>25
yCSçû ά'	34	4.18	>25
,χ>Ά^;ο	35	4.50		2.70	70.4
°/_Or ^IX’	36	4.53		3.03	97.0
l 0 fi <v^F XJ	37	5.02		2.99	>100

-136-

STRUCTURE	Co. Νο.	HepG2 2.15 EC50 (μΜ)	HepG2 6 days CC50(gM)	HepG2 117 EC50 (μΜ)	HepG2 4 days CC50 (μΜ)
	38	<6.25	18.4	15.54	22.10
0	39	6.77		4.68	>100
ο ^/Ί ° ° MY^F	40	7.10		6.29	>100
^Αζθνηη Ο ° °	41	8.49	-	10.95	>100
ζΥ'ι_ν _ Χ+'-Ο	42	11.64	37,2	>25

-137-

STRUCTURE	Co. No.	HepG2 2.15 EC50 (μΜ)	IlepG2 6 days CC50(pM)	HepG2 117 EC50(pM)	HcpG2 4 days CC5Q (μΜ)
	43	15.13	36.3	>25	>25
	44	26.49		11.08	>100
xbxfb'	45	59.33		16.03	>100
	46	2.61		11.09	23.8
	47	0.74		0.96	57.5

-138-

STRUCTURE	Co. No.	HepG2 2.15 EC50 (UM)	HepG2 6 days CC50(pM)	IIcpG2 Π7 EC50(pM)	HepG2 4 days CC50 (UM)
Xr'^C'P	48	2.92		1.88	97.2
a,. ., 6cr^v	49	13.4		9.15	>100
	50	45.9		15.80	11.3
A. ‘5>^w	51	3.98		9.44	20.8
vOÇ° cP a.	52	1.94		2.44	>50

-139·

STRUCTURE	Co. No.	HepG2 2.15 EC50 (μΜ)	HepG2 6 days CC5O0aM)	HepG2 117 EC50(pM)	HepG2 4 days CC50 (μΜ)
’Ο·>· V*O AA F	53	0.36		0.44	>50
%AAt'	54	1.63		1.55	>50
	55	3.06		3.26	>100
_fjCtAîX	56	1.64		5.45	>100
	57	15.53		12.74	52.1

STRUCTURE	Co. No.	HepG2 2.15 EC50 (μΜ)	HepG2 6 days CC50 (μΜ)	llepG2 117 EC50 (μΜ)	HepG2 4 days CC50 (μΜ)
U ° ^hnO	58	14.62		19.94	62.5
C-iHGÇ. Ό	59	12.79		19.27	46.7
	60	0.85		0.67	29.1
o.	61	7.07		15.44	35.7
Cl/ 7 „ kq-p >-^NH o	62	7.06		10.07	>50

-141-

STRUCTURE	Co. No.	HcpG2 2.15 EC50 (μΜ)	lkpG2 6 days CC50 (μΜ)	IkpG2 117 EC50 (μΜ)	IIcpG2 4 days CC50 (μΜ)
Q JUGULA Q	63	9.94		21.12	>100
CX χ,^Λα Wxn-Q	64			7.83	>25
_n___j( jCji Cj 4 Xj	65	10.76		>25	35.3
ι^ύ^ρ___î Xjl Q o^z XjT	66	4.27		14.49	>100
	67	11.10		18^55	>100
<A/LI Ό U </YyW	68	18.60		>25	68.0

-142-

STRUCTURE	Co. No.	HcpG2 2.15 EC50 (μΜ)	HcpG2 6 days CCSO (μΜ)	IlepG2 117 EC50 (μΜ)	IIepG2 4 days CCSO (μΜ)
,jCr“ï°/ï5	69	3.90		10.38	>25
	70	0.34		0.89	>25
	71	0.75		8.63	>25
	72	0.12		0.37	>25
γ/χ/Α	73	0.073		0.15	>25
? Oû	74	0.64		0.53	>25

-143-

STRUCTURE	Co. No.	HepG2 2.15 EC50 (μΜ)	IlepG2 6 days CC50(pM)	HcpG2 117 EC50 (μΜ)	MepG2 4 days CC50 (μΜ)
/J.·⁰ A XI CT d'mp™	75	0.39		0.82	>25
	76	0.72		2.5	>25
	77	0.27		0.43	>25
/vAkxJ xr cr /yyW a^^ci	78	0.90		0.65	>25
? XX o' 'iQj	79	0.96		1.69	>25
^H 0 0 iî^xM^CN	80	8.4		17.9	>25

STRUCTURE	Co. No.	HepG2 2.15 EC50 (μΜ)	HcpG2 6 days CC50 (μΜ)	HcpG2 117 EC50 (μΜ)	HepG2 4 days CC50 (μΜ)
H p o AX	81	0.24		0.81	15.3
/--JJ’? ό \_J (TqIk™	82	1.20		3.13	>25
O-xvj xx^F° Xj	83	1.04		1.23	>25
v^iLUt XX	84	0.32		0.91	>25
	85	0.05		0.38	>25

-145-

STRUCTURE	Co. No.	HepG2 2.15 EC50 (μΜ)	HepG2 6 days CC50(pM)	HepG2 117 EC50 (μΜ)	IIepG2 4 days CC50 (μΜ)
	86	0.14		0.11	>25
	87	0.41		0.89	>25
	88	0.21		0.40	>25
	89	0.54		0.72	>25
F /-Λ^ΐ JO 0 /χΧ^	90	0.38		0.51	>25

-146-

STRUCTURE	Co. No.	IIepG2 2.15 EC50 (μΜ) .	IIepG2 6 days CC50(pM)	IIcpG2 117 EC50 (μΜ)	l!cpG2 4 days CC50 (μΜ)
	91	0.53		0.77	>25
ox . » Jl V'v'· nrjr^Y	92	0.31		2.59	>25
	93	0.07		0.22	>25
	94	0.15		0.23	>25
'Î^av	95	1.4		2.79	>25
ΎθΙ^Η W °nQ°^r	96	0.10		0.29	>25

-147-

STRUCTURE	Co. No.	HepG2 2.15 EC50 (uM)	HepG2 6 days CC50(pM)	IIepG2 117 EC50 (μΜ)	HepG2 4 days CC50 (μΜ)
y_ ^{0 0}	97	0.12		0.37	>25
\ oaA _fAu A'o M?	98	0.10		0.31	>25
A o.»	99	0.09		0.46	>25
XX^FT“-Aa ^f	100	0.13		0.43	>25
α%Α	101	0.43		1.51	>25
z^a·^/ î XX f °Cj 6' OA« ;	102	0.18		0.33	>25

STRUCTURE	Co. No.	IkpG2 2.15 EC50 (μΜ)	HepG2 6 days CC50(gM)	HepG2 117 EC50 (μΜ)	IkpG2 4 days CC50 (μΜ)
JÛC^F°Cj 0^?όΑη^^^ομ,!	103	2.33		2.66	>25
Z-Λ? A XX^F<J /ηπΑ î'	104	0.29		0.78	>25
/-eiA/ î XX <J	105	0.81		0.98	>25
σ'/ζ/Ζ^1,	106	2.22		3.30	>25
σ'/χ/Ά⁰'	107	7.82		13.82	>25
°0<^θΑΛ_ΟΗ	108	7.20		9.27	>25

-149-

STRUCTURE	Co. No.	HcpG2 2.15 EC50 (μΜ)	IIcpG2 6 days CC50 (μΜ)	IIepG2 117 EC50 (μΜ)	HepG2 4 days CC50 (μΜ)
	109	1.23		2.53	>25
	110	0.66		0.85	>25
KX^^QAjjXXxOH	111	4.48		1.48	>25
/A-sLLa A' w °'Xj »	112	0.03		0.14	>25
* H O ° AV^F	113	0.15		0.18	>25
As? â XA t o'OfA^F	114	1.35		3.15	>25

-150-

STRUCTURE	Co. No.	HepG2 2.15 EC50 (μΜ)	llcpG2 6 days CC50 (μΜ)	HepG2 117 EC50 (μΜ)	HepG2 4 days CC50 (uM)
x ü ο 9 r^îÿV^F	115	2.74		1.65	>25
Ho 9 <V^F ό'ΑΛ⁰'	116	1.94		0.90	>25
	117	0.88		0.50	>25
F Ho 0	118	3.63		1.91	>25
	119	3.06		1.91	>25
	120	0.53		0.51	>25

-151-

STRUCTURE	Co. No.	HepG2 2.15 EC50 . (μ«)	IIepG2 6 days CC50(pM)	HepG2 117 EC50 (μΜ)	HepG2 4 days CC50 (μΜ)
ΑΌ Xj	121	0.16		0.13	>25
πλΑ-? î n^F	122	0.13		0.18	>25
Cl	123	0.15		0.3	>25
H o Cl Ο A<^Faxa	124	0.33		0.68	>25
ΑχΑ	125	1.44		1.15	>25
σ“Χ/Α	126	1.38		0.89	>25

-152-

STRUCTURE	Co. No.	IIcpG2 2.15 ECSO (μΜ)	HepG2 6 days CC50(pM)	HcpG2 117 EC50(pM)	11epG2 4 days CC50 (μΜ)
	127	0.23		0.58	>25
Xx V <* χ/W	128	0.23		0.54	>25
zfefe1XX^FO °'Xj	129	0.35		0.78	>25
i XX (S /ΥΊτ ΌΗ XX	130	0.88		1.03	>25
A XX WhXJ h	131	2.63		1.74	>25
rlfeM’ A XX (jC/ferr^	132	0.59		0.73	>25

-153-

STRUCTURE	Co. No.	HepG2 2.15 EC50 (μΜ)	llepG2 6 days CC5Q(gM)	HcpG2 117 EC50 (μΜ)	HcpG2 4 days CC50 (uM)
î XX'	133	0.60		1.69	>25
	134	0.18		0.57	>25
	134a	0.66		0.72
	134b	0.57		0.20
	134c	0.49		0.38
	134d	0.25		1.22
	135	0.56		0.36	>25
Xy-c/X	136	0.47		0.81	>25
	137	0.66		0.92	23.7

-154-

STRUCTURE	Co. No.	HepG2 2.15 EC50 . (μΜ)	HcpG2 6 days CC50 (μΜ)	IïepG2 117 EC50 (μΜ)	HepG2 4 days CC50 (μΜ)
	138	1.28		2.27	>25
	139	1.00		1.75	>25
W'sC-J. xx^F<aj ₀· Xj tr^	140	1.10		1.12	>25
	141	0.36		0.60	>25
	141a	0.70		1.65	>25
	141b	0.27		0.23	>25
	141c	0.17		0.29	>25
	141d	0.56		1.14	>25
	142	0.14		0.56	>25

-155-

STRUCTURE	Co. No.	llepGÎ 2.15 EC50 (μΜ)	IIepG2 6 days CC50 (μΜ)	HcpG2 117 EC50 (μΜ)	HepG2 4 days CC50 (uM)
	143	0.91		2.66	>25
	144	0.13		0.24	>25
	145	0.22		0.27	>25
	145a	0.14		0.21	>25
	145b	0.44		0.58	>25
	145c	0.34		0.34	>25
	145d	0.40		0.64	>25
	146	0.45		0.42	>25
	147	0.26		0.15	>25

-156-

STRUCTURE	Co. No.	HepG2 2.15 EC50 (UM)	IkpG2 6 days CC50 (pM)	Hep G 2 117 EC50 (pM)	IkpG2 4 days CC50 (UM)
	148	0.90		3.11	18.2
y/aa	149	0.22		0.73	20.8
	150	0.10		0.73	>25
x^yAyi^XX	151	0.66		2.74	>25
	152	<0.1		0.57	>25
Ay^/A	153	0.22		0.25	>25

STRUCTURE	Co. No.	HepG2 2.15 EC50 (UM)	HepG2 6 days CC50(pM)	HepG2 117 EC50(gM)	IïepG2 4 days CC50 (UM)
	155	0.36		0.81	>25
	156	0.19		0.21	>25
	157	0.13		0.23	>25
	15S	0.15		0.50	>25
	159	0.15		0.30	>25
	159a	0.17		0.86
	159b	0.16		0.23

STRUCTURE	Co. No.	HepG2 2.15 EC50 (UM)	HcpG2 6 days CC50 (μΜ)	HepG2 117 EC50 (μΜ)	HepG2 4 days CC50 (uM)
	160	0.20		0.69	>25
	161	0.20		0.35	>25
	162	0.17		1.26	>25
^^Β/θΑ_ΗΧΧ	163	0.53		8.53	>25
kpypl’	164	3.71		0.97	>25
Ο-γ»/θΑ_ηΧΧ	165	0.71		0.36	>25

-159-

STRUCTURE	Co. No.	HepG2 2.15 EC50 (μΜ)	IIepG2 6 days CC50(p5I)	Hep G 2 117 EC50 (μΜ)	HcpG2 4 days CCSO (μΜ)
	166	0.19		2.39	14.6
	167	0.62		9.84	>25
	168	0.27		0.37	11.8
errVys-A	169	0.24		1.41	14.9
v^soaxx ° IL ^H	170	0.26		0.45	>25
^HQ h _o Λγ V___£ XX v ° Xa«	171	0.79		4.39	>25

-160-

STRUCTURE	Co. No.	HcpG2 2.15 EC50 (μΜ)	IlepG2 6 days CCSO (μΜ)	IIcpG2 117 EC50 (μΜ)	HcpG2 4 days CC50 (μΜ)
	172	0.26		0.61	>25
M./ î XY^F<T /r/iA %H O	173	0.37		0.36	>25
v/qâA	174	0.47		2.84	>25
WA	175	0.23		0.15	>25
	176	0.62		0.56	>25
	177	0.77		0.72	>25

-161-

STRUCTURE	Co. No.	HepG2 2.15 EC50 (UM)	HepG2 6 days CC50 (μΜ)	HepG2 117 EC50 (μΜ)	HepG2 4 days CC50 (μΜ)
OH H _ ojs.y^.XX	178	0.75		2.54	>25
_A’° JL iY	179	0.21		0.44	>25
	179a	0.38		0.25	>25
	179b	1.11		1.84	>25
jYSÇyLCC bf ° V d	180	0.76		1.30	>25
_ji-— a î ΓΥ γΟυυ^ Sr»° V^{1 H} 1	181	2.59		2.04	>25
JkAj. XX Y «ΎΥιΥ^ Boc	182	0.31		0,88	>25

-162-

STRUCTURE	Co. No.	HepG2 2.15 EC50 (μΜ)	HcpG2 6 days CC50(pM)	IkpG2 Π7 EC50 (μΜ)	IkpG2 4 days CC50 (μΜ)
	183	0.08		0.84	>25
	184	0.15		0.40	>25
	I84a	0.31		0.77	>25
	184b	0.30		0.33	>25
	185	0.22		0.62	>25
ΎΫ'φΛ¹¹'^	186	0.20		1.34	>25

STRUCTURE	Co. No.	HepG2 2.15 EC50 (μΜ)	HepG2 6 days CC50(pM)	HepG2 117 EC50 (μΜ)	HepG2 4 days CC50 (μΜ)
Br	187			0.95	>25
	188			0.24	>25
	189			0.35	>25
Br	190			0.27	>25
/ ο o F o fV^F	191	0.33		0.36	>25
a	192			0.19	>25

-164-

STRUCTURE	Co. No.	IkpG2 2.15 EC50 (UM)	IkpG2 6 days CC50 (μΜ)	HepG2 117 EC50 (μΜ)	IkpG2 4 days CC50 (μΜ)
	193			0.10	13.5
V ! A	194	0.38		0.31	>25
χχ /00 Ç ™' ~^a <oÇ^	195	0.27		0.18	>25
_F_Z~\ \°X^XO y /—^nh Vz *o F	196	0.13		0.07	>25
,-<v \<o NH V / % F	197			0.09	>25
_F_/~\ F AO /—NH \ / *₀ r	198			0.15	>25

-165-

STRUCTURE	Co. No.	HcpG2 2.15 EC50 (uM)	HcpG2 6 days CC50 (μΜ)	HepG2 117 Εϋ50(μΜ)	HepG2 4 days CC50 (μΜ)
f-ΖΛ \ X 5—NH V / % F	199			0.43	>25
~ ₀ hnU.Z'Î f-ΖΎ \ X χ-¹/~~^NH \ / *_o F^Z	200			0.45	>25
₀ ΗΝΙιΧ⁵/''·? \ V VJ y—NH V / % F	201	0.06		0.06	>25
	202			0.11	>25
h p f P YÀÀA ΑΛχ i d'	203			0.24	16.7

-166-

STRUCTURE	Co. No.	IIcpGÎ 2.15 EC50 (μΜ)	HcpG2 6 days CC50 (μΜ)	HepG2 117 EC50 (μΜ)	IïepG2 4 days CC50 (μΜ)
	204			0.09	>25
·., I A Α-Ά-	205			0,35	>25
. ..XX	206			0.64	>25
y .. X-	207			>1	>25
F SX F o ΑίΑ	208			>1	>25
SX F 0 Χγ^F	209			0.15	>25

-167-

STRUCTURE	Co. No.	HepG2 2.15 EC50 (μΜ)	HcpG2 6 days CC50(gM)	HcpG2 117 EC50 (μΜ)	HepG2 4 days CC50 (μΜ)
Τζ, . Λ·	210			0.46	>25
χγ H 0 CI	211			0.65	>25
OCt	212			7.3	>25
Br	213			0.28	>25
XX AéA	214			>1	>25
xkAX· $·Ά	215			>1	>25

168-

STRUCTURE	Co. No.	HepG2 2.15 EC50 (μΜ)	ÏIepG2 6 days CC50(pM)	IIepG2 117 EC50 (μΜ)	IIcpG2 4 days CC50 (μΜ)
.., -A ^<;,c	216			0.29	>25
a	217	0.20		0.60	>25
	218	0.12		0.10	>25
f^xxf F	219			0.46	>25
	220	0.11		0.09	>25
τΆψ,	221			0.13	>25

-169-

STRUCTURE	Co. No.	IIepG2 2.15 EC50 (μΜ)	HepG2 6 days CC50 (μΜ)	llepG2 117 EC50 (μΜ)	IIepG2 4 days CC50 (μΜ)
	222	0.05		0.10	>25
	223			0.21	>25
ΟΎ“ο>χ/»^Λ'	224	0.16		0.76	>25
A . ^γ·	225	0.09		1.34	>25
^Fx/j>' _F	226	0.27		1.9	>25

-170-

STRUCTURE	Co. No.	HepG2 2.15 EC50 (μΜ)	IIepG2 6 days CC50 (μΜ)	HepG2 117 EC50(gM)	IIepG2 4 days CC50 (μΜ)
F	227	0.16		0.71	>25
	228	0.17		1.19	>25
	229	0.20		0.49	>25
	230	0.73		1.52	>25
	231	0.21		0.32	>25
λ”ζ -CT a	232			0.31	>25

-171-

STRUCTURE	Co. No.	ITcpG2 2.15 EC50 (μΜ)	HcpG2 6 days CC50(pM)	IIepG2 117 EC50 (μΜ)	IIepG2 4 days CC50 (μΜ)
CI	233	>1		>1	>25
Xy° Cl	234	0.72		0.34	>25
/qma	235	0.83		0.33	>25
Qyÿ.XX·	236	0.48		1.58	>25
Qx^vCC.·	237	0.43		0.13	>25
	238	0.61		0.50	>25

-172-

STRUCTURE	Co. No.	lkpG2 2.15 EC50 (μΜ)	IkpG2 6 days CC50 (μΜ)	IkpG2 117 Εϋ50(μΜ)	HcpG2 4 days CC50 (μΜ)
	239	0.48		0.53	>25
aAx	240	0.40		2.86	>25
F aAa	241	0.38		1.79	>25
O _F Ax XX °'Ou	242	1.91		1.80	>25

-173-

Claims

Claims

1. A compound of Formula (la) or a stereoisomer or tautomeric form thereof, wherein:

B represents a monocyclic 5 to 6 membered aromatic ring, optionally containing one or more heteroatoms each independently selected from the group consisting of O, S and N, such 5 to 6 membered aromatic ring optionally being substituted with one or 10 more substituents each independently selected from the group consisting of hydrogen, halo, Ci-C₃alkyl, CN, CFH₂, CF₂H and CF₃;

Ri represents hydrogen or C]-C₃alkyl;

15 R₂ represents Ci-C_ealkyl, CrCîalkyl-Rj, benzyl, C(=O)-R₃, CFH₂₁CF₂H, CFj or a 3-7 membered saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of O, S and N, such 3-7 membered saturated ring or Ci-Cealkyl optionally being substituted with one or more substituents each independently selected from the group consisting of

20 hydrogen, halo, Ci-C₄alkyloxy, oxo, C(=O)-Ci-C₃alkyl, Ci-C₄ alkyl, OH, CN, CFHî, CF₂H and CF₃;

Or Ri R₂ together with the Nitrogen to which they are attached form a 1,4-dioxa8-azaspiro[4.5] moiety or a 5-7 membered saturated ring, optionally containing one 25 or more additional heteroatoms each independently selected from the group consisting of O, S and N, such 5-7 membered saturated ring optionally being substituted with one or more substituents each independently selected from the group consisting of hydrogen, halo, Ci-C₄alkyloxy, oxo C(=O)-Ci-C₃alkyl, C_rC₄alkyl, OH, CN, CFH₂, CF₂H and CF₃;

Each R< is independently selected from hydrogen, halo, Ci-C₄alkyloxy, Ci-C₄alkyl,

OH, CN, CFH₂, CFîH, CF₃or a 3-5 membered saturated ring optionally containing

-174one or more heteroatoms each independently selected from the group consisting of O and N;

R; represents Ci-Cealkyl, CFH₂, CF₂H, CFjor a 3-7 membered saturated ring optionaily containing one or more heteroatoms each independently selected from the group consisting of O, S and N, such 3-7 membered saturated ring optionaily being substituted with one or more substituents each independently selected from the group consisting of hydrogen, halo, Ci-C₄alkyloxy, oxo, C(=O)-Ci-Cjalkyl, Cj-C₄alkyl, OH, CN, CFH₂, CF₂H and CFj;

or a pharmaceutically acceptable sait or a solvaté thereof.
2. The compound according to claim 1, wherein R₂ represents a 3-7 membered saturated ring, containing one or more heteroatoms each independently selected from the group consisting of O, S and N, such 3-7 membered saturated ring optionaily being substituted with one or more substituents each independently selected from the group consisting of hydrogen, halo, Ci-C₄alkyloxy, C(=O)- CiCjalkyl, Ci-C₄alkyl, OH, CN, CFH₂, CF₂H and CF₃;

Or Ri Rî together with the Nitrogen to which they are attached form a 5-7 membered saturated ring, optionaily containing one or more additional heteroatoms each independently selected from the group consisting of O, S and N, such 5-7 membered saturated ring optionaily being substituted with one or more substituents each independently selected from the group consisting of hydrogen, halo,

Cj C₄alkyloxy, oxo, C(=O)-C|-C₃aIkyl, Ci-C₄alkyl, OH, CN, CFH₂, CF₂H and CF₃.
3. The compound according to claim 1 or 2, wherein R₂ represents a 4-7 membered saturated ring containing carbon and one or more oxygen atoms, such 4-7 membered saturated ring optionaily being substituted with one or more substituents each independently selected from the group consisting of hydrogen, halo,

Ci C₄alkyloxy, C(=O)- Ci-C₃alkyl, Cj-Qalkyl, OH, CN, CFH₂, CF₂H and CF₃.
4. A compound according any one of daims I to 3, wherein B represents phenyl or thiophene, optionaily being substituted with one or more substituents each independently selected from the group consisting of hydrogen, halogen, Cj-C₃alkyl, CN.CFHi, CF₂H andCF₃.
5. A compound ofFormula (I) according to any one ofthe previous daims, wherein

-175-

R.2 représente C|-Cjalkyl-R« or a 4-7 membered saturated ring consisting of carbon atoms and one or more heteroatoms each independently selected from the group consisting of O or S, such 4-7 membered saturated ring optionally being substituted with one or more substituents each independently selected from the group consisting of hydrogen, halo, Cj-Qalkyloxy, oxo, C(=O)-Cj-C₃alkyl, Ci-C₄alkyl, OH, CN, CFH₂, CF₂H and CF_3;

Each R4 is independently selected from hydrogen, halo, Ci-C₄alkyloxy, Ci-C₄alkyl, OH, CN, CFH₂, CF₂H, CFjor a3-5 membered saturatedringoptionally containing one or more heteroatoms each independently selected from the group consisting of O and N; and

R< représente a 4-7 membered saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of O or S, such

4-7 membered saturated ring optionally being substituted with one or more substituents each independently selected from the group consisting of hydrogen, halo, Cj-C₄alkyloxy, oxo, C(=O)-Ci-C₃alkyl, Ci-C₄alkyl, OH, CN, CFH₂, CF₂H and CF₃.
6. A compound according to any one ofthe previous claims, which is ofFormula (1b) wherein Rj, R₂, R4 are defined as in any one of the previous claims and R₃ is selected from the group comprising hydrogen, halo, C)-C₃alkyl, CN, CFH₂, cf₂h, cf₃.
7. A compound according to any one of the previous claims, wherein at least one R4 représente Fluor, C)-C₃alkyl or cyclopropyL
8. A compound according to any one ofthe previous claims, wherein one R4 on the para position représente Fluor and the other one R4 on the meta position représente methyl and such compound is not
9. A compound according to any one of the previous claims, wherein Rj represents Fluor.
10. A compound according to any one of claims 1 to 9, wherein B represents phenyl or thiophene, optionally being substituted with one or more substituents each independently selected from the group consisting of hydrogen, halogen, Ci-Cjalkyl, CN, CFH₂, CF₂H and CF₃.
11. A compound according to any one of the previous claims for use in the prévention or treatment of an HBV infection in a mammal.
12. A pharmaceutical composition comprising a compound according to any of claims

15 1 to 10, and a pharmaceutically acceptable carrier.
13. A product containing (a) a compound of formula 1 as defïned in any one of claims 1 to 10, and (b) another HBV inhibitor, as a combined préparation for simultaneous, separate or sequential use in the treatment of HBV infections.